Het Rijksvaccinatieprogramma in Nederland : Surveillance en ontwikkelingen in 2014-2015 by Schurink-van 't Klooster TM & de Melker HE
The National 
Immunisation 
Programme in  
the Netherlands
Surveillance and developments  
in 2014-2015

The National 
Immunisation Programme 
in the Netherlands
Surveillance and developments in 2014-2015
RIVM Report 2015-0134
Colophon
© RIVM 2015
Parts of this publication may be reproduced, provided acknowledgement is given to: National 
Institute for Public Health and the Environment, along with the title and year of publication.
Editors:
T.M. Schurink-van ‘t Klooster, H.E. de Melker 
Report prepared by:
N. Alberts, M. Beerling, K. Benschop, B. van Benthem, G.A.M. Berbers, R. van Binnendijk,  
J.A. Bogaards, M. Bouwknegt, M. van Boven, P. Bruijning-Verhagen, A. Buisman, J. Cremer, 
A.S.G. van Dam, R. Donken, E. Duizer, R. Eilers, K. Elberse, C.A.C.M. van Els, A. van der Ende,  
L. Fievez, I.H.M. Friesema, M. van Gent, B. de Gier, S. Gouma, S. Hahné, F. van Heiningen,  
S. Hofstraat, P. Jochemsen, P. Kaaijk, J.M. Kemmeren, H. van Keulen, A.J. King,  
D. Klinkenberg, F.R.M. van der Klis, M.J. Knol, E.A. van Lier, A.K. Lugnér, W. Luytjes,  
N.A.T. van der Maas, S. McDonald, H.E. de Melker, L. Mollema, L. Nic Lochlainn, M. Nielen,  
D.W. Notermans, S. Parkkali, W. van Pelt, M. Pot, M.B. van Ravenhorst, M. Renkema,  
F.A.G. Reubsaet, P. Rog, N.Y. Rots, W.L.M. Ruijs, E.A.M. Sanders, M.F. Schim van der Loeff,  
T.M. Schurink-van ’t Klooster, L. Spanjaard, S.P. Stoof, A.W.M. Suijkerbuijk, E. Swart,  
I. Veldhuijzen, J. Wallinga, P.J. Woestenberg, T. Woudenberg
Contact:
H.E. de Melker
Centre for Epidemiology and Surveillance of Infectious Diseases
hester.de.melker@rivm.nl
This investigation has been performed by order and for the account of Ministry of Health, 
Welfare and Sports, within the framework of V/150202, Development future National 
Immunisation Programme
Surveillance and developments in 2014-2015   |  3
Contents
Publiekssamenvatting 4
Synopsis  5
Preface  8
Comprehensive summary 9
Uitgebreide samenvatting 19
1 Introduction 29
2 Vaccination coverage 33
3 Burden of disease 37
4 Acceptance of vaccination and communication 45
5 Adverse events 51
6 Current National Immunisation Programme 75
 6.1 Diphtheria 76
 6.2 Pertussis 77
 6.3 Tetanus 83
 6.4 Poliomyelitis 85
 6.5 Haemophilus infuenzae serotype b (Hib) disease 88
 6.6 Mumps 92
 6.7 Measles 98
 6.8 Rubella 105
 6.9 Meningococcal serogroup C disease 107
 6.10 Hepatitis B 112
 6.11 Pneumococcal disease 116
 6.12 Human papillomavirus (HPV) infection 127
7 Future NIP candidates 139
 7.1 Rotavirus infection 140
 7.2 Varicella zoster virus (VZV) infection 146
 7.3 Hepatitis A 159
 7.4 Meningococcal serogroup B disease 164
 7.5 Meningococcal non-serogroup B and C types 169
8 Other possible future NIP candidates 173
List of abbreviations 177
Appendix 183
 Appendix 1  Surveillance methodology 184
 Appendix 2  Morbidity and mortality figures 192
 Appendix 3  Overview of changes in the NIP since 2000 220
 Appendix 4  Composition of currently used vaccines in the NIP 222
 Appendix 5  Overview of relevant websites 225
4  |   The National Immunisation Programme in the Netherlands
Publiekssamenvatting
Het Rijksvaccinatieprogramma in Nederland
Surveillance en ontwikkelingen in 2014-2015
In Nederland is de vaccinatiegraad binnen het Rijksvaccinatieprogramma (RVP) hoog, 
waardoor weinig mensen de ziekten krijgen waartegen zij worden ingeënt. Alleen de deelname 
aan de vaccinatie van meisjes tegen het humaan papillomavirus (HPV) ligt lager. Na de 
vaccinaties komen weinig ernstige bijwerkingen voor. Bijwerkingen die gerapporteerd worden 
zijn doorgaans niet ernstig van aard zijn. Continue monitoring is nodig om een optimaal 
vaccinatieprogramma te behouden.
Wijzigingen in het vaccinatieschema in 2014-2015
Sinds januari 2014 is de vaccinatie tegen het HPV-virus, dat baarmoederhalskanker kan 
veroorzaken, teruggebracht naar twee prikken. De vaccinatie wordt aan alle twaalfjarige 
meisjes aangeboden. 
Ontwikkelingen voor RVP-ziekten
Door de uitbreiding van het pneumokokkenvaccin met drie typen in 2011 is het aantal kinderen 
gedaald dat van deze drie typen ziek werd. Deze daling was ook te zien onder volwassenen, die 
mogelijk indirect door de vaccinatie van kinderen zijn beschermd.
Kinkhoest nam in 2014 weer toe na een daling in 2013. Het aantal zieken was minder hoog dan 
tijdens de epidemie in 2012. De bof kwam weinig voor in 2014, al steeg het aantal meldingen 
weer in de eerste maanden van 2015. De meeste mazelengevallen zijn in de eerste twee 
maanden van 2014 gerapporteerd, aan het einde van de epidemie die in 2013 begon. De 
mazelen kwam voor in gebieden waar mensen zich om religieuze redenen vaak niet laten 
vaccineren. 
Er zijn geen gevallen van polio gemeld. Vorig jaar waren de controles op polio geïntensiveerd 
in regio’s in Nederland waar vluchtelingen worden opgevangen. Dit betrof vluchtelingen uit 
enkele niet-Europese landen waar het aantal poliogevallen was gestegen, zoals Syrië. 
Aangezien polio in die landen in 2014 minder voorkwam zijn de controles tot een normaal 
niveau teruggebracht. 
Ontwikkelingen voor toekomstige RVP-kandidaten
De Gezondheidsraad kan de minister adviseren om het aantal ziekten die onder het RVP vallen 
uit te breiden. Het RIVM houdt in de gaten hoe ziekten die hiervoor in aanmerking komen, zich 
ontwikkelen. In 2014 kwamen uitzonderlijk weinig infecties met het rotavirus voor. Ook daalde 
het aantal zieken door meningokokken serogroep B. Het aantal mensen met het waterpokken, 
gordelroos en hepatitis A is de afgelopen jaren stabiel gebleven.
Kernwoorden: Rijksvaccinatieprogramma, rotavirus, varicella zoster, meningokokken B, 
hepatitis A.
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Synopsis
The National Immunisation Programme in the Netherlands
Surveillance and developments in 2014-2015
In the Netherlands, participation in the National Immunisation Programme (NIP) is high, 
resulting in low incidences of most diseases included in the NIP. Yet coverage for vaccination 
against human papillomavirus (HPV) in girls is lower. Only a few severe adverse events 
following immunisation occurred. Reported adverse events are mostly mild and transient. 
Continuous monitoring of effectiveness and safety is necessary for the programme to remain 
optimal.
Changes in the vaccination schedule in 2014-2015
Since 2014, girls have been receiving a reduced number of doses against human papillomavirus 
(HPV). Two doses of HPV vaccine are offered to 12-year-old girls. 
 
Developments for diseases included in the NIP
The switch to the 10-valent pneumococcal vaccine (PCV10) in 2011 reduced the number of 
invasive pneumococcal diseases caused by the additional PCV10 serotypes in the vaccinated 
age groups. A decrease in the incidence of IPD caused by the additional PCV10 serotypes was 
also seen in the adult age groups, which is probably due to indirect protection.
The incidence of pertussis increased in 2014 after a lower incidence in 2013, but was somewhat 
lower than during the epidemic year 2012. The incidence of mumps was low in 2014, but a 
resurgence of mumps and an endemic transmission were encountered in the first few months 
of 2015. The majority of the measles cases reported in 2014 belonged to the measles epidemic 
in the Bible Belt, which started in 2013. 
No cases of polio were reported. The environmental routine surveillance, which was intensified 
in the region where refugees were first cared for in 2013, was changed to routine level again in 
April 2015.
Developments for future NIP candidates
The Health Council could advise the Dutch Minister of Health, Welfare and Sports on expansion 
of the NIP. The National Institute for Public Health and the Environment in the Netherlands 
(RIVM) investigates developments in potential future NIP candidates. 
In 2014, the rotavirus season was exceptionally low. A decrease in meningococcal serogroup B 
disease was seen in 2014. Incidences of varicella zoster virus and hepatitis A remained stable 
over the previous years.
Keywords: National Immunisation Programme, rotavirus, varicella zoster, meningococcal B, 
hepatitis A.
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Preface
This report presents an overview of the surveillance and developments in 2014-2015 with 
respect to the diseases included in the current National Immunisation Programme (NIP): 
diphtheria, pertussis, tetanus, poliomyelitis, Haemophilus influenzae serotype b (Hib) disease, 
mumps, measles, rubella, meningococcal serogroup C disease, hepatitis B, pneumococcal 
disease and human papillomavirus (HPV) infection. It also describes surveillance data 
concerning potential target diseases for which a vaccine is available: rotavirus infection, 
varicella zoster virus infection (VZV), meningococcal serogroup B and hepatitis A infection.  
This report also covers meningococcal non-serogroup B and C types to facilitate the study of 
trends in these serogroups. In addition, an overview of vaccines for infectious diseases tested 
in clinical trials that are relevant for the Netherlands is included in this report.
Some changes were made in the structure of the report following an evaluation of last year’s 
report. The report is now structured as follows: Chapter 1 gives a short introduction. Recent 
results on vaccination coverage are discussed in Chapter 2 and the burden of diseases included 
in the NIP is the focus of Chapter 3. Public acceptance of vaccination and the communication of 
the NIP and adverse events following immunisation (AEFI) are described in Chapter 4 and 
Chapter 5, respectively. Chapter 6 focuses on the current target diseases of the NIP. For each 
disease, key points mark the most prominent findings, followed by an update of information 
on epidemiology, the pathogen, the results of current and ongoing studies and international 
developments. Chapter 7 describes potential new target diseases that are under consideration 
for inclusion in the future NIP. Finally, in Chapter 8 an overview is given of vaccines for 
infectious diseases that are being tested in clinical trials and are relevant for the Netherlands. 
In Appendix 1, the surveillance methods used to monitor the NIP are described and in Appendix 
2 mortality and morbidity figures taken from various data sources for 1997 onwards are 
reported. Appendix 3 gives an overview of changes in the NIP since 2000 and Appendix 4 
presents the composition of vaccines used in 2014-2015. Appendix 5 provides an overview of 
relevant websites.
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Comprehensive summary
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This report presents current vaccination schedules, surveillance data and scientific 
developments in the Netherlands for vaccine-preventable diseases (VPDs) which are included 
in the National Immunisation Programme (NIP) (diphtheria, pertussis, tetanus, poliomyelitis, 
Haemophilus influenzae serotype b (Hib) disease, measles, mumps, rubella, meningococcal 
serogroup C (MenC) disease, hepatitis B, pneumococcal disease and human papillomavirus 
(HPV)). Furthermore, surveillance data and scientific developments are presented with regard 
to potential future target diseases for which a vaccine is available (rotavirus, varicella zoster 
virus (VZV), hepatitis A, meningococcal serogroup B (MenB) and other serogroups (i.e. Y, W, A, 
X, Z, 29E)).
Current vaccination schedule
Vaccination schedule
D Diphtheria
aP Pertussis (whooping cough)
T Tetanus
IPV Poliomyelitis
Hib Haemophilus influenzae tye b
HBV Hepatitus B
PCV Pneumoccal disease
M Mumps
M Measles
R Rubella
MenC Meningococcal C disease
HPV Human papillomavirus
Phase 1
6-9
weeks
3
months
4
months
11
months
14
months
4
year
9
year
12
year
Phase 2 Phase 3 Phase 4
Injection 1
Injection 2
DTaP-IPV
HBV
Hib
DTaP-IPV
HBV
Hib
DTaP-IPV
HBV
Hib
DTaP-IPV
HBV
Hib
HPV
(2 times
1 injection)
MMR DT-IPVDTaP-IPV
MMRMenCPCV PCVPCV
Figure 1 Vaccination schedule of the NIP from 2014 onwards
Changes in vaccination schedule
Since January 2014, adolescent girls are being vaccinated against HPV using a two-dose 
schedule (0, 6 months); up to that time a three-dose schedule had been recommended  
(0, 1, 6 months). 
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Vaccination coverage
Vaccination coverage in the Netherlands is high. For HPV vaccination, the participation 
continued to increase compared with the previous report year. The uptake of the second MMR 
vaccination does not reach the target of 95% set by the World Health Organization (WHO).
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Figure 2 Vaccination coverage per vaccine for age cohorts of newborns, toddlers, schoolchildren 
and adolescent girls in 2015 
*DTaP-IPV total = Sum of DTaP-IPV revaccinated and base-immune at 2-5 years (not eligible for revaccination) 
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Burden of Disease
National burden of disease estimates are expressed in Disability Adjusted Life Years (DALYs), 
which consists of the years lived with a disability (YLD) and the years of life lost (YLL) due to 
the disease or infection. The highest burden was estimated for invasive pneumococcal disease, 
followed by pertussis, measles and rotavirus infection.
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Figure 3 Estimated average annual burden for new cases in the period 2010-2014, with the 
Years Lived with Disability (YLD) and Years of Life Lost (YLL) components shown separately 
Note 1: red lines indicate 95% uncertainty intervals. 
Note 2: for the three invasive diseases there was only a vaccine available against certain serotypes in the period 2010-2014: Haemophilus influenzae 
serotype b (Hib), meningococcal C and pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and, from 2011 onwards, also serotypes 1, 5, 7F.
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Acceptance of vaccination and communication
In the coming years the acceptance of vaccination among parents and child vaccine providers 
will be monitored using a recently developed system consisting of: a) focus groups containing 
members of the public and professionals, b) questionnaires at a certain time interval focused 
on the public and professionals, c) Child Welfare Centres as a sentinel, and d) monitoring 
online (social) media.
Vaccines not included in the public vaccination programme are underused at present.  
To improve vaccination care, RIVM has started to conduct research on the perception of 
those vaccines not included in a public vaccination programme. The aim is to develop 
communication materials for the public and professionals. These materials may support the 
making of a well-considered decision on whether to vaccinate or not.  
Behavioural inoculation seemed not to be an effective strategy to induce resistance to myths 
concerning the topic of HPV vaccination. 
Adverse events
In 2014, Lareb received 982 reports concerning a total of 1,950 adverse events following 
immunisation (AEFI), which is a decrease of almost 20% compared with 2013. The spectrum of 
reported AEFI is mostly in line with past years. No signals emerged indicating that vaccines 
used in the NIP would be unsafe.
1 
3 
15 
15 
16 
59 
63 
91 
122 
274 
323 
0 50
 
10
0 
15
0 
20
0 
25
0 
30
0 
35
0 
Synflorix® 
NeisVac-C® 
Other 
MMRvaxPro® 
DTP-NVI 
Cervarix® 
Infanrix hexa® 
MMRvaxPro® + DTP-NVI 
MMRvaxPro® + NeisVac-C® 
Infanrix-IPV® 
Infanrix hexa® + Synflorix® 
Number 
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Current NIP
Diphtheria
In 2014 one diphtheria case was notified. In 2015, up to week 22, one diphtheria notification 
was also reported. Both patients contracted the disease abroad. One case received more than 
3 vaccinations against diphtheria; the date of the last dose was unknown. In total, 
12 Corynebacterium strains were tested on diphtheria-toxin using PCR and Elek-test. Two 
strains tested positive. In a large seroprevalence study performed in 2006-2007, the general 
population, eligible for NIP-vaccination, had high and long-lasting seroprotection. People born 
before NIP-introduction or adhering to an orthodox reformed religion had the highest 
susceptibility to diphtheria.
Pertussis
The incidence of pertussis shows a biannual pattern, with epidemic peaks every two-years in 
both notifications and hospital admissions. The incidence based on notifications increased to 
55 per 100,000 in 2014, following a lower incidence in 2013. In 2012, the incidence based on 
notifications was the highest since 1976 (83 per 100,000). In 2014, 2 deaths due to pertussis 
were registered. 
The vaccine effectiveness (VE) of the primary series with the acellular pertussis vaccine, 
calculated using the screening method, is high until the age of 4 years. At this age, a booster 
dose is given. The VE of this booster dose decreases after 4-5 years.
During recent years, we observed an increase in Pertactin (Prn)-deficient strains circulating in 
the Netherlands. This is in line with findings in other countries and is probably related to the 
use of acellular vaccines. In a mouse model, VE was lower when mice, vaccinated with acellular 
pertussis, were challenged with Prn-deficient strains. Studies to assess the VE of three and five 
component acellular vaccines in a mouse model are planned. 
Vaccination during pregnancy has been implemented in the UK, Belgium (Flanders) and several 
other countries. High effectiveness (91-93%) and a good safety profile were observed. 
Interference of maternal antibodies with the infant’s immune response after vaccination was 
observed after the primary series, but restored after a booster dose. A survey showed that the 
intention to accept maternal pertussis vaccination in the Netherlands is about 60%. 
Tetanus
In 2014, no tetanus cases were notified. In 2015, up to week 24, one unvaccinated young adult 
was reported with tetanus. A Dutch study to assess the added value of a Tetanus Quick Stick 
(TQS), a bedside test for tetanus immunity, showed over-immunisation if the current practice 
of tetanus post-exposure prophylaxis (T-PEP) is followed. However, people born before the 
introduction of the tetanus vaccination were not always eligible for T-PEP according to the 
current guideline, but had a negative TQS, probably indicating non-protection.
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Poliomyelitis
In the Netherlands, no cases of poliomyelitis were reported in 2014 and 2015 until week 24. In 
January 2015, a Sabin type 1 oral polio vaccine (OPV) strain was found once in a sewage sample 
at the point where refugees and asylum seekers receive first care after entry. Through routine 
enterovirus-surveillance, a VDPV type 3 was found in a young Syrian refugee in July 2015. 
Follow up of the case and surrounding contacts revealed no circulation of the poliovirus.
Great progress has been made in the worldwide efforts to eradicate polio. After eradication, 
vaccination remains necessary, preferably with the inactivated polio vaccine (IPV) instead of 
OPV. Furthermore, the World Health Organization (WHO) adopted a plan to minimize 
poliovirus facility-associated risks.
Haemophilus influenzae type b (Hib) disease
The total number of cases of invasive disease caused by Haemophilus influenzae serotype b (Hib) 
in 2014 (n=29) was the same as previous year. The incidence among 0-4 year-olds decreased 
from 1.43 per 100,000 (n=13) in 2013 to 0.89 per 100,000 in 2014 (n=8), whereas in the other 
age-groups, except for 65 years and older, the incidence increased slightly. Since 2006 (n=14) 
the number of vaccine failures for invasive Hib disease decreased to an average of 7 vaccine 
failures per year with a range of 4 to 9 vaccine failures per year. Since 2004, there has been a 
steady increase in the number of cases caused by nontypeable Hi strains (NTHi) (71 in 2004 to 
117 in 2014).
Mumps
The number of mumps notifications was low in 2014 (n=40). It increased in the first 5 months 
of 2015 and new molecular methods suggest the endemic transmission of mumps in this 
period. The mumps virus genotype that causes most of the mumps cases in the Netherlands is 
genotype G.
Measles
In 2014, 140 cases of measles were reported, the majority of which belonged to the epidemic in 
areas with low vaccination coverage (‘Bible Belt’) in the Netherlands that lasted from May 2013 
to March 2014, in which a total of 2,700 cases were reported. Later in 2014, some small clusters 
occurred that were import related. A 17-year-old patient died of subacute sclerosing 
panencephalitis (SSPE), a late complication of a measles infection at 4 years of age. Many 
research projects related to the 2013-2014 epidemic are still ongoing.
Rubella
In 2014 and in 2015 up to week 25, only two cases of rubella were reported. A national guideline 
on rubella screening during pregnancy is being developed and is expected in 2015/2016.
Meningococcal serogroup C (MenC) disease
In 2014, 3 cases and in 2015 (until June) 5 cases of MenC disease were reported, including one 
vaccine failure. This is the fourth vaccine failure case to occur since the introduction of the 
conjugated MenC vaccine in 2002. 
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Hepatitis B
In 2014, the incidence of acute hepatitis B virus infections (HBV) notifications decreased 
slightly and remained low at 0.8 cases per 100,000 people. For acute cases, sexual contact was 
the most common reported transmission route. Similar to previous years, genotype A was the 
most common genotype among acute cases in 2014. A platform to combine molecular data 
with epidemiological and transmission data is being developed to facilitate the efficient 
surveillance of HBV and the detection of antiviral resistance and immune escape variants.
Pneumococcal disease
Introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2006 decreased vaccine-
type invasive pneumococcal disease (IPD) from 7.4 per 100,000 per year in 2004-2006 to less 
than 1 per 100,000 per year in 2013-2015. The switch to 10-valent pneumococcal conjugate 
vaccine (PCV10) in 2011 reduced the number of IPD cases caused by the additional PCV10 
serotypes (1, 5 and 7F) in the vaccine-eligible age groups. A decrease in the incidence of IPD 
caused by the additional PCV10 serotypes in the adult age groups was seen in 2013-2015. This 
is probably due to herd protection as a result of PCV10 introduction for children. However, 
longer follow-up is needed to establish this since natural fluctuations over time cannot be 
ruled out yet. The incidence of non-vaccine-type IPD increased after the introduction of PCV7. 
The increase in 2013-2015 was very small. 
Human papillomavirus (HPV)
Incidences of HPV-associated cancers and deaths have slightly increased over the last decade 
in the Netherlands. The VE of the bivalent vaccine against incident and persistent infections in 
a cohort study is high up to four years post-vaccination. Persistent HPV16/18 infections were 
found to have significantly higher baseline viral loads than clearing infections. Antibody avidity 
after a two-dose schedule (0, 6 months) showed no remarkable differences with a three-dose 
schedule, indicating the similar quality of the antibody response.
 
Future NIP candidates
Rotavirus
The incidence of rotavirus-associated gastroenteritis seen in the Netherlands was 
exceptionally low in 2014. In total, 607 diagnoses were reported by the Working Group Clinical 
Virology in 2014. The number of diagnoses in 2015 was in line with the 2012 season, which had 
been a low season. Genotype G9P[8] was most commonly found in the Netherlands in 2014. 
The relative prevalence of G2P[4] shows a slight but steady increase since 2011.
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Varicella zoster virus (VZV) infection
The VZV epidemiology (varicella and herpes zoster) is comparable to previous years. The 
incidence based on GP consultations in 2013 amounted to 280 per 100,000 for varicella and  
510 per 100,000 for herpes zoster. The cost-effectiveness of varicella vaccination is strongly 
affected by its impact on herpes zoster and the time horizon for economic assessment: in the 
absence of exogenous immune boosting, varicella vaccination with high coverage is expected 
to be cost-effective and may even be cost-saving, while it is not expected to be cost-effective 
on reasonable time scales if immune boosting is present.
Hepatitis A
In 2014, the incidence of reported hepatitis A infections (0.6 cases per 100,000) remained low, 
as in recent years. More than half of the 105 cases were younger than 20 years and clusters 
occurred almost only amongst these cases. Fifty-three per cent of the Dutch cases were 
reported to be travel-related, almost half of them in Morocco.
Meningococcal serogroup B (MenB) disease
In 2014, a decrease in MenB disease was seen (60 cases in 2014 (0.36 per 100,000), compared 
with 88 in 2013 (0.52 per 100,000), which was mostly due to a decrease among 0-4 year-olds 
and 40-64 year-olds, while among 5-9 year-olds the incidence increased slightly. 
Meningococcal non-B and non-C disease
In 2014, 19 (23%) meningococcal cases were caused by non-serogroup B or C types from a total 
of 83 cases. 
Dutch Caribbean
The participation among infants from the Caribbean Netherlands for the DTaP-IPV, MMR and 
pneumococcal vaccination is high. In 2014, the Department for Vaccine Supply and Prevention 
Programmes (DVP/RIVM) prepared for the vaccine distribution and delivery to the Dutch 
Caribbean municipalities, Bonaire, St Eustatius and Saba (BES). 
HPV immunisation will be introduced on Bonaire from September 2015 onwards.
General conclusion
Continuous monitoring of both current and potential future target diseases is necessary to 
optimize the prevention of these diseases by maintaining or adapting the programme.
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Uitgebreide samenvatting 
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In dit rapport worden surveillance data en wetenschappelijke ontwikkelingen in Nederland 
gepresenteerd voor ziekten waartegen binnen het Rijksvaccinatieprogramma (RVP) 
gevaccineerd wordt (difterie, kinkhoest, tetanus, polio, Haemophilus influenzae serotype b (Hib), 
mazelen, bof, rodehond, meningokokken serogroep C (MenC), hepatitis B, 
pneumokokkenziekte en humaan papillomavirus (HPV)). Ook worden surveillance data en 
wetenschappelijke ontwikkelingen beschreven voor ziekten waarvoor het beschikbare vaccin 
(nog) niet is opgenomen in het RVP (rotavirus, varicella zoster-virus (VZV), hepatitis A, 
meningokokken serogroep B (MenB) en andere meningokokken serogroepen (n.l. Y, W, A, X, Z, 
29E).
Huidig vaccinatieschema
Vaccinatieschema
D Difterie
K Kinkhoest
T Tetanus
P Polio
Hib Haemophilus influenzae tye b
HepB Hepatitus B
Pneu Pneumokokken
B Bof
M Mazelen
R Rodehond
MenC Meningokokken C
HPV Humaan Papillomavirus
Fase 1
6-9
weken
3
maanden
4
maanden
4
jaar
9
jaar
12
jaar
11
maanden
14
maanden
Fase 2 Fase 3 Fase 4
Prik 1
Prik 2
DKTP
Hib
HepB
DKTP
Hib
HepB
DKTP
Hib
HepB
DKTP
Hib
HepB
HPV
(2 keer
1 prik)
BMR DTPDKTP
BMRMenCPneu Pneu Pneu
Figuur 1 Vaccinatieschema van het RVP vanaf 2014
Wijzigingen in het vaccinatieschema
Sinds januari 2014 worden meisjes in het jaar dat ze 13 worden gevaccineerd tegen HPV in een 
twee-doses schema (0, 6 maanden). Voorheen gebeurde dit middels een drie-doses schema 
(0, 1, 6 maanden). 
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Vaccinatiegraad
De vaccinatiegraad in Nederland is hoog. Voor HPV-vaccinatie is de vaccinatiegraad verder 
gestegen ten opzichte van het vorige rapportage jaar. De opkomst voor de tweede BMR 
vaccinatie bereikt niet de 95% die de World Health Organization (WHO) als doel heeft gesteld.
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Figuur 2 Vaccinatiegraad per vaccin voor pasgeborenen, kleuters, schoolkinderen en 
adolescente meisjes in 2015 
* DKTP totaal = som gerevaccineerd (DKTP revac) + basisimmuun 2-5 jaar (komen niet in aanmerking voor revaccinatie).
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Ziektelast
De schattingen van de ziektelast in Nederland worden uitgedrukt in Disability Adjusted Life 
Years (DALY’s), die bestaat uit het aantal jaren geleefd met ziekte (YLD) en het aantal verloren 
levensjaren (YLL) door de ziekte of infectie. De hoogste ziektelast is geschat voor invasieve 
pneumokokkenziekte gevolgd door kinkhoest, mazelen en rotavirusinfectie.
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Figuur 3 Geschatte jaarlijkse ziektelast voor nieuwe cases in de periode 2010-2014, met jaren 
geleefd met ziekte (YLD) en verloren levensjaren (YLL) apart gepresenteerd 
ad 1: de rode lijnen geven het 95% betrouwbaarheidsinterval weer 
ad 2: voor de invasieve ziekten was alleen een vaccin beschikbaar tegen bepaalde serotypen in de periode 2010-2014: Haemophilus influenzae 
serotype b (Hib), meningokokken C en pneumokokken serotype 4, 6B, 9V, 14, 18C, 19F, 23F en vanaf 2011 ook serotype 1, 5, 7F.
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Acceptatie van vaccinatie en communicatie
In de komende jaren zal de acceptatie van vaccinatie onder ouders en professionals worden 
gemonitord met behulp van een recent ontwikkeld systeem. Het systeem bestaat uit: a) 
focusgroepen bestaande uit burgers en professionals, b) vragenlijsten met een bepaalde 
tijdsinterval voor burgers en professionals, c) consultatiebureaus en d) monitoring van online 
(sociale) media. 
Het RIVM is gestart met onderzoek naar de beleving rondom vaccins die niet in een RVP zijn 
opgenomen. Het doel is communicatiemateriaal te ontwikkelen voor het publiek en 
professionals zodat ouders een weloverwogen beslissing kunnen nemen om hun kind al dan 
niet te laten vaccineren. Gedragsinenting leek geen effectieve strategie om weerstand te 
induceren tegen mythes over HPV-vaccinatie.
Bijwerkingen
In 2014 ontving Bijwerkingencentrum Lareb 982 meldingen met 1950 mogelijke bijwerkingen 
van vaccins. Dit is een daling van het aantal meldingen van bijna 20% ten opzichte van 2013. 
De aard van de gemelde bijwerkingen is vergelijkbaar met de vorige jaren. De meldingen van 
vermoede bijwerkingen in 2014 geven geen aanleiding tot verontrustende signaleringen.
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Huidig RVP
Difterie
In 2014 was er 1 melding van difterie. Ook in de eerste 22 weken van 2015 is er één geval van 
difterie gemeld. Beide patiënten hebben de ziekte opgelopen in het buitenland. Eén van de 
patiënten was drie keer gevaccineerd, de datum van de laatste dosis is onbekend. In totaal zijn 
er in deze periode 12 Corynebacterium stammen onderzocht op toxigeniciteit. Twee stammen 
werden positief bevonden. In PIENTER 2, een grote seroprevalentiestudie uitgevoerd in 
2006-2007, is voor de algemene bevolking die in aanmerking kwam voor het RVP, een goede, 
langdurige bescherming tegen difterie aangetoond. Mensen die zijn geboren vòòr invoering 
van het RVP en streng orthodox-gereformeerde mensen lopen meer risico om difterie te 
krijgen.
Kinkhoest
De incidentie van kinkhoest laat tweejaarlijkse pieken zien in meldingen en ziekenhuis-
opnames. De incidentie van kinkhoestmeldingen was in 2014 gestegen naar 55 per 100.000  
na een lagere incidentie in 2013. In 2012 was de incidentie van meldingen met 83 per 100.000 
het hoogst sinds 1976. In 2014 werden 2 overlijdens door kinkhoest geregistreerd.
Na de invoering van een acellulair kinkhoest combinatievaccin in 2005, is de vaccineffectiviteit 
(VE) van de primaire serie, tot aan de leeftijd van 4 jaar, hoog. De VE van de herhalings-
vaccinatie op 4 jaar neemt 4-5 jaar na deze booster af.
De laatste jaren zien we in Nederland en andere landen een toename van het percentage 
Pertactine (Prn)-deficiënte stammen. Waarschijnlijk houdt dit verband met de introductie van 
acellulaire vaccins. In proeven met muizen die gevaccineerd waren met een acellulair vaccin, 
was de VE lager als de muis werd geïnfecteerd met een Prn-deficiënte stam. Aanvullende 
proeven om de VE van acellulaire vaccins met een verschillend aantal componenten met elkaar 
te vergelijken zijn in voorbereiding.
Vaccinatie tijdens de zwangerschap is al ingevoerd in Engeland, Vlaanderen en diverse andere 
landen. Een hoge effectiviteit (91-93%) en een goede veiligheid werden geobserveerd. Studies 
hebben laten zien dat maternale antistoffen het immuunrespons van het kind verstoren na de 
primaire serie. Dit lijkt zich echter na de boostervaccinatie te herstellen. Onderzoek toont aan 
dat de acceptatie van kinkhoestvaccinatie tijdens de zwangerschap in Nederland ongeveer 
60% bedraagt.
Tetanus
In 2014 zijn er geen meldingen van tetanus gedaan. In de eerste 24 weken van 2015 is er 1 geval 
van tetanus gemeld. Het betrof een ongevaccineerde jongvolwassene. Een Nederlands 
onderzoek naar de eventuele meerwaarde van de tetanus Quick Stick (TQS), een sneltest om 
antistoffen tegen tetanustoxoid aan te tonen, laat zien dat er bij de huidige praktijk van 
tetanus-post expositie profylaxe (T-PEP) vaak sprake is van overbehandeling. Mensen die zijn 
geboren vòòr invoering van tetanusvaccinatie in het RVP, krijgen echter vaak geen T-PEP, 
terwijl ze waarschijnlijk niet beschermd zijn.
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Polio
In Nederland zijn er in 2014 en in 2015 tot week 24 geen gevallen van poliomyelitis gemeld. Wel 
is er in januari 2015 éénmalig een Sabin oraal polio vaccin (OPV) 1 vaccin stam gevonden via de 
rioolwatersurveillance van ter Apel, de eerste opvangplaats van asielzoekers. 
Er is grote vooruitgang geboekt bij de wereldwijde eradicatie van polio. Ook na eradicatie zal 
er gevaccineerd moeten worden tegen polio. Hierbij wordt aanbevolen om OPV te vervangen 
door geïnactiveerd polio vaccin (IPV). De World Health Organization (WHO) heeft een plan 
opgesteld om de aanwezigheid en het gebruik van poliovirussen in laboratoria en andere 
instituten in kaart te brengen om de risico’s op uitbraken via deze route te minimaliseren.
Haemophilus influenzae type b (Hib) ziekte
Het totaal aantal invasieve ziekten veroorzaakt door Haemophilus influenzae serotype b (Hib) in 
2014 (aantal=29) was gelijk aan in het jaar daarvoor. De incidentie in 0-4-jarigen is gedaald van 
1,43 per 100.000 in 2013 naar 0,89 per 100.000 in 2014. In de overige leeftijdsgroepen, met 
uitzondering van 65-jarigen en ouder, is de incidentie licht gestegen. Sinds 2006 is het aantal 
vaccinfalen (aantal=14) van invasieve Hib-ziekten gedaald tot gemiddeld 7 per jaar met een 
range van 4 tot 9 vaccinfalen per jaar. Sinds 2004 is een constante stijging te zien in het aantal 
ziektegevallen veroorzaakt door een niet-typeerbare Hi stam (71 in 2004 tot 117 in 2014). 
Bof
Het aantal gevallen van bof was laag in 2014 (40). In de eerste vijf maanden van 2015 is de 
incidentie toegenomen. Nieuwe moleculaire onderzoeksmethoden toonde endemische 
transmissie aan. Bofinfecties worden in Nederland voornamelijk veroorzaakt door bof virus 
genotype G.
Mazelen
In 2014 werden 140 gevallen van mazelen gemeld, waarvan de meesten behoorden tot de 
epidemie in de ‘bible belt’ die tussen mei 2013 en maart 2014 plaatsvond. Tijdens deze 
epidemie werden in totaal 2700 gevallen van mazelen gemeld. Later in 2014 werden enkele 
kleine import gerelateerde clusters gezien. Een 17-jarige patiënt is overleden aan subacute 
scleroserende panencefalitis (SSPE), een late complicatie van een mazeleninfectie op 4-jarige 
leeftijd. Er lopen nog diverse onderzoeksprojecten gerelateerd aan de mazelen epidemie in 
2013-2014.
Rodehond
In 2014 en 2015 tot week 25 werden twee gevallen van rodehond gemeld. Een landelijke 
richtlijn over rubellascreening tijdens de zwangerschap is in ontwikkeling en wordt verwacht  
in 2015/2016.
Meningokokken serogroep C (MenC)-ziekte
In 2014 werden 3 gevallen van MenC-ziekte gerapporteerd. In 2015 (tot juni) waren dit er 5, 
inclusief 1 geval van vaccinfalen. Dit is het vierde geval van vaccinfalen sinds de introductie van 
het geconjugeerd MenC-vaccin in 2002. 
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Hepatitis B
In 2014 is de incidentie van acute hepatitis B-virusinfectie (HBV) iets verder afgenomen en blijft 
laag met 0,8 gevallen per 100.000 inwoners. Onder acute gevallen is seksueel contact de meest 
gerapporteerde transmissieroute. Vergelijkbaar met eerdere jaren is genotype A het meest 
voorkomende bij acute HBV-infectie. Om de surveillance van HBV en de detectie van antivirale 
resistentie en immuun-escape varianten te faciliteren wordt gewerkt aan een platform 
waarbinnen moleculaire en epidemiologische gegevens gecombineerd kunnen worden.
Pneumokokkenziekte
Introductie van het 7-valente pneumokokkenvaccin (PCV7) in 2006 heeft geleid tot een daling 
in vaccin-type invasieve pneumokokkenziekten van 7,4 per 100.000 per jaar in 2004-2006 naar 
minder dan 1 per 100.000 per jaar in 2013-2015. Door de verandering naar het 10-valente 
pneumokokkenvaccin (PCV10) in 2011 is het aantal invasieve pneumokokkenziekten 
veroorzaakt door de additionele PCV10 serotypen (1, 5 en 7F) gedaald in de gevaccineerde 
leeftijdsgroepen. In 2013-2015 werd ook een daling in incidentie van invasieve pneumokokken-
ziekte veroorzaakt door de additionele PCV10 serotypen in volwassen leeftijdsgroepen gezien. 
Dit wordt waarschijnlijk veroorzaakt door kudde-immuniteit na introductie van PCV10 voor 
kinderen. Langere follow-up is echter noodzakelijk om natuurlijke fluctuaties uit te sluiten. De 
incidentie van invasieve pneumokokkenziekte veroorzaakt door niet-vaccintypen is gestegen 
na de introductie van PCV7. In 2013-2015 was deze stijging echter zeer klein.
Humaan papillomavirus (HPV)
In Nederland is in het laatste decennium de incidentie van HPV-geassocieerde kankers en 
sterfte licht gestegen. Uit de resultaten van een cohortstudie kwam een hoge VE van het 
bivalente vaccin tegen incidente en persistente infecties tot 4 jaar na vaccinatie. Persisterende 
HPV16/18 infecties hebben hogere virale loads dan klarende infecties. Er zijn geen opmerkelijke 
verschillen gevonden in antistof aviditeit na een twee-doses schema (0, 6 maanden) 
vergeleken met een drie-doses schema (0, 1, 6 maanden), wat een vergelijkbare kwaliteit van 
antistof respons suggereert.
Toekomstige RVP kandidaten
Rotavirus
De geregistreerde incidentie van rotavirus-geassocieerde gastro-enteritis in Nederland was 
uitzonderlijk laag in 2014. In totaal werden in 607 rotavirusdiagnoses gerapporteerd door de 
Werkgroep Klinische Virologie. Het genotype G9P[8] werd in 2014 het meest gezien. Sinds 2011 
is er een kleine, maar gestage toename van het voorkomen van G2P[4] zichtbaar.
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Varicella zoster virus (VZV) infectie
De VZV-epidemiologie (waterpokken en gordelroos) is vergelijkbaar met voorgaande jaren. De 
incidentie gebaseerd op huisartsenbezoeken in 2013 was voor waterpokken 280 per 100.000 
en voor gordelroos 510 per 100.000. De kosteneffectiviteit van waterpokkenvaccinatie wordt 
sterk beïnvloed door de impact op gordelroos en de tijdshorizon voor economische analyse: in 
afwezigheid van exogene immuunboosting wordt verwacht dat waterpokkenvaccinatie bij een 
hoge vaccinatiegraad kosteneffectief of zelfs kostenbesparend is, terwijl verwacht wordt dat 
vaccinatie niet binnen redelijke termijn kosteneffectief is als er wel sprake is van immuun- 
boosting.
Hepatitis A
De incidentie van gerapporteerde hepatitis A-infecties bleef in 2014, evenals in de afgelopen 
jaren, laag (0,6 per 100.000). Meer dan de helft van de 105 patiënten was jonger dan 20 jaar  
en clusters ontstonden vrijwel alleen binnen deze groep patiënten. 53% van de hepatitis 
A-infecties waren in het buitenland opgelopen, waarvan bijna de helft in Marokko.
Meningokokken serogroep B (MenB)-ziekte
In 2014 is het aantal MenB-ziekten gedaald van 88 in 2013 (0,52 per 100.000) tot 60 in 2014 
(0,36 per 100.000). Deze daling werd voornamelijk gezien in 0-4-jarigen en 40-64-jarigen. 
Onder 5-9-jarigen was een lichte stijging te zien. 
Meningokokken niet-B en niet-C ziekten
In 2014 waren 19 (23%) van de in totaal 83 meningokokken gevallen veroorzaakt door een 
niet-B of -C serogroep. 
Nederlandse Cariben
De vaccinatiegraad voor DTaP-IPV-, BMR- en pneumokokkenvaccinatie onder zuigelingen  
in de Caribisch Nederland is hoog. In 2014 treft de Dienst Vaccinvoorziening en 
Preventieprogramma’s (DVP) van het RIVM voorbereidingen voor de distributie en levering 
van vaccins aan de Nederlandse Caribische gemeenten Bonaire, St Eustatius en Saba (BES).
HPV-vaccinatie wordt vanaf september 2015 geïntroduceerd op Bonaire. 
Algemene conclusie
Continue monitoring van zowel ziekten waartegen in het huidige RVP gevaccineerd wordt als 
potentiele toekomstige ziekten is nodig voor het optimaliseren van de preventie van deze 
ziekten door het behouden of aanpassen van het programma.
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Introduction
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1.1 Vaccination schedule of the NIP
The vaccination of a large part of the population of the Netherlands against diphtheria, 
tetanus and pertussis (DTP) was introduced in 1952. The National Immunisation Programme 
(NIP) started in 1957, offering DTP and inactivated polio vaccination (IPV) in a programmatic 
approach to all children born from 1945 onwards. Nowadays, in addition to DTPIPV, 
vaccinations against measles, mumps, rubella (MMR), Haemophilus influenzae serotype b (Hib), 
meningococcal C disease (MenC), invasive pneumococcal disease, hepatitis B virus (HBV) and 
human papillomavirus (HPV) are included in the programme (Figure 1.1). In the Netherlands, 
vaccinations within the NIP are administered to the target population free of charge and on a 
voluntary basis.
Vaccination schedule
D Diphtheria
aP Pertussis (whooping cough)
T Tetanus
IPV Poliomyelitis
Hib Haemophilus influenzae tye b
HBV Hepatitus B
PCV Pneumoccal disease
M Mumps
M Measles
R Rubella
MenC Meningococcal C disease
HPV Human papillomavirus
Phase 1
6-9
weeks
3
months
4
months
11
months
14
months
4
year
9
year
12
year
Phase 2 Phase 3 Phase 4
Injection 1
Injection 2
DTaP-IPV
HBV
Hib
DTaP-IPV
HBV
Hib
DTaP-IPV
HBV
Hib
DTaP-IPV
HBV
Hib
HPV
(2 times
1 injection)
MMR DT-IPVDTaP-IPV
MMRMenCPCV PCVPCV
Figure 1.1 Vaccination schedule of the National Immunisation Programme (NIP)  
from 2014 onwards.  
Source: http://www.rivm.nl/Onderwerpen/R/Rijksvaccinatieprogramma/ Professionals 
1.1.1 Changes in vaccination schedule in 2014/2015
Since January 2014, vaccination against HPV for adolescent girls has been changed from a 
three-dose schedule (0, 1, 6 months) to a two-dose schedule (0, 6 months), following the 
licensing of the bivalent vaccine for a two-dose schedule. When started after the fifteenth 
birthday, three doses are still needed (0, 1, 6 months).
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1.2 Dutch Caribbean
In 2014, the Department for Vaccine Supply and Prevention Programmes of the National 
Institute for Public Health and the Environment in the Netherlands (DVP/RIVM) prepared for 
vaccine distribution and delivery to the Dutch Caribbean municipalities, Bonaire, St Eustatius 
and Saba (BES). A quality control system has been set up, procedures have been tested and 
staff have been trained. A carrier has been selected, an audit carried out and some corrective 
measures have been taken so that by Q4 2015 vaccines from Dutch stock at RIVM will be 
transported following validated procedures.
HPV immunisation will be introduced on Bonaire from September 2015 onwards. This is the 
last adaptation to harmonise the immunisation programme in the Caribbean and European 
Netherlands.
1.3 Vaccination of risk groups
In addition to diseases included in the NIP, influenza vaccination is offered through the 
National Influenza Prevention Programme (NPG) to people aged 60 years and over and to 
those with an increased risk of morbidity and mortality following influenza. Vaccination 
against tuberculosis is offered to the children of immigrants from high-prevalence countries. 
For developments on influenza and tuberculosis, we refer readers to the reports of the Centre 
for Infectious Disease Control (CIb), the Health Council and the KNCV Tuberculosis Foundation 
[1-4]. Besides vaccination against HBV included in the NIP, an additional vaccination 
programme targeting groups particularly at risk of HBV due to sexual behaviour or profession 
is in place in the Netherlands.
1.4 Literature
1*. RIVM. Griepprik. Available from: www.rivm.nl/griepprik/voor_wie/.
2*. Slump E, Erkens CGM, van Hunen R, Schimmel HJ, van Soolingen D, de Vries G. 
Tuberculosis in the Netherlands 2013. RIVM, KNCV Tuberculosis Foundation, 2015 
2014-0106.
3.  Tacken M, Jansen B, Mulder J, Tiersma W, Braspenning J. Monitoring Vaccinatiegraad 
Nationaal Programma Grieppreventie 2013. Nijmegen: LINH, IQ healthcare; 2014.
4*. Teirlinck CJPM, van Asten L, Brandsema PS, Dijkstra F, Euser SM, van Gageldonk-Lafeber 
AB, et al. Annual report surveillance respiratory infectious diseases 2013, the Netherlands. 
Bilthoven: RIVM, 2014 150002006.
* RIVM publication
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2
Vaccination coverage
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2.1 Key points
• Vaccination coverage in the Netherlands is high.
• For HPV vaccination, the participation continued to increase, compared with the 
previous report year, to 61%.
• The uptake of the second MMR vaccination does not reach the target of 95% set by the 
World Health Organization (WHO).
2.2 Vaccination coverage
As in previous years, the participation for the different vaccinations included in the NIP is, at 
92% to 99%, high in report year 2015 (Table 2.1) [1]. The exception is the HPV vaccination 
against cervical cancer, for which the participation continued to increase compared with the 
previous report year (to 61%). The participation for the hepatitis B vaccination for children 
born in 2012, the first year in which all infants were eligible for the hepatitis B vaccination, is 
94%. The participation among infants from the Caribbean Netherlands for the DTaP-IPV, MMR 
and pneumococcal vaccination is also high.
The participation for the MMR vaccination for 9-year-olds (93%) is identical to the 
participation for the DT-IPV vaccination this time; usually the participation for the MMR 
vaccination is slightly lower. This is an improvement, but the required participation has not yet 
been reached. A participation of at least 95% is important because of the aim of the WHO to 
eliminate measles worldwide. Such a high vaccination coverage is important to protect the 
general population against outbreaks (herd immunity).
To protect infants effectively against the diseases of the NIP, it is also important to give 
vaccinations on time. The proportion of infants that received the first DTaP-IPV vaccination on 
time, i.e. before they are 10 weeks old, increased further to 89%. In addition, the timely and 
full participation in the primary DTaP-IPV series (the first three vaccinations) improved from 
60% for children born in 2007 to 69% for children born in 2012.
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2.3 Tables and Figures
Table 2.1 Vaccination coverage per vaccine for age cohorts of newborns, toddlers, 
schoolchildren and adolescent girls in 2006-2015
 
Newborns*
Report
Year
cohort DTaP
-IPV
Hib HBV a Pneu
**
MMR MenC
2006 2003 94.3 95.4 15.2 - 95.4 94.8
2007 2004 94.0 95.0 17.1 - 95.9 95.6
2008 2005 94.5 95.1 17.9 - 96.0 95.9
2009 2006 95.2 95.9 18.6 94.4 96.2 96.0
2010 2007 95.0 95.6 19.3 94.4 96.2 96.1
2011 2008 95.4 96.0 19.4 94.8 95.9 95.9
2012 2009 95.4 96.0 19.5 94.8 95.9 95.9
2013 2010 95.5 96.1 19.7 95.1 96.1 96.0
2014 2011 95.4 95.9 51.4 95.0 96.0 95.8
2015 2012 94.8 95.4 94.5 94.4 95.5 95.3
Toddlers* Schoolchildren* Adolescent 
girls*
Report
Year
cohort DTaP
-IPV b
DTaP
-IPV c 
DTaP
-IPV d
cohort DT
-IPV 
MMR
***
cohort HPV
2006 2000 92.5 1.4 93.9 1995 93.0 92.9
2007 2001 92.1 1.6 93.7 1996 92.5 92.5
2008 2002 91.5 1.6 93.1 1997 92.6 92.5
2009 2003 91.9 2.0 93.9 1998 93.5 93.0
2010 2004 91.7 2.6 94.3 1999 93.4 93.1
2011 2005 92.0 2.6 94.7 2000 92.2 92.1
2012 2006 92.3 2.1 94.4 2001 93.0 92.6 1997 56.0
2013 2007 92.3 2.4 94.7 2002 93.1 92.9 1998 58.1
2014 2008 92.0 2.4 94.4 2003 92.7 92.4 1999 58.9
2015 2009 91.9 2.2 94.1 2004 92.7 92.7 2000 61.0
* Vaccination coverage is assessed at the ages of 2 years (newborns), 5 years (toddlers), 10 years (schoolchildren) and 14 years (adolescent girls).
** Only for newborns born on or after 1 April 2006.
*** Two MMR vaccinations (in the past ‘at least one MMR vaccination’ was reported).
a  Percentage of the total cohort. In 2011 universal hepatitis B vaccination was introduced; risk groups were vaccinated previously.
b  Revaccinated toddlers.
c  Toddlers that reached basic immunity at age 2-5 years and were therefore not eligible for revaccination at toddler age.
d  Sufficiently protected toddlers (sum of b and c).
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2.4 Literature
1*. van Lier EA, Oomen PJ, Giesbers H, Conyn-van Spaendonck MAE, Drijfhout IH, 
Zonnenberg-Hoff IF, et al. Immunisation coverage of National Immunisation Programme 
in the Netherlands: Year of report 2015. Bilthoven: RIVM, 2015 RIVM report 2015-0067.
* RIVM publication
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3 
Burden of disease
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3.1 Key points
• The estimated average annual disease burden expressed in Disability Adjusted Life 
Years (DALYs) for the period 2010-2014 was, from high to low: invasive pneumococcal 
disease (8,746 DALYs/year), pertussis (4,337 DALYs/year), measles (1,805 DALYs/year), 
rotavirus infection (1,539 DALYs/year), invasive meningococcal disease (736 DALYs/
year), invasive Haemophilus influenzae infection (482 DALYs/year), acute hepatitis B 
infection (402 DALYs/year), rubella (133 DALYs/year), hepatitis A infection (117 DALYs/
year), rabies (15 DALYs/year), tetanus (5 DALYs/year), mumps (4 DALYs/year), diphtheria 
(0.5 DALYs/year) and poliomyelitis (0 DALYs/year).
3.2 Burden of disease
In the State of Infectious Diseases in the Netherlands, 2013 [1] national burden of disease 
estimates expressed in Disability Adjusted Life Years (DALYs) were presented for 32 infectious 
diseases in the period 2007-2011. Here we present an update for the disease burden of 
13 vaccine-preventable diseases in the period 2010-2014. We used the same methodology  
and assumptions that were used in the State of Infectious Diseases [1, 2], except that for 
mumps, measles, pertussis and rubella multiplication factors to correct for underestimation  
(under-ascertainment and/or under-reporting) of the incidence have been updated.  
Under-ascertainment refers to the extent to which incidence is underestimated because  
there are cases in the community who do not contact health services (such as their general 
practitioner), either because their infection is asymptomatic or because they suffer from mild 
illness only. Under-reporting refers to those cases who do contact health services, but whose 
disease status is either incorrectly diagnosed or classified, or fails to be reported to the 
organisation responsible for surveillance. Additionally, we have included the estimated disease 
burden of rotavirus infection based on a methodology developed by Havelaar et al. [3, 4] For 
HPV and varicella, models to estimate disease burden are not yet available.
The total number of reported cases per year, the selected multiplication factors and the 
estimated average annual incident cases and deaths over the period 2010-2014 for all diseases 
are provided in Table 3.1. Table 3.2 gives a comprehensive overview of the national burden 
estimates for each of the diseases investigated, reporting several measures (Years Lived with 
Disability (YLD) per year, Years of Life Lost (YLL) per year, DALYs/year, DALYs per 100 infections).
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The estimated average annual burden for new cases for the period 2010-2014 is depicted in 
Figure 3.1. For poliomyelitis, the estimated disease burden was zero because there were no 
cases reported in this period. For diphtheria, mumps, tetanus and rabies, the disease burden 
was estimated to be very low, while the highest burden was estimated for invasive 
pneumococcal disease, followed by pertussis, measles and rotavirus infection.
The relationship between individual-level burden (DALYs/100 infections) and population-level 
burden (DALYs/year) is depicted in Figure 3.2. Mumps has a relatively low burden at both the 
population and the individual levels. Rotavirus infection and pertussis have a relatively low 
burden at the individual level, whereas the disease burden at the population level is rather 
high due to the high incidence. In contrast, rabies, tetanus and diphtheria have a relatively high 
burden at the individual level, but a low burden at the population level due to the limited 
number of cases.
Compared with the disease burden estimated for the earlier period of 2007-2011 reported in 
the State of Infectious Diseases, there are some notable differences:
• The measles burden is higher because of the measles outbreak that occurred in 2013/2014 
and mainly affected unvaccinated orthodox reformed individuals.
• The pertussis burden is higher because of the epidemics in 2012 and 2014, in which the 
highest number of cases were notified since the introduction of mandatory notification in 
1975. Furthermore, a different methodology was used to derive the multiplication factor. 
This improved methodology estimated a higher average annual incidence of symptomatic 
infection, mainly due to higher symptomatic probabilities estimated for adults (40% and 
35% for persons aged 20-59 and ≥60 years, respectively), compared with the symptomatic 
probability previously applied for all cases >9 years (25%).
• The rubella burden is higher because there was a single case of congenital rubella, which can 
lead to severe lifelong sequelae.
It must be noted that the total disease burden for pneumococcal disease, meningococcal 
disease and Haemophilus influenzae infection is higher than presented here because we limited 
our analyses to invasive disease. Finally, our analyses only reflect the burden of new cases of 
acute hepatitis B infection in the period 2010-2014, which means that the disease burden of 
(chronic) hepatitis B cases infected prior to this period is not included.
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3.3 Tables and Figures
Table 3.1 Total number of reported new cases in the years 2010-2014, multiplication factors 
(MFs) chosen to adjust for underestimation, and the estimated average annual number of new 
infections (averaged over the period 2010-2014 and adjusted for underestimation) and 
deaths, per disease.  
Disease Total number of reported  
new cases
MF(s) chosen
using Uniform or Pert 
distribution
Estimated annual 
number 2010-2014
2010 2011 2012 2013 2014 Infections Deaths
Diphtheria 0 1 1 0 1 UE: 1d 0.6 0.02
Hepatitis A 262 125 121 109 105 See Havelaar et al.[3, 4] 711 2
Hepatitis B 
(acute)
199 159 174 145 141 UA: 1.33c
UR: Uniform (1.20,1.22)c
894 11
Invasive 
Haemophilus 
influenzaea
143 139 140 159 160 UE: Uniform (1.05,1.20)c 167 13
IMDa 137 101 98 116 83 UE: 1.05c 112 12
IPDb 2252 2496 2472 2592 2152 UE: Uniform (1.05,1.20)c 2,692 404
Measles 15 51 10 2688 140 UE: Pert(8.44,11.21,15.02)e 6,612 24
Mumpsa 569 614 397 205 39 UE: Pert(1.55,1.79,2.13)f 659 0.005
Pertussisa 3733 5450 13853 3422 8575 UE: Pert(23,41,66) (<1 yr)g
 Pert(17,25,34) (1-4 yrs)
 Pert(16,26,39) (5-9 yrs)
 Pert(6,10,15) (10-19 yrs)
 Pert(37,47,59) (20-59 yrs)
 Pert(49,69,96) (60+ yrs)
250,038 33
Poliomyelitis 0 0 0 0 0 - 0 0
Rabies 0 0 0 1 1 UE: 1c 0.4 0.4
Rotavirus 5,834 3,947 3,363 3,913 1,607 See Havelaar et al.[3, 4] 284,906 44
Rubella 0 3 1 57 2 UE: Pert(8.44,11.21,15.02)e
(MF measles used as proxy)
143 0.2
Tetanus 1 6 2 1 0 UE: Uniform(1.0,1.41)c 2 0.2
UA = under-ascertainment, UR = under-reporting, UE = underestimation (UA + UR combined), IMD = invasive meningococcal disease, 
IPD = invasive pneumococcal disease
a Cases with unknown age and/or sex were imputed using the univariate method.
b Corrected for 25% coverage of the sentinel surveillance system.
c Same multiplication factor as used in State of Infectious Diseases in the Netherlands, 2013 [1].
d No multiplication factor available.
e New multiplication factor based on random effects meta-analysis of data from measles outbreaks in 1999/2000 [5] and 2013/2014 
(preliminary data).
f New multiplication factor based on random effects meta-analysis of data from mumps outbreaks in 2009/2010 [6] and 2012 [7].
g New multiplication factor derived by evidence synthesis approach [8].
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Table 3.2 Estimated average annual burden in the period 2010-2014 for new cases in this 
period: mean (with 95% uncertainty intervals) YLD/year, YLL/year, DALYs/year, and DALYs/100 
infections. 
 
Disease YLD/year YLL/year DALYs/year DALYs/100 
infections
Diphtheria 0.01 0.48 0.49 81
(0.01-0.01) (0.39-0.56) (0.40-0.57) (67-95)
Hepatitis A 42 75 117 17
(29-66) (45-124) (76-187) (13-21)
Hepatitis B 
(acute)
204 198 402 45
(203-205) (178-216) (382-421) (43-47)
Invasive  
H. influenzae
113 370 482a 289
(103-123) (347-392) (458-508) (275-304)
IMD 53 682 736b 654
(43-65) (551-834) (593-898) (596-709)
IPD 138 8,608 8,746 325
(136-140) (8,098-9,109) (8,237-9,248) (307-343)
Measles 157 1,648 1,805 27
(139-176) (1,182-2,128) (1,336-2,290) (20-34)
Mumps 3.3 0.3 3.6 0.5
(3.1-3.4) (0.2-0.4) (3.4-3.8) (0.5-0.6)
Pertussis 2,626 1,711 4,337 1.7
(2,520-2,733) (1,532-1,915) (4,087-4,605) (1.7-1.8)
Poliomyelitis 0 0 0 n.a.
Rabies 0.01 15 15 3,729
(0.01-0.02) (15-15) (15-15) (3,729-3,729)
Rotavirus 1,027 512 1,539 0.51
(340-2,234) (393-658) (837-2,752) (0.32-0.95)
Rubella 114 19 133 93
(91-140) (15-23) (106-162) (74-113)
Tetanus 0.05 5.0 5.1 210
(0.05-0.06) (4.6-5.4) (4.6-5.5) (199-221)
YLD = Years Lived with Disability, YLL = Years of Life Lost, DALYs = Disability Adjusted Life Years, IMD = invasive meningococcal disease, 
IPD = invasive pneumococcal disease
a  Proportion caused by the vaccine-preventable type b: 29%,
b Proportion caused by the vaccine-preventable type C: 3%; proportion caused by type B: 82%.
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Figure 3.1 Estimated average annual burden in the period 2010-2014 for new cases in this 
period, with the Years Lived with Disability (YLD) and Years of Life Lost (YLL) components 
shown separately. 
Note 1: red lines indicate 95% uncertainty intervals. 
Note 2: for the three invasive diseases, there was only a vaccine available against certain serotypes in the period 2010-2014: Haemophilus influenzae 
serotype b (Hib), meningococcal C and pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and, from 2011 onwards, also serotypes 1, 5, 7F.
0 
1000 
2000 
3000 
4000 
5000 
6000 
7000 
8000 
9000 
Di
ph
th
eri
a 
He
pa
tit
is 
A i
nf
ec
tio
n 
He
pa
tit
is 
B i
nf
ec
tio
n (
ac
ut
e) 
Inv
as
ive
 Ha
em
op
hil
us 
inf
lue
nza
e i
nf
ec
tio
n 
Inv
as
ive
 m
en
ing
oc
oc
ca
l d
ise
as
e 
Inv
as
ive
 pn
eu
mo
co
cca
l d
ise
as
e 
Me
as
les
 
Mu
mp
s 
Pe
rtu
ssi
s 
Po
lio
my
eli
tis
 
Ra
bie
s 
Ro
tav
iru
s i
nf
ec
tio
n 
Ru
be
lla
 
Te
tan
us
 
D
A
LY
s/
ye
ar
 
YLD YLL 
Diphtheria 
Hepatitis A
infection   
Hepatitis B
infection
(acute)  
Invasive Haemophilus
influenzae infection    
Invasive
meningococcal
disease
Invasive
pneumococcal
disease     
Measles 
Mumps 
Pertussis 
Rabies 
Rotavirus
infection
Rubella 
Tetanus 
0 
0 
1 
10 
100 
1000 
10000 
0 1 10
 
10
0 
10
00
 
10
00
0 
D
A
LY
s/
10
0 
in
fe
ct
io
ns
 
DALYs/year 
Surveillance and developments in 2014-2015   |  43
Figure 3.1 Estimated average annual burden in the period 2010-2014 for new cases in this 
period, with the Years Lived with Disability (YLD) and Years of Life Lost (YLL) components 
shown separately. 
Note 1: red lines indicate 95% uncertainty intervals. 
Note 2: for the three invasive diseases, there was only a vaccine available against certain serotypes in the period 2010-2014: Haemophilus influenzae 
serotype b (Hib), meningococcal C and pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and, from 2011 onwards, also serotypes 1, 5, 7F.
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Figure 3.2 Ranking of diseases by estimated average annual burden at population (DALYs/year) 
and individual level (DALYs/100 infections) in the period 2010-2014; poliomyelitis could not be 
included because there were no cases reported in this period. 
The area of each bubble is proportional to the average number of estimated annual cases  
(100 cases were added to each bubble to aid visibility). 
Note 1: both axes are on a logarithmic scale. 
Note 2: blue bubbles = included in NIP, orange bubbles= not included in NIP. 
Note 3: for the three invasive diseases, there was only a vaccine available against certain serotypes in the period 2010-2014: Haemophilus influenzae 
serotype b (Hib), meningococcal C and pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and, from 2011 onwards, also serotypes 1, 5, 7F.
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4 
Acceptance of vaccination 
and communication
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4.1 Key points
• The acceptance of vaccination will be monitored using a system consisting of 
information from the public, professionals and social media.
• RIVM has started to conduct research on the perception of vaccines not included in a 
public vaccination programme in order to be able to develop communication materials 
for the public and professionals to help them make a well-considered decision on 
whether to vaccinate or not.
• The intention to vaccinate against HPV was lower among groups originating in Surinam, 
the Netherlands Antilles and Aruba (47%), the Middle East and North Africa (30%), and 
Sub-Saharan Africa (37%) compared with the indigenous Dutch group (61%).
• Clinical symptoms, vaccine effectiveness and mortality are relevant in the decision-
making process of older adults.
• Behavioural inoculation seemed not to be an effective strategy to induce resistance to 
myths on the topic of HPV vaccination.
4.2  Acceptance of vaccination 
The average vaccination coverage in the Netherlands is high (95%). To prevent outbreaks of 
infectious diseases, it is essential that this level be sustained. The RIVM, therefore, performs 
research to gain insight into factors that are associated with the intention to vaccinate and 
aims to monitor the trust in vaccination among the public and professionals. This information 
will be used to strengthen communication about the NIP and to perform research in this area 
in order to keep the vaccination coverage high. A brief description of new results from various 
studies is given below.
4.2.1 Monitoring system for acceptance of vaccination
The four-year SOR (Strategic Research RIVM) project (S/210086 ‘Setting-up monitoring system 
NIP’) has resulted in a proposal to set-up a monitoring system for the acceptance of vaccination 
among parents and child vaccine providers (see link to thesis of Irene Harmsen: http://
digitalarchive.maastrichtuniversity.nl/fedora/get/guid:072c7383-8a0a-4d67-87cb-615c3217b5f5/ASSET1) 
[1]. This proposed monitoring system will be evaluated and implemented in the coming years.
4.2.2 HPV vaccine acceptability among parents and their daughters in a multi-ethnic city,  
 Amsterdam
Ethnic groups that may benefit most from the HPV vaccination have a lower acceptance and 
uptake of the HPV vaccine than the indigenous Dutch population. Research that provides 
estimates on HPV vaccine acceptance and uptake, and the factors associated with HPV vaccine 
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acceptance and uptake in these groups is needed for the design of effective public health 
interventions.
In Amsterdam, a multi-ethnic city, we invited all girls and their parents/guardians to participate 
in a study on HPV vaccine acceptance. The invitation was restricted to parents/guardians of 
girls that were invited for the HPV vaccination in 2014. The analyses of the questionnaire data 
on girls are not yet finished. In total, 33% of the parents/guardians, mostly mothers, 
completed the questionnaire on HPV vaccine acceptance. The ethnicities of respondents were 
grouped by region-of-origin: parents/guardians from (i) the Netherlands, (ii) Surinam, the 
Netherlands Antilles and Aruba, (iii) the Middle East and North Africa, (iv) Sub-Saharan Africa, 
(v) Europe, and (vi) Other. Among the participating parents, the intention to have their 
daughter vaccinated against HPV was high in the Dutch group (61%, indicating they certainly 
wanted to vaccinate their daughter against HPV), and lower in the other groups: 47% in the 
Surinamese group, 30% in the group with origins in the Middle East and North Africa, 37%  
in the group originating in sub-Saharan Africa, 59% among those originating from other 
European countries and 52% in Others. This intention was significantly lower in the first  
three groups compared with the Dutch group. Lower intention-to-vaccinate against HPV  
in non-Dutch ethnicities in Amsterdam can be largely explained by differences in crucial 
social-psychological factors between ethnic groups. More in-depth analyses are planned to 
determine the most important social-psychological factors and to discuss possible 
interventions for increasing vaccine uptake in these risk groups.
4.2.3 Interventions to increase vaccine uptake 
4.2.3.1 Interactive web-based, tailored education promoting the acceptability of HPV vaccination among the  
 mothers of invited girls
This year a randomised controlled trial has been conducted to examine whether an interactive 
web-based, tailored Decision Aid (DA) is an effective tool for mothers to help them make an 
informed decision about the HPV vaccination of their daughter and whether exposure to this 
communication results in a higher vaccination uptake compared with the education usually 
provided. The study took place between January and March 2015 before the first HPV 
vaccination round. Mothers of girls to be invited for the HPV vaccination in 2015 received an 
invitation to participate in the study via Praeventis and via Internet panels. Those who gave an 
informed consent to participate in the study were randomized into one of the following 
conditions: experimental (i.e. a link to the tailored DA) or control group (i.e. no information).
The DA consisted of a website providing tailored feedback on the following HPV vaccination 
themes: facts and rumours on the vaccination, vaccine effectiveness, risk of getting HPV and 
cervical cancer, what other mothers do, side effects of the vaccination, protective methods for 
cervical cancer, the developmental stages from HPV to cervical cancer. Furthermore, mothers 
were able to weigh the pros and cons of the HPV vaccination in a decisional balance. Mothers 
were guided through the DA by means of two virtual assistants; a mother-like assistant was 
used to help mothers navigate through the DA, and a female doctor-like assistant was used to 
deliver tailored feedback about the HPV vaccination.
More than 4,000 mothers completed the RCT study. Results are currently being examined via 
data analyses and are expected in 2016.
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4.2.4 The effect of media attention on the use of injection needles that possibly contain  
 glue and/or plastic particles on the vaccination intention of mothers of girls to be  
 invited for the HPV vaccination
This year data has been collected by means of a Randomized Controlled Trial (RCT; see Section 
4.2.3 for information) among mothers of girls to be invited for the HPV vaccination. This data 
included attitudes and intentions towards the HPV vaccination. At the start of the HPV 
vaccination campaign in March 2015, media messages appeared about the use of injection 
needles that possibly contain glue and/or plastic particles, and the consequences of this for 
human health. These injection needles were also used in the NIP. The government decided to 
stop the use of these injection needles until further research indicated they were safe. An 
experiment was therefore conducted on the effects of media attention on the attitudes and 
intentions of mothers regarding the HPV vaccination of their daughter. This experiment was 
performed among a subsample of the afore mentioned RCT (Section 4.2.3). Of the invited 
mothers (N = 462), 348 (75%) completed the third survey. Results are currently being examined 
via data analyses and are expected in October 2015.
4.2.5 Determinants of students’ willingness to accept a MMR booster vaccination during a  
 mumps outbreak
In 2012, during the mumps epidemic, university students filled in a questionnaire developed to 
assess their willingness to accept a MMR booster vaccination [2]. Of these participants, 60% 
would be willing to accept the hypothetical booster vaccination. Especially those students who 
perceived mumps as a serious disease, who expected the vaccination to prevent individual 
illness and who believed their own vaccination would help stop the epidemic were willing to 
accept an extra vaccination.
4.2.6 Maternal pertussis vaccination
Pertussis vaccination during pregnancy has been implemented in several countries (the United 
States, the United Kingdom, Belgium) with good effectiveness and no adverse safety signals to 
date [3-5]. In the Netherlands, van Lier et al. conducted a questionnaire survey to assess 
parental attitudes towards the implementation of new vaccines in the NIP, e.g. varicella 
vaccination [6]. Part of this survey was to measure the acceptance of pertussis vaccination 
during pregnancy (unpublished data). Sixty-one per cent of the participating parents (n=491) 
said they would accept pertussis vaccination during pregnancy if this would protect their infant 
against whooping cough. A slightly higher percentage of participants (64%) would accept 
maternal pertussis vaccination directly after birth to protect the newborn, while 55% of the 
participants would vaccinate their newborn directly after birth for protection.
4.2.7 Vaccines not included in a public vaccination programme
RIVM has started to conduct research on the perception of vaccines not included in a public 
vaccination programme (e.g. chickenpox, gastroenteritis caused by rotavirus infection and 
shingles) in order to be able to develop communication materials for the public (e.g. children, 
adults and the elderly) and professionals (e.g. child vaccine providers, general practitioners, 
paediatricians) to help them make a well-considered decision on whether to vaccinate or not. 
At the moment, there is little information on these vaccines, which might be one of the 
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reasons for underutilisation [7]. Research will consist of literature searches and qualitative and 
quantitative studies.
4.2.8 Acceptance of vaccination among Dutch older adults
Insight into the determinants that older adults take into account in their vaccination decision-
making process is crucial to provide them with adequate information and to predict the uptake 
of vaccines in this specific group. Much information is already known about the different 
factors that are important; but there is a lack of knowledge on the relative importance of these 
factors. A discrete choice experiment was conducted to obtain this information. A set of two 
choices each is presented to the respondents, with each choice consisting of a vaccine 
containing different characteristics. In our experiment, the clinical symptoms, mortality rate of 
the infectious disease, the susceptibility for a certain disease, the vaccine effectiveness, side 
effects of the vaccine and the number of vaccinations needed varied between the choices. 
With respondents favouring one choice over the other, vaccine preferences are revealed. 
Concerning vaccine and disease characteristics, pneumonia symptoms (vs influenza 
symptoms), 100% vaccine effectiveness (vs 50% effectiveness), 100% susceptibility (vs 1% 
susceptibility) and protection against a disease with 20% mortality (vs 1% mortality) were 
significantly revealed as vaccine preferences in the vaccination decision-making of older 
adults. Symptoms of pertussis and herpes zoster (vs influenza symptoms), side effects (mild  
vs severe) and the number of vaccinations (1 vs 2 doses) were considered less important.  
These results give leads for the communication strategies used when these vaccines are 
implemented. Expected vaccination acceptance rates were 56% for pneumococcal disease 
and 45% for both pertussis and herpes zoster vaccination.
4.3  Communication of NIP
4.3.1 Behavioural HPV inoculation experiment
Anti-vaccination messages are widespread on the Internet and might negatively influence a 
parent’s vaccination decision. 
Recently, a behavioural inoculation experiment was conducted to find out whether this is an 
effective communication strategy to induce resistance towards these negative Internet messages 
about HPV vaccination. The inoculation strategy [8] is a communication tool that posits that 
individuals can be made resistant to persuasive attacks by exposing them to weak arguments 
against their current attitude, including a refutation of these arguments (McGuire, 1961). 
An online two-phase experiment with three conditions was carried out among 390 parents 
and guardians of 12 and 13 year-old girls. Phase 1 consisted of a baseline measurement. In 
addition, during phase 1 participants in condition 1 were asked to read a message written 
according to the principles of behavioural inoculation and participants in condition 2 were 
asked to read the mini-magazine that is currently used by the RIVM to inform parents about 
the HPV vaccination. Condition 3 was the control condition, they did not receive any 
information. 
Seven days after the participants completed phase 1, participants read a persuasive attack in 
the form of an Internet message that was critical of the vaccine and filled out the follow-up 
measurement (phase 2).
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The results showed that behavioural inoculation is not an effective strategy to induce 
resistance to myths on the topic of HPV vaccination. The behavioural inoculation treatment 
was less effective than the currently used HPV mini-magazine and only slightly more effective 
than not giving any additional information to the parents. In addition, the results suggest that 
the persuasive attack was responsible for the negative attitude change among parents. This 
finding indicates that more attention needs to be paid to strategic communication 
interventions that induce resistance towards negative media messages on the topic of HPV 
vaccination.
4.3.2 Communication with the public and professionals
There is a new NIP website for the public (www.rvp.nl) and next year the website for 
professionals will be adapted. A media strategy for HPV has been developed that consists of 
an article containing objective information about the risks and benefits of HPV vaccination in 
regional newspapers in cooperation with the municipal health services, an HPV story 
incorporated into a TV series for teenagers and HPV messages on social media where 
teenagers are present (e.g. Instagram).
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5 
Adverse events
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5.1 Key points
• In 2014, Lareb received 982 reports concerning a total of 1,950 AEFI, which is a decrease 
of almost 20% compared with 2013.
• The spectrum of reported AEFI is mostly in line with previous years.
• No signals emerged indicating that vaccines used in the NIP would be unsafe.
5.2  Passive surveillance system
The enhanced passive surveillance system, managed by Lareb, receives reports of AEFI for all 
vaccines included in the NIP. 
In 2014, Lareb received 982 reports concerning a total of 1,950 AEFI (Table 5.1) [1]. Compared 
with 2013, this was a decrease of almost 20%. Of the reports, 78 (7.9%) were classified as 
serious.
Table 5.2 summarizes the adverse events per vaccination moment. The spectrum of reported 
AEFI is mostly in line with past years. The majority of the reports represent well-known AEFI 
such as fever, crying and injection site reactions. Again, the most (n=205) reported adverse 
events – ‘injection site reactions’ – occur in 4-year-old children after the administration of the 
fifth DTP-IPV vaccine (Infanrix-IPV®) with ‘extensive limb swelling’ (ELS) as an remarkable 
phenomenon (n=76). In 2013, this ELS was also reported in 11 children that received the DT-IPV 
vaccine at 9 years of age. This trend continued in 2014 (n=10). Besides that, the increase in the 
number of reports after vaccination at the age of 9 (42 in 2012 vs. 78 reports in 2013 and 108 
reports in 2014) is also remarkable. The results of a reactogenicity study on this signal are 
expected in 2016. 
In 13-year-old girls, Lareb received in 2013 fewer reports of chronic fatigue after a sudden rise 
in reports of this condition in 2012 (24 reports in 2013 vs 46 in 2012). This decline continued in 
2014 (n=13; Table 5.2). The occurrence of long-lasting fatigue will be further monitored in the 
Netherlands in two studies conducted by the RIVM and Lareb, respectively.
5.3  International developments
5.3.1 Vaccines targeting diseases included in the current NIP
5.3.1.1 DTaP-IPV-Hib-HBV
One study evaluated whether maternal Tdap vaccination during pregnancy was associated 
with increased risks of adverse obstetric events or adverse birth outcomes [2]. This retrospective 
observational cohort study showed that, in women with singleton pregnancies that ended in 
live birth, receipt of Tdap during pregnancy was not associated with an increased risk of hyper - 
tensive disorders of pregnancy or preterm births or small-for-gestational age births. However, 
a small but statistically significant increased risk of chorioamnionitis diagnosis was observed.
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A Phase IV study which assessed the safety and reactogenicity of a new DTwP-HBV-Hib vaccine 
found that this vaccine has a similar safety profile to that of Tritanrix (GSK Beecham) in Indian 
infants [3]. A comparison of DTaP and DTwP vaccines in infancy showed, however, that DTaP 
vaccines were found to cause fewer local, systemic and febrile reactions than DTwP vaccines 
[4]. In an open-label, randomized, controlled study, Iro showed that the use of different limbs 
for the administration of sequential doses does not influence the proportion of infants who 
had adverse events (AEs) [5]. Also, syringe types and needle diameter played no role in 
precipitating the AEs following DTwP immunization in children aged 2 months to 6 years [6].
Canada replaced the pre-school booster vaccination from DTaP-IPV to Tap-IPV in May 2012. 
This replacement resulted in a decline in the number of reports and AEFI reporting rates, most 
notably a substantial decrease in injection site reactions [7]. Marshall et al. showed that Tdap5, 
which is licensed for use in children beginning at 11 years of age, is as safe and immunogenic in 
10-year-olds as it is in 11-year-olds [8]. These data support the conclusion that Tdap5 is safe in 
10-year-olds. Carlsson conducted two consecutive randomised controlled pertussis booster 
trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five 
component Tdap vaccine to 5-year-olds and the second with five component or 
monocomponent Tdap vaccines at the age of 14-15 years [9]. A large swelling or redness of 
more than half of the upper arm circumference was reported in 8/475 5-year-olds and in 6/230 
15-year-olds. The frequency of AEs was nevertheless low in both preschool children and 
adolescents. The results of a Phase II trial also support co-administration of Tdap-IPV and HBV 
to adolescents and suggest that vaccination with Tdap-IPV can offer protection for 10 years 
after an adolescent booster vaccination [10]. In a phase III clinical trial, Han et al. demonstrated 
a good safety profile of a new Td vaccine in healthy adolescents [11].
Vandermeulen et al. showed that decennial booster vaccination with combined, reduced dTap 
vaccines (containing 0.5 or 0.3 mg of aluminium) are well-tolerated in young adults [12]. Similar 
results were found in a phase IV study among healthy adults [13]. A multicentre study assessed 
the safety of one dose of Tdap-IPV followed by two doses of Td-IPV in adults who had not 
received a DT-containing vaccine in the last 20 years [14]. More AEs were reported following 
vaccination with Tdap-IPV than with Td-IPV. However, both vaccines were well-tolerated. 
Mayet presented the results of a surveillance of vaccine AEs reported from 2011 to 2012 in the 
French armed forces [15]. High rates of AEs were observed for dTap-IPV (106.1 per 100,000 
doses) and MenACWY-CRM (39.3 per 100,000 doses). However, AEs appear to be relatively 
rare, particularly serious AEs, which indicates an acceptable tolerance of vaccines.
5.3.2.1 Hepatitis B
Sharma investigated the persistence of serum antibodies against hepatitis B surface antigens 
3.1-3.5 years following primary vaccination with 3 doses of HBvacPro→ in healthy adults aged 
≥50 years [16]. The safety profile of HBvacPro→ challenged with 1 dose of recombinant 
hepatitis B antigen was consistent with the well-established safety profile of the vaccine 
HBvaxPro→. Avdicova et al. showed that administration of HBV challenge dose 10-11 years 
after the 3, 5, 11-12 months primary schedule was well-tolerated [17]. In a randomised trial, the 
safety of a recombinant hepatitis B vaccine was assessed in adult dialysis and pre-dialyses 
patients [18]. There were 22 serious AEs; none were considered to be related to the study 
vaccine. Gaggar studied GS-4774, a hepatitis B virus-specific therapeutic vaccine [19]. The 
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results showed that GS-4774 was safe and well-tolerated in healthy adults with injection site 
reactions being the most frequently reported AEs. Further evaluation of GS-4774 is ongoing in 
patients with chronic HBV infection. 
Hieu et al. evaluated the safety of thiomersal-free and thiomersal-containing vaccines in 
healthy neonates [20]. Both formulations were well-tolerated although there was evidence 
that the thiomersal-free vaccine was associated with fewer local AEs. No serious AEs were 
reported during the study. However, in a hypothesis testing case-control study, Geier et al. 
found that cases diagnosed with specific delays in development were significantly more likely 
than controls to have received increased organic mercury from thimerosal-containing hepatitis 
B vaccine administered in the first, second and sixth month of life [21]. Data from a murine 
model support the concept that different components of hepatitis B vaccines may be linked 
with immune and autoimmune mediated AEs [22]. The same author analysed the medical 
records of 19 patients with chronic fatigue syndrome and/or fibromyalgia following HBV 
vaccination. The results suggest that, in some cases, these disorders can be temporally related 
to immunisation as part of autoimmune syndromes induced by adjuvants (ASIA). ASIA criteria 
were fulfilled in all patients eluding the plausible link between ASIA and the disorders [23]. 
However, current studies of ASIA are so diverse that there is currently a lack of reproducible 
evidence for any consistent relationship between adjuvant and autoimmune conditions [24]. 
The addition of a mandatory criterion requiring temporal association and clinically relevant 
adjuvant dose would allow a better definition of what constitutes a diagnosis of ASIA. For the 
NIP, these results have no consequences, since thimerosal is not used as a preservative in 
routinely recommended childhood vaccines in the Netherlands.
5.3.1.3 MMR
Several studies examined the safety of the MMR vaccine. Evidence was found that this vaccine 
is associated with already known serious AEs such as febrile convulsions [25] and anaphylaxis 
[26]. But these events are extremely rare. Also, in adults no new or unexpected safety concerns 
for MMR vaccination were detected [27]. Furthermore, other studies suggested that vaccines 
could have non-specific effects on mortality, depending on the type of vaccine. Schurink et al. 
investigated whether there are differences in gender-specific mortality among Dutch children 
according to the last vaccination received. No differences were found in gender-specific 
mortality related to the MMR ± MenC vaccination [28]. 
One study evaluated whether the safety of the MMR vaccine delivered to infants by a 
disposable-syringe jet injector was non-inferior to that administered by needle and syringe 
[29]. The results showed that most AEs were mild or moderate. Crying after injection was more 
frequent in the needle and syringe group, and local skin reactions were more common in the 
jet injector group. Five serious AEs were judged to be causally unrelated to treatment and all 
were resolved.
5.3.1.4 Meningococcal C disease
Several phase III studies demonstrated the safety of a single dose of the MenACWY-CRM 
vaccine in different age-groups [30-34], or administered concomitantly with a hepatitis A  
and/or B vaccine [35] or 4CMenB vaccine [36]. When given as a booster, 5 years after the initial 
vaccination, also no safety concern was raised [37], suggesting that 5 years may be an 
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appropriate interval to revaccinate children. A two-dose series of MenACYW-D given 
concomitantly with the DTaP-IPV-Hib booster dose at 18 months of age also demonstrated a 
good safety profile [38]. A similar result was found for children primed with three doses of 
HibMenCY-TT, who then received a single dose of MenACWY-TT or a fourth dose of 
HibMenCY-TT [39]. These data provide support that MenACWY-TT, given with or without the 
fourth scheduled dose of DTaP, could be administered as an alternative to a fourth dose of 
HibMenCY-YY in the second year of life. In such a case, the fourth Hib dose should be 
administered as either a monovalent or combination Hib vaccine. 
The routine booster DTaP has an acceptable safety profile when co-administrated with the 
MenACWY-TT vaccine in HibMenCY-TT-primed toddlers [40]. The CRM or TT-conjugated 
MenACWY vaccine in teenagers primed with different meningococcal conjugate vaccines at 
pre-school age were also well-tolerated with no attributable serious AEs [41]. In laboratory 
workers, no safety concerns were reported for the Hib/MenC-TT vaccine, with minor local 
reactions being reported by 21 % of the subjects [42]. This provides evidence that this vaccine 
may be used for providing protection in an occupational setting. 
Two phase II studies assessed the safety and reactogenicity of investigational formulations of 
meningococcal serogroups ABCWY vaccines [43, 44]. Both formulations had acceptable 
reactogenicity profiles, with no safety concerns identified. In another phase II trial, the safety 
of a heptavalent combination vaccine administered to infants at 2, 4 and 12 months of age was 
compared with those of licensed control vaccines [45]. No differences in safety and 
reactogenicity profiles were detected between the groups.
5.3.1.5 Pneumococcal disease
A post-licensure study which was conducted to assess the safety of 7-valent pneumococcal 
vaccination (PCV7) in catch-up regimes in previously unvaccinated older infants and young 
children in China demonstrated the safety of this vaccine [46]. A new heptavalent conjugate 
vaccine (PCV7-TT) was also well-tolerated and was as safe as a 10-valent pneumococcal 
vaccine (PCV10), which was used as a control vaccine [47]. PCV10, co-administered with routine 
childhood vaccines, were also shown to be safe in infants [48-50] and in a two-dose 10valent 
pneumococcal, nontypeable Haemophilus influenza protein D conjugate vaccine (PHiD-CV) 
catch-up regimen in the second year of life [51].
In an analysis of paediatric spontaneous reports, Trotta observed a trend towards increased 
risk of neurological events or convulsions following 13-valent pneumococcal vaccination 
(PVC13) used in routine practice, although, given the methodological limitations, these findings 
cannot be conclusive and require further investigations [52]. Wysocki found that, in 3 catch-up 
schedules with PCV13, a trend was present towards greater local tenderness with increasing 
age and subsequent dose administration, although, when comparing the three schedules, 
similar tolerability and safety profiles were found [53]. PCV13 was also well-tolerated as a 
follow-on dose in children previously vaccinated with 4 doses of either PCV7 or PCV13 [54].  
A phase III trial showed that the addition of polysorbate 80 (P80), a non-ionic detergent used 
to solubilise proteins, to PCV13 did not adversely affect PCV13 safety when compared with 
vaccine formulated without P80 [55]. 
An observational study among the elderly showed a good safety and tolerability of PCV13 in 
routine clinical practice, further confirming the evidence coming in from clinical trials in the 
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same age-group [56, 57]. In HIV-infected adults, paediatric patients with inflammatory  
bowel disease and children with sickle-cell disease previously vaccinated with 23-valent 
pneumococcal polysaccharide vaccine (PPSV23), PCV13 was shown to be safe [58-60].  
A three-dose regimen of PCV13 followed by one dose of PPSV23 was well-tolerated in 
pneumococcal vaccine-naïve, HIV infected individuals [61] and in patients after hematopoietic 
stem cell transplant, although dose 4 was associated with increased local and systemic 
reactions [62].
In an open-labelled randomised study among elderly people aged 80 or older, PPSV23 and 
PCV7 were tolerated without any severe adverse events, although adverse reaction such as 
redness and localised swelling were more common in the PCV7 group [63]. The PPSV23 also 
had a good tolerability in 2 to 70 year-old healthy people [64] and in juvenile idiopathic 
arthritis patients [65]. When co-administrated with an adjuvanted trivalent inactivated 
influenza vaccine, local and systemic AEs were more common in subjects receiving PPSV23 and 
influenza vaccination simultaneously, compared with those receiving the influenza vaccine 
alone [66].
New vaccines are being developed to provide broader protection against pneumococcal 
disease. Investigational vaccine formulations containing detoxified pneumolysin (dPly) and 
pneumococcal histidine triad D (PhtD) were well-tolerated when administered to healthy 
adults as stand-alone protein vaccine or combined with PHiD-CV conjugates [67]. A 15-valent 
pneumococcal conjugate vaccine was evaluated in healthy adults. PCV15 displayed an 
acceptable safety profile, although higher frequencies of erythema, swelling and myalgia were 
reported among PCV15 versus PCV7 recipients [68].
5.3.1.6 HPV
Several studies were conducted into the safety of HPV vaccines. An acceptable safety profile 
was reported for the bivalent HPV vaccine (HPV2) up to 4 years after the first vaccination [69]. 
Also, the quadrivalent HPV vaccine (HPV4) was generally well-tolerated [70], although the 
reporting rates of syncope or loss of consciousness and seizures were higher for the HPV4 
vaccine than for other vaccines given in adolescence [71]. When given as a booster, both 
vaccines were shown to have an acceptable safety profile [72]. Comparing the safety of 2 doses 
of the bivalents HPV vaccine vs. 2 or 3 doses of the quadrivalent HPV vaccines in girls aged 9-14 
years showed that the reactogenicity and safety were in line with the known profile of each 
vaccine [73]. However, there was a tendency towards a higher incidence of local injection site 
reactions in girls administered 2 doses of the bivalent vaccine than was the case in those 
administered 2 or 3 doses of the quadrivalent vaccines. Also, in HIV-infected adolescents, 
HPV4 was generally safe and well-tolerated [74], and bivalent HPV vaccine was well-tolerated 
in juvenile idiopathic arthritis patients [75]. Post-licensure monitoring data with a follow-up of 
up to 9.4 years post-vaccination indicates that both vaccines are safe [76-80]. This is confirmed 
in a review about the safety of HPV vaccines [81]. Furthermore, in women older than the main 
population for prophylactic HPV vaccines, HPV4 and the bivalent HPV vaccine had a clinically 
acceptable safety profile [8285].
However, along with the introduction of the HPV vaccines, several cases involving the onset of 
exacerbations of autoimmune diseases following the vaccine shot have been reported in the 
literature and pharmacovigilance databases. In the past year, several studies were conducted 
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into the relationship between HPV vaccines and autoimmune diseases. In a case report, 
Poddighe described a girl with pseudo-neurological syndrome that occurred shortly after the 
administration of the bivalent HPV vaccine [86]. It was supposed to be ASIA, given the 
temporal link with vaccination and the presence of anti-phospholipid autoantibodies. No 
causal relationships were found between HPV4 and demyelinating diseases [87] nor between 
bivalent HPV and migraine [88], although in the latter study the number of cases was low. 
Pellegrino [89] analysed comprehensively all case reports and studies dealing with either the 
onset of an autoimmune disease in vaccinated subjects or the safety in patients with 
autoimmune diseases in order to define the role of the HPV vaccines in these diseases and 
hence their safety. They concluded that solid evidence of a causal relationship was provided in 
a few cases in the examined studies and the risk vs. benefit of vaccination has still to be solved. 
So, although there is no evidence of statistical association with many post-vaccination events, 
the ongoing vigilance with respect to the safety of these vaccines remains important. The 
European Medicines Agency (EMA) has started a review of HPV vaccines to further clarify 
aspects of their safety profile. This review will look at available data with a focus on rare 
reports of two conditions: complex regional pain syndrome and postural orthostatic 
tachycardia syndrome. Reports of these conditions in young women who have received an 
HPV vaccine have been previously considered during routine safety monitoring. It will now be 
reviewed whether the number of cases reported with HPV vaccine is greater than would 
normally be expected. If so, the EMA will decide whether to recommend any changes to 
product information to better inform patients and health care professionals.
A nonavalent human papillomavirus (9vHPV) vaccine has been developed to prevent infections 
and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV vaccine), as well 
as 5 additional oncogenic HPV types (HPV 31/33/45/52/58). The 9vHPV and HPV4 vaccines 
showed comparable safety profiles, although the incidence of injection site swelling was 
higher in the 9vHPV vaccine group [90]. Other studies also showed that 9vHPV was generally 
well-tolerated [91-93].
5.3.2 Other possible future NIP candidates
5.3.2.1 Varicella
Four studies showed that the administration of MMRV has an acceptable safety profile in 
children 12 to 23 months of age, although a small increased risk of fever and rash [94], and 
febrile seizures following the first dose of MMRV were found as compared with MMR+V [95, 96]. 
MMRV-related injection site reactions occurred more frequently when given concomitantly 
with a hexavalent vaccine. However, the safety profile was in line with that of the individual 
Summaries of Product Characteristics [97]. Bechini et al. evaluated the impact of varicella 
vaccination on the incidence and hospitalizations due to varicella and its complications in the 
period 2003-2012 in Italy [98]. They concluded that AEs due to varicella vaccines are rare and 
without permanent sequelae, so solid evidences in support of universal varicella vaccination 
arise from the experiences available in Italy. Macartney et al. concluded that monovalent 
varicella vaccine at age 18 months is not associated with an increased risk of febrile 
convulsions [99].
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In a phase III trial conducted to evaluate the safety and tolerability of a freeze-dried live 
attenuated Oka strain Varicella vaccine, it was shown that AEs in this test vaccine were not 
different from the control group receiving Varilrix [100]. The safety of Varilrix in adults who had 
undergone autologous hematopoietic stem cell transplantation was shown by Sasadeuasz 
[101], although Grade 3 solicited AEs that were causally related to vaccination were reported by 
44.8% of the patients after dose 1 and by 10.3% of the patients after dose 2. However, no 
major safety signals were detected.
5.3.2.2 Herpes zoster
The safety of herpes zoster vaccination was demonstrated in healthy adults [102], as well as in 
adults on chronic/maintenance corticosteroids [103]. A randomised non-inferiority clinical trial 
demonstrated that, in adults aged ≥50 years, intramuscular administration of zoster vaccine 
was well-tolerated, with fewer injection site reactions than with subcutaneous administration 
[104]. However, a case report by Bhalla et al. described the fatality of an immunocompromised 
patient who received the varicella vaccine [105]. Within 3 months of vaccination, this patient 
developed recurrent rashes with fever, malaise, weakness, hepatitis, weight loss, and renal 
failure. This syndrome was eventually determined to be associated with persistent 
disseminated zoster caused by the vaccine virus. This case illustrates the concerns about the 
use of live attenuated vaccines in immunocompromised individuals. For such patients, a 
subunit vaccine may be an appropriate alternative. A phase I/II study showed the clinically 
acceptable safety profile of an investigational herpes zoster subunit vaccine in HIV-infected 
adults [106]. A phase III study confirmed this result [107]. Although solicited reports of injection 
site reactions and systemic reactions within 7 days after vaccination were more frequent in the 
vaccine group than in the placebo group, the proportions of participants who had serious AEs 
or potential immune-mediated diseases or who died were similar in the two groups.
5.3.2.3 Hepatitis A
The result of a 5-year follow-up phase IV study showed that a single dose of live attenuated 
hepatitis A vaccine is well-tolerated in healthy children [108]. Jain et al. investigated the safety 
of a virosomal hepatitis A vaccine compared with an aluminium-absorbed hepatitis A vaccine 
[109]. The overall incidence of AEs (solicited and unsolicited) after each vaccination was similar 
in both groups, so both vaccines were well-tolerated. Van der Meeren et al. assessed the safety 
profile of the inactivated hepatitis A vaccine in healthy adults aged ≥40 years compared with 
subjects aged 20-30 years [110]. Safety profiles were found to be similar in both groups.
5.3.2.4 Meningococcal B disease
Three studies were published about meningococcal B vaccination. In the first one, Prymula et 
al. indicates that by using paracetamol prophylaxis, post-vaccination reactions are reduced 
without clinically relevant negative consequences in vaccine immunogenicity [111].
In the second one, Esposito et al., investigated whether reducing the outer membrane vesicle 
(OMV) and/or protein content influences 4CMenB reactogenicity in healthy 2-month-old 
infants [112]. Groups with no or low-dose OMV displayed slightly lower reactogenicity profiles, 
but all formulations were generally well-tolerated. However, decreasing or removing the OMV 
content had an unacceptable negative impact on the immunogenicity profile.
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5.3.2.5 Rotavirus
In general, rotavirus vaccines have a good safety profile in healthy infants [113] and in 
hospitalised infants [114]. Regarding intussusception, several studies were published which 
show that the intussusception risk after rotavirus vaccination is small and exists mainly after 
the first dose and marginally after the second and third dose [113, 115-117]. Escolano et al. 
assessed the risk of intussusception following the pentavalent rotavirus vaccine using a 
self-controlled case series [116]. They found an incidence risk ratio for the 3 to 7 day period 
compared with the risk in the 15 to 30 day period of 3.45 (95%CI 1.84-6.55), 1.63 (95%CI 
0.86-3.13) and 1.73 (95%CI 0.86-3.51) after the first, second and third dose, respectively. Similar 
results were found by Bauchau in a post-marketing monitoring study into the association 
between intussusception and a monovalent rotavirus vaccine (observed-to-expected ratio 
2.96, 95%CI 1.45-5.45 and 0.66, 95%CI 0.21-1.53 for 7 days post-dose 1 and post-dose 2, 
respectively) [115]. With a self-controlled risk interval method, Haber et al. also found in VAERS 
a significant increased risk of intussusception 3-6 days after dose 1 of a monovalent rotavirus 
vaccine (daily reporting ratio 7.5, 95%CI 2.3-24.6) [118]. The daily reporting ratio was elevated 
but not significant after dose 2 (2.4, 95%CI 0.8-7.5). Two other studies focused on a 
monovalent rotavirus vaccine did not find an increased risk [119, 120]. In France, however, 
because of three infant deaths and many serious side effects, rotavirus vaccines are no longer 
recommended for the routine immunisation of children [121]. Two of the deaths following 
vaccination were due to very severe forms of intussusception. The third death following 
rotavirus vaccination was due to necrotizing enterocolitis in an infant treated by a human 
varicella-zoster immunoglobulin. Furthermore, there were 508 notifications of side effects 
(103.8/100,000), 201 of which were serious side effects (40.9/100,000). There were also 47 
intussusceptions and, among them, 14 (29.8%) required surgical treatment. Most of them 
occurred after the first dose and the median age for post-vaccinal intussusception was 
3 months. The conclusion of the pharmacovigilance committee was that the rate of side effects 
was worrying when compared with other paediatric vaccines. It noted that the intussusceptions 
were more severe, probably, in some part, because they occurred in younger infants.
Based on post-marketing studies and post-vaccination surveillance data, the European society 
for paediatric infectious diseases recommends that prematurely born infants should be 
vaccinated according to their calendar age as recommended for full-term infants. Furthermore, 
they recommend that all HIV-infected or HIV-exposed infants should be vaccinated with oral 
rotavirus vaccine. Although specific information on many immunodeficiencies is lacking, 
infants with known severe combined immunodeficiency should not receive live rotavirus 
vaccine [122].
In the Netherlands, a recommendation by the Health Council about including rotavirus 
vaccination in the NIP is expected in the near future. Baseline incidences of intussusception 
were calculated to observe a possible increase after possible introduction (see Table 5.3 and 
Table 5.4). In comparison with other countries, the incidence of intussusception in the 
Netherlands based on International Classification of Diseases (ICD)-9 discharge codes appears 
to be slightly lower than rates reported in the neighbouring countries of Germany and 
Denmark [123-125]. Whether this reflects a truly lower incidence or incomplete coding practices 
is currently unknown. Furthermore, data on the severity of intussusception among Dutch 
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infants, including the rate of surgical procedures and resection, the occurrence of long-term 
sequelae or deaths, are currently lacking. Further research on this matter is needed.
Not only in children, but also in the elderly rotavirus may be an important causative agent of 
acute gastroenteritis. Lawrence et al. demonstrated that RV5 was generally safe and well-
tolerated in healthy adults, whereby 9% of placebo recipients and 27% of RV5 recipients 
experienced a vaccine-related adverse event of mild or moderate intensity [126]. So, further 
evaluation of RV5 as a candidate vaccine in this age group may be warranted.
5.4 Tables and Figures
Table 5.1 Number of AEFI-reports per dose and suspected vaccine(s) 
Vaccines Total 
2013
Total 
2014
2m 3m 4m 11m BMR
-0
14m 4yr 9yr 12-
13yr
Infanrix hexa® 
+ Synflorix®
497 323 145 13 72 93
Infanrix hexa® 20 63 2 51 2 8
Synflorix® 11 1 1
MMRvaxPro® 
+ NeisVac-C®
110 122 122
MMRvaxPro® 37 15 14 1
NeisVac-C® 3 3
Infanrix-IPV® 335 274 274
MMRvaxPro® 
+ DTP-NVI
78 91 91
DTP-NVI 11 16 16
Cervarix® 82 59 59
Other 42 15
Total 1223 982 148 64 74 101 139 274 108 59
 
Source: Lareb [1]
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Table 5.2 Reported adverse events per vaccination moment 
Event Total 
2014
2m 3m 4m 11m 14m 4yr 9yr 12-
13yr
Other
Death 1 1
Injection site  
reactions
447 27 26 22 50 13 227 64 15 3
Abnormal body 
temperature
391 53 22 28 55 78 88 45 15 7
Infections 45 2 0 3 5 22 3 7 1 2
Malaise and fatigue 109 26 14 4 7 13 14 8 18 5
Allergic reaction 10 1 0 4 0 3 1 0 1 0
Disorders of the 
immune system
8 1 1 0 0 3 2 1 0 0
Crying 226 58 29 31 29 36 28 8 2 5
Haematological 
disorders
2 0 1 0 0 1 0 0 0 0
Gastrointestinal 
complaints
155 25 13 9 11 23 18 27 25 4
Respiratory 
symptoms
19 7 2 3 1 1 1 2 2 0
Cardiovascular 
diseases
3 2 0 0 0 1 0 0 0 0
Muscle and joint 
disorders
50 3 1 0 5 4 9 9 17 2
Skin symptoms 190 22 9 16 20 73 26 9 8 7
Discoloured legs 27 12 3 10 1 0 0 0 0 1
Headache/dizziness 89 0 0 0 0 0 13 43 30 3
Faints 80 28 5 5 7 5 13 8 7 2
Fits 37 6 2 2 4 17 4 0 1 1
Other disorders of  
the nervous system
38 3 3 6 4 3 4 8 4 3
Other disorders 23 3 1 1 3 6 3 3 3 0
 
Source: Lareb
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Table 5.3 Baseline incidences of intussusception per 100,000 per year per age*
Age 2008 2009 2010 2011 2012 Mean
0 years 35.5 50.0 53.4 46.6 52.9 47.7
1 year 19.2 28.5 22.4 25.4 22.1 23.6
2 years 15.9 17.3 20.8 22.2 14.5 18.2
3 years 12.0 17.1 14.1 12.1 11.2 13.3
4 years 8.7 9.0 10.2 3.8 3.3 7.1
5 years 7.9 5.2 7.7 2.5 7.3 6.2
 
Data source: DHD 
* adjusted for the estimated decline for the national coverage of the Dutch Hospital Data of about 88% in 2008 to about 82% in 2012.  
Source: Statistics Netherlands (CBS) up to 2009 and Dutch Hospital Data (DHD) from 2010 onwards.
 
Table 5.4 Baseline incidences of intussusception per 100,000 per year in infants* 
Age 2008 2009 2010 2011 2012 Mean
0-2 months 7.5 19.7 14.6 20.7 13.7 15.3
3-5 months 62.2 69.0 102.4 51.8 76.9 72.5
6-8 months 49.8 49.3 36.6 93.2 74.2 60.6
9-11 months 22.4 61.6 61.0 20.7 46.7 42.5
 
Data source: DHD 
* adjusted for the estimated decline for the national coverage of the Dutch Hospital Data of about 88% in 2008 to about 82% in 2012.  
Source: Statistics Netherlands (CBS) up to 2009 and Dutch Hospital Data (DHD) from 2010 onwards.
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6.1  Diphtheria
F.A.G. Reubsaet, G.A.M. Berbers, E. Swart, D.W. Notermans, N.A.T. van der Maas
6.1.1 Key points
• Both in the calendar year 2014 and in 2015 up to week 22, one case of diphtheria,  
both cutaneous, was reported in the Netherlands.
6.1.2 Epidemiology
In 2014 and in 2015 up to week 22, two diphtheria notifications were received (Figure 6.1.1).
6.1.3 Pathogen
In 2014 and in 2015 up to week 22, the RIVM received one Corynebacterium ulcerans and eleven  
C. diphtheriae strains, all with the suspicion of cutaneous diphtheria. Two strains were 
diphtheria-toxin-PCR and Elek-test positive. Both patients had travelled abroad (Ethiopia and 
Indonesia, resp.), one was vaccinated, one was not.
6.1.4 Research
Routine surveillance through mandatory notification is in place for signal detection. Results of the 
PIENTER 2 study indicate long-term protection against diphtheria provided by the NIP, although 
antibody levels decline after vaccination. Two susceptible groups were identified.  
As a result of natural waning immunity, a substantial proportion of individuals born before the 
introduction of diphtheria vaccination in the NIP lack adequate levels of diphtheria antibodies. 
Susceptibility is highest among strictly orthodox Protestants due to a lack of vaccination.
6.1.5 International developments
No relevant international developments have occurred in 2014 and 2015.
6.1.6 Tables and Figures
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Figure 6.1.1 Diphtheria notifications per year for 1940-1960 and 1961-2015* 
* reports up to week 22, 2015 are included
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6.2  Pertussis
N.A.T. van der Maas, A.K. Lugnér, A.W.M. Suijkerbuijk, E.A. van Lier, A. Buisman, G.A.M. Berbers,  
C.A.C.M. van Els, H.E. de Melker, M. van Gent
6.2.1 Key points
• Epidemic peaks of pertussis occur every two years; i.e. the incidence of pertussis 
notifications increased in 2014 (55 per 100,000) compared with 2013 (20 per 100,000).  
The incidence of pertussis notifications was not as high as in 2012 (83 per 100,000), 
which was the largest number since 1976 reported during a large epidemic. 
• Since the introduction of acellular pertussis in the primary series, the vaccine effectiveness 
of the infant vaccinations has remained high until the preschool booster dose. 
• The estimated vaccine effectiveness of the preschool booster dose remains high for about 
4-5 years. Thereafter, vaccinated children become more easily infected with Bordetella pertussis.
• A Dutch study on the acceptance of new vaccinations in the NIP showed that about 
60% of parents intended to accept pertussis vaccination during pregnancy.
• The prevalence of pertactin-deficient (i.e. a component of acellular vaccines) strains was 
10% in 2014, compared with 8% in 2013. In 2015, up to August, prevalence increased to 21%.
6.2.2 Epidemiology
6.2.2.1 Disease
Following a very low incidence of notifications in 2013, numbers in 2014 increased again (Figure 
6.2.1). A slight decrease in notifications was seen in the first quarter of 2015. For age categories 
up to five years of age, incidence rates for 2014 were higher than in 2012, the last epidemic. For 
older age groups, rates were lower (Figure 6.2.2).
The hospitalisation rate showed a similar pattern: low for 2013, followed by an increase in 
2014. Statistics Netherlands (CBS) reported no pertussis-related deaths in 2013 and one infant 
in 2014. Within the notifications, 2 deaths were reported in 2013 (1 zero-year old infant and an 
88-year-old female), 2 in 2014 (1 male infant, 1 month old, and an 11-year-old vaccinated girl). 
In 2015 up to week 25, 1 infant too young to be vaccinated was reported to be deceased within 
the notifications.
6.2.2.2 Vaccine effectiveness
In Figure 6.2.3, vaccine effectiveness (VE), estimated through the ‘screening method’ for the 
infant vaccination series, is shown. We would like to emphasize that the presented VE should 
not be interpreted as ‘true’ absolute efficacies. Data are used to study trends in VE estimations. 
In 2005, an infant combination vaccine with an acellular pertussis component was introduced 
in the NIP, resulting in an increase in the VE of the primary series for 1-3 year-olds [1]. In the first 
few years after introduction, the VE in 2 and 3 year-olds was lower compared with the current 
estimates because these children still received a whole-cell vaccine during infancy. From 2007 
onwards, the VE in 1 to 3 year-olds remained well above 80%.
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The VE for the booster dose at 4 years of age decreases after ~4 years, i.e. when children reach 
the age of 8 years, especially in epidemic years (Table 6.2.1).
6.2.3 Pathogen
Strain surveillance focuses primarily on the analysis of Bordetella pertussis antigens that are used 
in acellular pertussis vaccines: pertussis toxin (Ptx), pertactin (Prn), filamentous 
haemagglutinin, serotype 2 fimbriae (Fim2) and serotype 3 fimbriae (Fim3). Both changes in 
genotype and phenotype are monitored to identify novel antigenic variants and strains that 
are deficient in one or more vaccine components, respectively. With one exception, no major 
shifts were found compared with previous years (2010-2013). The exception concerned the 
emergence of strains that are deficient in Prn. The Prn-deficient strains were observed for the 
first time in 2010. The prevalence fluctuated between 1% and 8% in the years 2010-2013. In 
2014 and 2015 (up to August), we observed an increase to 10% and 21%, respectively. In 
countries where acellular pertussis vaccines have been used longer than they have been in the 
Netherlands, prevalences of Prn-deficient strains have been found of between 14% and 55%.  
It should be noted that in previous years, filamentous haemagglutinin (FHA)-deficient strains 
have also been detected at low prevalences (<1%). In collaboration with the Radboudumc  
(Dr. D. Diavatopoulos), the efficacy of the acellular vaccines against Prn-deficient strains 
compared with wild type strains was studied in a mouse model. The preliminary results are 
indeed indicative of a lower VE when the mouse was challenged with a Prn-deficient strain [2]. 
These results need to be confirmed in further experiments.
6.2.4 Research
6.2.4.1 Cellular and humoral immunity
In humans the immune modulating effect of currently circulating pertussis strains, including 
vaccine antigen deficient strains, on innate immune responses is being studied. So far it has 
been found that Bordetella pertussis isolates that fail to fully activate the immune response due 
to alterations in their TLR4 signalling molecules occur naturally [3]. Also, other mechanisms of 
the waning and aging of the human specific immune response to pertussis will be studied in 
greater depth using clinical samples from the ‘SKI-study’ and it’s follow-up, the ‘Imm-f@ct 
study’. To be able to focus specifically on the long-term quality of the immune response, we 
recently developed an innovative T cell method at the single-cell level [4].
In a longitudinal study, we are investigating the B and T cell memory immune responses in 
9-year-old children who have been fully vaccinated with the acellular vaccine. The children 
included in the study received Boostrix as a second booster vaccine at 9 years of age and are 
monitored up to a year after the booster vaccination (KIM-study). Results are expected next 
year. In a second study, the long-term humoral and cellular responses of adults aged 25-29 
years will be analysed after a booster vaccination with Boostrix. The participants of this 
so-called VIKING study have only been vaccinated in their first year of life with whole-cell 
vaccine. Blood has been sampled up to one year post-booster and participants will be 
followed up to 3 years post-booster. Results will be available in 2016.
In a clinical study using clinical samples from pertussis patients (SKI-study), it was found that 
the size of the specific memory B cell population induced early on after pertussis infection 
appeared to increase with age [5], while the breadth of the long-term memory T cell response 
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was found to decrease with age [6]. This indicates that various age-related mechanisms 
co-occur that may influence pertussis immunity.
Although, in general, the pertussis-specific immunological responses in 6year-old Dutch 
children seem adequate, epidemiological studies from the USA show that, as early as 4 years 
after the 5th acellular vaccination, children in the USA were infected during the last epidemic. 
This fast decrease in VE over time has also been encountered in the Netherlands, as illustrated 
in Table 5.2.1, with VE estimates ranging between 34% and 82% at 9 years of age, i.e. 5 years 
after the pre-school booster. To study the long-term pertussis-specific memory immunity, we 
have collected a longitudinal follow-up sample at more than 5 years after an extra aP pertussis 
booster vaccination of children 9 years of age who had been primed with a whole-cell vaccine 
in infancy. These samples are currently under investigation. Results are expected in 2016.
6.2.4.2 Pathogen
We also plan to compare the efficacy of two, three and five component pertussis vaccines 
against Prn-deficient strains. In theory, a five component vaccine should be more effective 
against Prn-deficient strains than two or three component vaccines. Recent results suggest 
that another vaccine component, FHA, is down-regulated in vaccinated mice. We will also 
investigate whether this affects vaccine efficacy. Finally, our work on the characterisation and 
spread of Prn-deficient strains by whole genomic sequencing, proteomics and transcriptomics 
will be continued. One of the aims of this work is to identify mutations that compensate for the 
lack of Prn production. Such mutations may lead to new, more effective vaccine components.
6.2.5 International developments
Maternal immunisation has been implemented in United Kingdom since 2012 and in Belgium 
(Flanders) since 2014. UK data show a good safety profile with no specific adverse outcomes 
observed and vaccine effectiveness estimates of 91-93% [5-7]. Preliminary data, presented at 
the EUPert-strain meeting in June 2015, point towards a possible small interference with infant 
primary series for diphtheria and Pertactin, assessed at 5 months of age. Hardy et al. also 
reported interference in infants whose mothers received a Tdap vaccine during pregnancy after 
the primary series, which was restored after a booster dose [8].
6.2.5.1 Cost-effectiveness
Thampi et al. assessed the cost-effectiveness of post-exposure prophylaxis (PEP) strategies  
for household contacts of pertussis cases in Canada [9]. Using a Markov model, 4 mutually exclusive 
strategies were examined: erythromycin, azithromycin, clarithromycin, or no intervention, stratified 
by age group of contacts (‘infant’, ‘child’, and ‘adult’). Azithromycin offered the highest quality-
adjusted life years (QALYs) in all scenarios. While this was the dominant strategy among infants,  
it produced an incremental cost-effectiveness ratio (ICER) of $ 16,963 per QALY among children and 
$ 2,415 per QALY among adults. The authors concluded that pertussis PEP is a cost-effective strategy 
compared with no intervention and plays an important role in contact management, potentially in 
outbreak situations. Azithromycin, which is generally the recommended drug in Dutch guidelines, 
proved to be the optimal strategy among all contact groups. In the Netherlands, pertussis PEP for all 
household members is recommended when unvaccinated or incompletely vaccinated infants or a 
woman in the third trimester of pregnancy is part of the household.
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Fernandez-Cano et al. performed a cost-benefit analysis of two strategies for pertussis 
prevention in infants: a cocoon vaccination strategy and the vaccination of pregnant women 
versus the current vaccination policy in Spain [10]. The number of parents needed to vaccinate 
with the cocoon strategy to prevent 1 pertussis hospitalisation would be 4,752 and to prevent  
1 death, more than 900,000. 1,331 pregnant women would have to be vaccinated to prevent  
1 hospitalisation and 200,000 to prevent 1 death. The benefit-to-cost ratio (the ratio of the 
benefits of the strategy, relative to its costs) was 0.04 for cocooning and 0.15 for vaccinating 
pregnant women. In the situation in Spain, the strategy of vaccinating pregnant women would 
be the most favourable option.
6.2.6 Tables and figures
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Figure 6.2.1 Pertussis notifications (left Y-axis) and hospitalisations (right Y-axis) per 100,000  
for 1976-2014 
Note: For 2014, the hospitalisation data are preliminary and incomplete. 
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Figure 6.2.3 Vaccine effectiveness (VE) for pertussis estimated for 1, 2 and 3 year-olds for 
2005-2014 by the ‘screening method’
Table 6.2.1 Estimates of vaccine effectiveness (VE) for pertussis of the preschool booster by 
the ‘screening method’ for 5-15 year-olds per birth cohort
Birth-
cohort/age
5y 6y 7y 8y 9y 10y 11y 12y 13y 14y 15y 16y
1998 74 68 77 73 60 - 45 - 18 - -
1999 77 70 71 75 63 - 11 3 - - -
2000 71 80 68 56 36 13 - 14 - 15
2001 82 79 71 47 49 24 5 - -
2002 86 71 51 35 34 59 - 27
2003 80 61 61 72 69 - 63
2004 84 89 67 80 82 64
2005 83 87 86 93 67
2006 93 90 82 81
2007 89 86 79
2008 85 87
2009 92
 
For some age groups, the proportion of vaccinated cases exceeded the vaccine coverage of the population (92%). Therefore, VE could not be 
estimated.
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6.3  Tetanus
N.A.T. van der Maas, A.W.M. Suijkerbuijk, R. Donken, D.W. Notermans, H.E. de Melker
6.3.1 Key points
• In the calendar year 2014 (n=0) and in 2015 (n=1) up to week 24, one case of tetanus 
was reported. 
• A bedside test for tetanus immunity could be helpful in the decision on tetanus 
post-exposure prophylaxis. 
6.3.2 Epidemiology
In 2014 and in 2015 up to week 24, one case of tetanus was notified in an 18-year-old 
unvaccinated male (Figure 6.3.1).
6.3.3 Pathogen
No isolates of Clostridium tetani were found. Clostridium tetani is rarely isolated, so the diagnosis 
mostly depends on clinical recognition. Serological diagnosis is not possible, as infection does 
not lead to an antibody response.
6.3.4 Research
In the Netherlands, the number of tetanus cases reported each year is nearly always low.  
A study into the use of tetanus post-exposure prophylaxis (T-PEP) guidelines by emergency 
departments (EDs) and general practitioners in the Netherlands demonstrated that the Health 
Council (HC) guideline on T-PEP is not always followed properly, resulting in over-immunisation 
and under-immunisation [1]. A study into the added value of a bedside test for tetanus immunity, 
the Tétanos Quick Stick® (TQS), among three EDs in the Netherlands showed that 22% of people 
who were born before the introduction of vaccination against tetanus in the NIP were not eligible 
for T-PEP according to the HC-guideline because they had a negative TQS (cut-off for positivity 
was 0.1 IU/ml), whereas this percentage was 8% amongst people born after NIP-start. These 
groups had low antibody titres and are probably not protected against tetanus. In contrast, 65% 
and 58% of the respective cohorts were eligible for T-PEP according to the HC-guideline but had 
a positive TQS, i.e. an antibody concentration above the protective level. Stricter adherence to 
the HC-guideline on T-PEP can prevent over-immunisation and decrease the risk of tetanus. 
Furthermore, the use of TQS would allow better targeting of T-PEP (van der Maas et al. submitted). 
Further research on the cost-effectiveness and the extension of the interval between consecutive 
tetanus toxoid (TT) booster doses in the Netherlands is necessary.
6.3.5 International developments
N’Diaye et al. evaluated the cost-effectiveness of using the TQS, a test for tetanus immunity 
screening for wounded patients in French emergency departments [2]. Two strategies were 
compared: a diagnosis of tetanus immunity by ‘TQS’ and a ‘Medical Interview’ (current practice). 
The outcome measures were the number of tetanus cases, life years gained and the costs from a 
84  |   The National Immunisation Programme in the Netherlands
societal perspective. The use of TQS proved to be as effective in the number of life years gained 
and less costly than ‘Medical Interview’ when applied in an emergency department to wounded 
patients with tetanus-prone wounds or aged ≥65 years. However, the use of TQS was more 
expensive compared with current practice involving patients with non-tetanus-prone wounds.
6.3.6 Tables and Figures
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Figure 6.3.1 Tetanus notifications in the Netherlands by year, 1952-2015  
Note: between 1999 and 2009, tetanus was not notifiable. For 2015 notifications up to week 24 were counted.
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6.4  Poliomyelitis
E. Duizer, W. Luytjes, H.E. de Melker, N.A.T. van der Maas
6.4.1 Key points
• In 2014 and 2015 up to week 24, no cases of poliomyelitis were reported in the 
Netherlands. 
• The temporary measures regarding the vaccination of Syrian refugee children below  
5 years of age and intensified environmental surveillance that started in November 
2013 at the first refugee entry point in the Netherlands were stopped as of April 2015. 
During this period, at least 1,283 children were vaccinated and 186 sewage samples 
were analysed. One poliovirus strain was found in a sewage sample collected at this 
refugee entry point: a Sabin 1 vaccine strain.
• Through routine enterovirus-surveillance, in July 2015 a VDPV type 3 was found in a 
young Syrian refugee. He had no clinical symptoms of polio. Follow-up of the case and 
surrounding contacts revealed no circulation of poliovirus.
• In the three polio-endemic countries (Afghanistan, Pakistan and Nigeria), reports on 
wild poliovirus type 3 have decreased substantially; In Nigeria, no cases of wild 
poliovirus have been reported since July 2014 to date.
• The WHO global action plan to minimize poliovirus facility-associated risk (GAPIII) was 
adopted at the 68th World Health Assembly, 18–26 May 2015. GAPIII aligns the safe 
handling and containment of poliovirus infectious and potentially infectious materials 
with the WHO Endgame plans.
6.4.2 Epidemiology
In 2014 and 2015 up to week 24, no cases of poliomyelitis were reported in the Netherlands 
(Figure 6.4.1).
6.4.2.1 Global situation
In 2014-2015, polio remained endemic in three countries – Afghanistan, Nigeria and Pakistan. 
In all three countries, a decrease in polio reports has been observed in 2015 relative to 2014. In 
Nigeria, no wild polio cases have been reported since July 2014 to date. In 2015 up to week 24, 
no importation of polio in non-endemic countries was observed.
Of the three strains of wild poliovirus (type 1, 2 and 3), wild poliovirus type 2 was eradicated in 
1999. No wild poliovirus type 3 cases have been reported in 2015 up to June. Case numbers of 
wild poliovirus type 1 are at the lowest level ever and circulate in Pakistan and Afghanistan 
only. No circulating vaccine derived poliovirus has been reported in 2015 up to June. In March 
2014, the WHO South-East Asia Region, including India, was certified polio-free.
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6.4.3 Pathogen
In 2014, no wild poliovirus was found during the routine surveillance activities in the 
Netherlands. In one sample collected on January 29th, 2015 at the first refugee entry point in 
Ter Apel, the Netherlands, a Sabin vaccine strain poliovirus type 1 was found. Furthermore, 
through routine enterovirus-surveillance, a VDPV type3 was found in a young Syrian refugee in 
July 2015. He had no clinical symptoms of polio. A follow-up of the case and surrounding 
contacts revealed no circulation of poliovirus.
Worldwide, vaccine-derived polioviruses (VDPVs) can still be found, mostly in 
immunocompromised children (iVDPV). In 2014, 55 cases of VDPV (all but one type 2) were 
reported, in contrast with zero VDPV cases in 2015, up to week 24.
6.4.4 Current/ongoing research
In 2015, the environmental surveillance performed in the Netherlands will be optimised and 
revalidated. We are developing poliovirus-specific molecular detection protocols to be 
included in the enterovirus detection workflow in the Laboratories of Medical Microbiology 
(MML) to allow for timely poliovirus exclusion in enterovirus positive samples.
An Indian study into the efficacy of an inactivated poliovirus vaccine showed that inactivated 
polio vaccine (IPV) compared with vaccination with exclusively oral polio vaccine (OPV) 
reduced excretion for poliovirus types 1 and 3 between 38.9 and 74.2% and 52.8 and 75.7%, 
respectively. Thus, IPV in OPV-vaccinated individuals boosts intestinal mucosal immunity [1].
6.4.5 International developments
To further support and maintain polio eradication, all countries must continue vaccination, 
with IPV replacing OPV. Furthermore, the WHO global action plan to minimize poliovirus 
facility-associated risk (GAPIII) was adopted at the 68th World Health Assembly, on 18–26 May 
2015. GAPIII aligns the safe handling and containment of poliovirus infectious and potentially 
infectious materials with the WHO Endgame plans. 
GAPIII 
1. Describes timelines and requirements to be completed in preparation for poliovirus type 2 
containment implemented throughout the poliovirus type 2 containment period and applied 
in the post-eradication and post-bivalent OPV (bOPV) phase;
2. Addresses type-specific containment of wild poliovirus (WPV) as well as OPV/Sabin polio 
vaccine viruses, consistent with the goal of sequential cessation of OPV use after type-
specific WPV eradication;
3. Balances the need for equitable access to polioviruses, e.g. for vaccine production, 
throughout the Poliovirus type 2 containment and post-eradication period, against the risk 
based on assessment findings, consequence models and management strategies; and
4. Establishes the long-term goal of minimizing the risk of facility-associated poliomyelitis in 
the post-eradication/post-bOPV era by providing continued access to safe and affordable 
IPV or Sabin-IPV and by reducing the number of facilities handling and storing polioviruses 
to a minimum while serving essential functions and meeting all required safeguards.
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6.4.6 Tables and Figures
0 
50 
100 
150 
200 
250 
19
57
 
19
59
 
19
61
 
19
63
 
19
65
 
19
67
 
19
69
 
19
71
 
19
73
 
19
75
 
19
77
 
19
79
 
19
81
 
19
83
 
19
85
 
19
87
 
19
89
 
19
91
 
19
93
 
19
95
 
19
97
 
19
99
 
20
01
 
20
03
 
20
05
 
20
07
 
20
09
 
20
11
 
20
13
 
0 
500 
1000 
1500 
2000 
2500 
19
24
 
19
26
 
19
28
 
19
30
 
19
32
 
19
34
 
19
36
 
19
38
 
19
40
 
19
42
 
19
44
 
19
46
 
19
48
 
19
50
 
19
52
 
19
54
 
19
56
 
Figure 6.4.1 Notifications of poliomyelitis in the Netherlands from 1924-1956 and 1957-2014
Wild Poliovirus & cVDPV1 Cases2, 2015
01 January - 02 June
1  cVDPV is associated with ≥ 2 AFP casese or non-household contacts. VDPV2 cases with ≥ 6 (≥ 10 for type 1) 
     nucleotides difference from Sabin in VP1 are reported here. 
2  Excludes viruses detected from environmental surveillance.
     Data in WHO HQ as of 02 June 2015
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Figure 6.4.2 Wild poliovirus cases worldwide
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6.5  Haemophilus influenzae serotype b (Hib) disease
L. Mollema, H.E. de Melker, F.R.M. van der Klis, P. Kaaijk, N.Y. Rots, A. van der Ende, G.A.M. Berbers,  
E.A.M. Sanders, L. Spanjaard
6.5.1 Key points
• The total number of invasive disease cases caused by Haemophilus influenzae serotype b 
(Hib) in 2014 (n=29) was the same as in the previous year. The incidence among 0-4 
year-olds decreased from 1.43 per 100,000 (n=13) in 2013 to 0.89 per 100,000 in 2014 
(n=8), whereas in the other age-groups, except for 65 years and older, the incidence 
increased slightly.
• Since 2006 (n=14), the number of vaccine failures of invasive Hib disease decreased to 
an average of 7 vaccine failures per year with a range of 4 to 9 vaccine failures per year.
• Since 2004, there has been a steady increase in the number of cases caused by 
nontypeable Hi strains (NTHi) (71 in 2004 to 117 in 2014).
6.5.2 Epidemiology
6.5.2.1 Hib disease
After the introduction of vaccination in 1993, the number of cases of Hib disease decreased 
from 247 in 1993 to 12 in 1999. However, in 2002-2005 the number of cases of Hib disease 
increased again, with a peak of 48 cases in 2004. Since then, the annual number of cases has 
varied between 22 and 37 cases. In 2014, the number of cases was 29 and in 2015 up to June, 
the number of cases was 13 (Figure 6.5.1). The incidence is highest among 0-4 year-olds and 
the elderly aged 65 years and older (Figure 6.5.2). The incidence among 0-4 year-olds 
decreased from 1.43 per 100,000 (n=13) in 2013 to 0.89 per 100,000 (n=8) in 2014, whereas in 
the other age-groups the incidence increased somewhat (from 0.05 per 100,000 (n=7) in 2013 
to 0.1 per 100,000 (n=13) in 2014), except for people 65 and older (from 0.32 per 100,000 (n=9) 
in 2013 to 0.27 per 100,000 (n=8) in 2014).
6.5.2.2 Nontypeable (unencapsulated) Hi (NTHi) strains
The number of cases caused by NTHi increased from 30 in 1993 to 90 in 2003, partially because 
the number of blood isolates submitted for serotyping increased. Thereafter, it decreased 
again to 71 in 2004. From 2004 to 2014, a gradual increase in the number of cases from 71 to 
117 was observed (Figure 6.5.1). In 2015, up to June, 80 NTHi cases were reported. In 2014, the 
highest incidence of NTHi was among the elderly aged 65 and older (2.06 per 100,000 (n=60)).
6.5.2.3 Hif and other Hi serotypes
In 2014, two cases of Hia, one case of Hid, three cases of Hie and 8 cases of Hif were reported. 
In 2015, up to June, one case of Hia, 4 cases of Hie and 7 cases of Hif were reported.
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6.5.2.4 Vaccine failures
In the cohorts eligible for vaccination, the number of infections due to Hib showed a peak in 
2005 (n=29), after which the number decreased until 2011 (n=7). Thereafter, it increased again 
(n=14 in 2013) and in 2014 the number of cases was at the same level as in 2012 (n=11). The 
number of vaccine failures showed a similar distribution (n=17 in 2005 and n=4 in 2011), except 
for the decrease in 2013 (n=6). In 2014, the number of vaccine failures was 7 and in 2015, up to 
June, the number of vaccine failures was 2. For 8 of the 9 vaccine failures in 2014 and 2015, up 
to June, it was known that they had no underlying disease. Five vaccine failures were in people 
under the age of five years and three were above that age.
6.5.3 Pathogen
There are no indications that the pathogenicity of Hib has changed.
6.5.4 International developments
Townsend et al. [1] performed a study to modify and optimise a serum bactericidal antibody 
(SBA) assay in order to evaluate the functional activity of Hib antibodies generated following 
Hib conjugate vaccination. The predictive protective SBA titre corresponding to a post-booster 
anti-PRP (polyribosyl-ribitol-phosphate) IgG of 1.0 mg/ml (long-term protective threshold 
derived by passive immunisation or immunisation with pure polysaccharide) was 8. The 
optimised SBA assay seemed to be specific and reproducible and correlated with anti-PRP IgG.
In England and Wales, the incidence of laboratory-confirmed neonatal invasive NTHi disease 
ranges between 2.1 and 4.8 cases per 100,000 live births, with nearly all infections occurring 
around the time of birth. Collins et al. [2] obtained detailed clinical information from all 
laboratory-confirmed cases in infants ≤ 31 days during 2009-2013 (n=118, of which 115 were 
NTHi). They found that early-onset neonatal NTHi disease was strongly associated with 
premature birth and caused significant morbidity and mortality. 
An open-label, randomised, controlled study was performed whereby eligible healthy infants 
6-12 weeks of age were randomly assigned in a 1:1 ratio to two vaccination groups: consistent 
limb (DTaP-IPV-Hib at 2, 3 and 4 months of age and PCV13 at 2, 4 and 12 months all 
administered to the right leg) or alternating limb (DTaP-IPV-Hib in the left leg at 2 months and 
in the right leg at 3 and 4 months and PCV13 in the left leg at 2 months, in the right leg at  
4 months and in the left arm at 12 months). All infants in both groups received Hib-MenC-TT 
administered in the left leg at 12 months. Results showed that anti-PRP geometric mean IgG 
concentrations (GMCs) were lower in the consistent limb group than in the alternating limb 
group at 5 months and at 12 months, and anti-TT antibody IgG GMCs were also lower in the 
consistent limb group compared with the alternating limb group at 13 months and 24 months. 
Anti-pneumococcal IgG GMCs were similar between both groups at all-time points [3]. For the 
safety results found in this study, see Chapter 5.
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6.5.5 Tables and Figures
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Figure 6.5.1 Absolute number of Haemophilus influenzae isolates per serotype, 1992-2015*  
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Figure 6.5.3 Annual number of Haemophilus influenzae type b (Hib) disease in people eligible  
for vaccination (i.e. born after April 1, 1993) and the number of vaccine failures, 2003-2015* 
(*up to June) 
Source: NRBM
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6.6  Mumps
T.M. Schurink-van ‘t Klooster, S. Gouma, S. Parkkali, N.Y. Rots, P. Kaaijk, W.L.M. Ruijs, R. van Binnendijk,  
S. Hahné
6.6.1 Key points
• The number of reports of mumps (n=40) in 2014 was low. 
• In the first five months of 2015, indications of a mumps resurgence and endemic 
transmission were encountered. 
• Most of the mumps cases in the Netherlands were caused by genotype G.
6.6.2 Epidemiology
Following the introduction of mumps vaccination in the NIP in 1987, there was a large decline 
in the incidence of mumps in the Netherlands. The first signs of an increase were observed in 
2004 with an outbreak among (mainly vaccinated) students [1]. Subsequently, an outbreak 
occurred among unvaccinated schoolchildren in the Bible Belt (2007-2009) [2]. From 2009 
onwards, a countrywide epidemic occurred that again particularly affected (vaccinated) 
student populations, with three epidemic seasons/peaks occurring up to the end of 2012 
(n=1850; Figure 6.6.1) [3]. Since 2012, the number of reported mumps cases among students 
has declined in the Netherlands. Conversely, there has been an increase in the number of 
mumps cases among non-students (>25 years of age) from non-university cities. This observed 
shift may be due to increased herd immunity among the student population. In 2013, two 
outbreaks were identified in the north-west of the Netherlands (‘Noord-Holland’), whereas the 
remaining cases were spread throughout the country.
In 2014, only 40 mumps cases were reported. Most of these cases were sporadic mumps cases 
or small clusters, which did not cause major outbreaks. This was also confirmed by genotyping 
the laboratory confirmed cases, because a high genotypic diversity was found among the cases 
tested. Fifty-three per cent were in males, the median age was 27 years (range 7-52). Sixty per 
cent were twice vaccinated, 8% once vaccinated and the vaccination status of 33% was 
unknown. Twenty-three per cent were students. One case was hospitalised, three cases were 
reported to have complications. 
In 2015, until the 31st of May, 43 mumps cases were reported (Figure 6.6.1). Sixty-three per cent 
were males, the mean age was 23 (range 12-43). Sixty-five per cent were twice vaccinated. 
Thirty-three per cent were University or higher vocational education (HBO) students and  
21% were intermediate vocational education (MBO) students. So far, two outbreak clusters 
have been identified. The first cluster is at a hockey club in the west of the Netherlands 
(‘Zuid-Holland’) and involves 11 reported mumps cases. The second cluster is linked to a pub 
and MBO college in the same area and involves 6 cases.
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6.6.3  Pathogen
Since the mumps outbreaks in 2009, the mumps virus genotype that causes most of the 
mumps cases in the Netherlands is genotype G. Besides genotyping based on the mumps virus 
small hydrophobic (SH) gene, we have expanded the typing tools for mumps virus and 
sequenced the haemagglutinin-neuraminidase (HN) gene and fusion (F) gene of a subset of 
samples. Contrary to the SH gene sequence, which only shows minor variation within 
genotype G, the nucleotide variation in the HN gene and F gene sequences is more divergent 
and enables the investigation of transmission pathways. Based on this new molecular tool, we 
were able to link the second outbreak cluster in 2015 to the first cluster, indicating a resurgence 
of mumps and an endemic transmission of the mumps virus between March and May 2015.
6.6.4  Research
6.6.4.1  Immunity in vaccinated persons
In 2014, data from a serological study carried out among mumps-exposed students were 
published, showing that no clear cut-off of immune protection could be established based on 
mumps-specific IgG concentrations. However, pre-outbreak IgG concentrations were generally 
lower in infected persons than they were in non-infected persons [4].
Data on the dynamics and functionality of mumps-specific antibody levels during a mumps 
epidemic were published in 2015 [5]. Blood samples were obtained longitudinally from 23 
clinically confirmed mumps cases, with or without a prior history of vaccination, and from 
20 healthy persons with no serological evidence of recent mumps virus infection. Mumps 
patients had significantly higher mumps-specific IgG geometric mean concentrations 
compared with healthy controls 1-2 and 7-10 months post-diagnosis. Moreover, previously 
vaccinated mumps patients had significantly higher mumps-specific IgG and neutralizing 
antibody concentrations compared with unvaccinated mumps patients. IgG and neutralizing 
antibody concentrations declined significantly between 1-2 and 7-10 months post-mumps-
diagnosis in vaccinated patients, whereas in non-vaccinated mumps patients concentrations 
where not significantly different at both time points. Other immunological mechanisms, 
including T-cell responses and neutralizing antibodies, are studied to investigate their 
contribution to immunological protection in vaccinated persons.
6.6.4.2  Severity of mumps disease and viral shedding
Twice MMR-vaccinated mumps patients have complications such as orchitis less often than 
unvaccinated patients. Furthermore, those people have mumps virus shedding in urine, which 
is a marker for a systemic mumps virus infection, less often. These findings indicate that, 
although the vaccine does not protect against mumps virus infection, MMR vaccination 
provides clinical protection to some extent.
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6.6.4.3  Genetic variability of mumps genotype G, the most prevalent genotype in mumps outbreaks
All significant mumps outbreaks since 2010, including the new 2015 outbreak, were caused by 
genotype G wild type mumps virus. The genotype classification is based on sequence analysis 
of the SH gene. However, molecular resolution of the SH gene, though internationally 
acknowledged as the first genotype standard for mumps, proved too small to detect a new 
introduction of G type mumps viruses in the population and, consequently, too small to detect 
ongoing virus transmission. Now that we have expanded our genetic analysis to other 
structural mumps genes, we have discovered a genetic variability which has increased our 
capabilities to detect virus importation and virus transmission. Further research into this 
genetic variability and extending the data input by whole genome sequencing is ongoing.
6.6.5  International developments
In many countries around the world, mumps outbreaks have occurred in recent years [6-19]. 
Jin et al. summarised the geographic and chronologic distributions of 12 mumps genotypes 
[20]. In the Western Hemisphere, genotypes C, G, H, J and K were observed. 
Several countries in Europe, including Finland and Belgium, have increased their research 
activities on the molecular, virological and immunological background of mumps vaccine 
failure. A collaborative effort between colleagues from the Belgian Scientific Institute of Public 
Health (WIV), Erasmus Medical Centre and the Centre for Infectious Disease Research, 
Diagnostics and Screening of the RIVM (RIVM/IDS) on epitope mapping has been initiated in 
2015.
Different studies on seroprevalence, carried out in different countries where mumps 
vaccination was introduced in the past, have shown a seroprevalence above 80% in different 
populations [21-23].
During an outbreak of mumps in a high school in Spain, a reduced vaccine effectiveness 
following one dose of mumps vaccine was found [24]. Fiebelkorn et al. found modest 
increased mumps virus neutralising antibodies one month and one year after a third MMR 
dose, which could decrease human susceptibility during an outbreak [25].
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Figure 6.6.1 Number of notified mumps cases by week of onset, 01/12/2009 -31/05/2015 
(n=1855)
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6.7  Measles
T. Woudenberg, R. van Binnendijk, L. Nic Lochlainn, A.W.M. Suijkerbuijk, A.S.G. van Dam, D. Klinkenberg,  
L. Fievez, N.Y. Rots, F.R.M. van der Klis, N.A.T. van der Maas, S. Hahné
6.7.1 Key points
• In the epidemic that occurred in the Bible Belt in 2013-2014, 2,700 cases were reported.  
After correcting for under-reporting (9% reported), an estimated number of 30,000 
measles infections occurred during this epidemic.
• In total, 140 cases were reported in 2014. The majority of the cases reported from 
January to March were part of the epidemic in the Bible Belt in 2013-2014. As a result of 
importations of measles cases, several other clusters emerged in the course of 2014.
• A 17-year-old was diagnosed with subacute sclerosing panencephalitis (SSPE). This 
SSPE patient had a history of having had measles at 4 years of age, during the 1999-
2000 epidemic. Four months following the diagnosis of SSPE, the patient died.
• Measles research activities in 2014 have been focused on themes and questions 
formulated in different projects that largely have emerged because of the measles 
epidemic in 2013-2014. Most projects are still ongoing.
6.7.2 Epidemiology
In 2014, 140 measles cases were reported in the Netherlands (Figure 6.7.1). In January and 
February 2014, most reported measles cases were related to the epidemic in the Bible Belt, 
which began in May 2013 [1]. The genotype in this epidemic was D8 and the last reported case 
was on 12 March 2014. This epidemic comprised of 2,700 reported cases.
Although the epidemic ended at the end of February 2014, other clusters of measles cases 
occurred throughout the Netherlands because of importations (Figure 6.7.2). These importations 
could be discriminated based on (molecular) epidemiology. Two measles clusters, caused by 
different strains of genotype B3, occurred at Amsterdam Schiphol Airport in January – April 2014 
(eight cases). These cases were linked to the measles outbreak that was ongoing in the 
Philippines. Additional clusters occurred in the province of Zuid-Holland in March-May 2014.  
The first cluster occurred among unvaccinated young infants in a day care centre (nine cases),  
a second among unvaccinated young infants at a day care centre social event (six cases but 
samples were not typed) and a third involved health care workers in a hospital (eight cases).  
The source of these clusters remains unknown but, based on genotyping results, a possible link 
with the first measles clusters around Amsterdam Schiphol Airport cannot be excluded. Lastly, 
two clusters of measles were independently reported in March and May 2014 in Zuid-Holland and 
Limburg. The sources of both importations were reported as coming from India (genotype D8). 
Most of the 140 reported cases were male patients (60%). Most cases were unvaccinated 
(69%), 36 (26%) had received at least one MMR vaccination, and the vaccination status was 
unknown for 7 (5%) reported cases. Of the vaccinated cases, 19 (53%) had been vaccinated 
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once, 16 (44%) had been vaccinated twice and one (3%) had been vaccinated three times.  
The last measles case in 2014 was reported in September. Since then, no cases have been 
reported up to June 2015.
6.7.2.1 Subacute sclerosing panencephalitis (SSPE)
In 2014, a 17-year-old male was diagnosed with SSPE [2]. SSPE is a progressive neurological 
disorder, which presents itself after a latency period of the virus from an acute measles 
infection. The SSPE case had had measles at the age of 4 during the 1999-2000 measles 
epidemic in the Netherlands. Four months following the diagnosis of SSPE, the patient died.
6.7.3 Pathogen
The measles epidemic in the Bible Belt in 2013-2014 was caused by the ‘Taunton’ genotype D8, 
which was the most prevalent genotype in Europe in 2013. Most cases reported between 
January and March 2014 were still epidemiologically linked to this outbreak and were 
genetically identified as D8.
Between January and March 2014, two variants of genotype B3 (Harare, Tonbridge) were identified 
at Amsterdam Schiphol Airport, which involved partially vaccinated and unvaccinated adults.  
These cases pointed to two separate measles virus importation events related to air travel [3]. 
While the Harare variant of genotype B3 and genotype D8 were the major genotypes reported 
in most European countries in 2014, it is the Tonbridge variant of B3 measles virus that was 
subsequently identified among an outbreak of measles cases among young unvaccinated 
infants and health care workers in the region of Zuid-Holland in March and April. This outbreak 
resulted in secondary and tertiary measles transmission. While a direct relationship between 
this outbreak and the measles cluster around Amsterdam Schiphol Airport is lacking, the 
sequence identity suggests there is a possible link between both events.
6.7.4 Research
Measles research activities in 2014 have been focused on themes and questions formulated in 
different projects that largely have emerged because of the measles epidemic in 2013-2014. 
Most projects are still ongoing. (Preliminary) results, if available, will be discussed here.
6.7.4.1 Evaluation of impact, coverage, tolerability and effects of early MMR vaccination
During the epidemic of 2013-2014, infants between 6-14 months of age were offered an early 
MMR vaccination in municipalities with MMR1 vaccination coverage below 90% and/or when 
people belonged to an orthodox reformed family.
6.7.4.1.1 Tolerability
From preliminary results, it can be concluded that the early MMR vaccination given to infants 
between 6 to 14 months is well-tolerated. Parents of 59 (6.1%) and 350 (36.4%) infants reported 
local and systemic adverse events (AEs), respectively. Lower frequencies of systemic AEs were 
found in 6-8 month-old infants, compared with 9-11 and 12-14 month-old infants. Frequencies of 
local AEs were not significantly different among the different age categories. Consequently, 
measles vaccination is a safe intervention to protect young infants against measles.
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6.7.4.1.2 Coverage
A study was conducted in 2014 to assess the uptake of early MMR during the measles epidemic 
in 2013-2014 using vaccination records from 2003-2013 in Praeventis. Over 10,000 children 
were invited for an early MMR vaccination, 6,552 (65.9%) of which received vaccination.
6.7.4.1.3 Vaccine effectiveness (VE)
Preliminary results from estimates of the VE of the early MMR vaccination suggest that 
vaccinated infants between 6 and 14 months old have a lower risk of contracting measles than 
unvaccinated infants. Vaccinated infants were 95% (95%CI: 80-98%) less likely to contract 
laboratory confirmed measles than unvaccinated infants. However, when adjusted for 
confounders related to measles exposure, this effect decreased to 73% and became 
insignificant (95%CI: 72-96%). Further investigation is needed into whether the effectiveness 
estimates reflect the protective effect of the vaccine or a difference in exposure between 
vaccinated and unvaccinated infants.
6.7.4.2  Immune responses to MMR vaccination of infants between 6 and 14 months old (EMI study)
This study was initiated during the measles epidemic in 2013-2014 and involves an 
observational study in young children who received an early measles immunisation between  
6 and 12 months of age, as well as the regular MMR immunisation at 14 months of age. The aim 
of this study is to investigate humoral and cell-mediated immunity against measles following 
this early measles immunisation and to compare this with a control group of children receiving 
measles immunisation only at 14 months of age. Based on the knowledge from literature, it is 
anticipated that both the presence of maternal antibodies and early measles immunisation 
will significantly influence vaccine efficacy and immunological outcome. Secondary objectives 
include the moderating effect on the immunogenicity of other infant concomitant vaccines 
(DTaP-Hib-HepB, Pneumo, MenC) that are routinely administered to infants between 2 and 14 
months of age as part of the Dutch NIP. The inclusion of the children is almost finalised.
6.7.4.3  Under-reporting
Measles is a notifiable disease but not all cases will consult their General Practitioner (GP), nor 
will all consultations be reported. The 2,700 cases of measles reported will therefore be an 
underestimation of the actual number of infections during the epidemic of 2013-2014. A survey 
was conducted to identify measles cases in persons up to 15 years old in a municipality with 
vaccination coverage of 80%. Self-identified cases were matched with the cases reported to 
the Dutch national surveillance system (Osiris) to estimate under-reporting. Nine per cent 
(95%CI: 6-12%) of the cases in the municipality where the study took place were reported. It 
can therefore be assumed that the number of measles infections was 11 times higher than the 
number of reported cases, so the actual number of infections during the epidemic of 2013-2014 
in the Netherlands was approximately 30,000.
6.7.4.4  Validity of measles antibody screening of personnel in the health care setting
We re-evaluated different immunoassays for assessing measles immunity among HCW, 
including multiplexed immuno assays (MIA, based on Luminex technology) - that has been 
developed for population-based serosurveys at RIVM (e.g. PIENTER). We compared these 
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assays with the plaque-reduction neutralisation (PRN) test, the best surrogate marker for 
vaccine efficacy and immune protection, and recently adopted by WHO. Commercial enzyme 
immunoassays (EIAs) failed to detect measles IgG antibodies in at least 10% of the vaccines, 
while this percentage was approximately 3% for the MIA. Negative IgG results rose up to 20% 
for those born between 1975 and 1985, pointing to an age group largely representing 
vaccinated persons from the first measles vaccination period in the Netherlands. The results 
show limitations to the usefulness of current EIAs for determining protective measles 
antibodies in persons with a vaccination history, except for MIA developed by RIVM, which 
proved much better in this context. The results have been recently published [4].
6.7.4.5  Measures taken by Dutch hospitals to prevent measles in health care personnel
A cross-sectional online survey among Dutch hospitals has been conducted to examine which 
preventive measures, in addition to hygiene and isolation measures, were taken by Dutch 
hospitals in order to prevent measles in health care personnel. The majority of Dutch hospitals 
took additional measures to prevent measles in health care personnel during the measles 
epidemic in 2013-2014, such as assessing susceptibility to measles among health care 
personnel, offering vaccination to health care personnel that are susceptible to measles and 
implementing adequate post-exposure policies. Preliminary results show that hospitals that 
consist of a single location more often had sufficient preventive measures in place then did 
hospitals that consist of multiple locations. This suggests that the development of future 
guidelines for preventing infection in hospitals can be improved by considering hospital 
characteristics.
6.7.4.6  Environmental surveillance for measles
Sewage-environmental surveillance, specifically carried out to exclude the circulation of 
poliovirus, was temporarily adopted for measles during the measles epidemic in 2013 at 
locations where vaccination coverage for both polio and measles is relatively low (schools/
villages in the Bible Belt). This was carried out as a proof of principle to investigate the 
resolution of this type of viral surveillance, both for poliovirus and for outbreaks with other 
viral ethology (e.g. norovirus). The detection of measles RNA in environmental samples was 
indeed successful and it also matched the clinical and laboratory reporting of measles in a 
temporal/geographic manner. These results will be integrated into a combined report/
manuscript on measles and polio in 2015.
6.7.4.7  Societal costs of the measles outbreak
In addition to the burden of disease, measles outbreaks have an economic impact on a society. 
Assessing the costs of the outbreak of 2013-2014 can help with planning for future outbreaks 
and optimising the allocation of public health authorities. A recently performed study showed 
that the outbreak was associated with substantial costs amounting up to approximately € 3.9 
million for 2,700 notified cases or € 1,741 per notified case. Outbreak management costs were 
the primary cost driver. This is probably due to demands for expert advice, extensive media 
attention, the registration of notified cases and additional surveillance activities. When taking 
the extent of under-reporting into account, the estimated costs of hospitalisations and 
consultations with the general practitioner would be approximately € 0.9 million higher [5].
102  |   The National Immunisation Programme in the Netherlands
6.7.4.8  Effect of vaccination on complications and the transmission of measles
The epidemic in the Netherlands provided an opportunity to investigate the effect of 
vaccination on the severity and transmission of the infection. We extracted information on 
vaccination status, complications (encephalitis, pneumonia and otitis media) and the most 
likely source(s) of infection from the national surveillance system (Osiris). A case was defined 
as having transmitted measles when it was listed as a likely source for at least one other case. 
We estimated the age-adjusted effect of vaccination on the outcomes, complications and 
transmission through logistic regression. Of 2,674 reported cases with known vaccination 
status and eligible for vaccination, 2,533 (94.7%) were unvaccinated, 125 (4.7%) had been 
vaccinated once and 16 (0.6%) had been vaccinated twice. Of all cases, 328 (13%) reported at 
least one complication, most often pneumonia (6%). Of the unvaccinated cases, 316 (13%) had 
at least one complication, compared with 12 (9%) vaccinated cases (OR 0.5 (95%CI 0.3-1)). 
None of the twice-vaccinated cases had complications. In total, 201 cases were indicated as a 
likely source. Of the unvaccinated cases, 194 (8%) were a likely source and seven (5%) of the 
vaccinated cases were (OR 0.7 (95%CI 0.3-1.5)). None of the twice-vaccinated cases was 
indicated as a likely source. Our findings suggest that vaccination has a protective effect on the 
occurrence of complications and transmission, and they support the WHO recommendation of 
a two-dose MMR vaccination schedule.
6.7.4.9  The effect of school holidays on measles transmission
The 2013-2014 epidemic occurred for a large part during the summer holidays, during which 
incidences decreased. As school closure is a public health measure often suggested for 
emerging infections, this observation provided an opportunity to obtain a good estimate of its 
effect. Preliminary results, based on subdividing the population into three regions based on 
the timing of the school holiday (South, Middle, North), suggest a total reduction in 
transmission of about 60% during the summer holidays. This would have prevented the 
measles epidemic if the virus had been introduced during summer. However, whereas 90% of 
all transmissions occurred locally during the school term, this declined to 20% during the 
holiday. This would suggest that school closure might increase the spread of infections across 
regions. At present, it is not yet clear if this is a specific summer effect (e.g. through summer 
camps) or whether this would also occur if schools were closed as a public health measure.
6.7.4.10  Research projects related to WHO
RIVM was chosen by the WHO to conduct a systematic review and critical appraisal of the 
evidence to ascertain whether the effect of a measles-containing vaccine (MCV) schedule that 
started younger than 9 months of age – in terms of immunogenicity, efficacy or effectiveness, 
the duration of protection and safety – is equal to or less than the effect of the current MCV1 
recommended at 9-12 months. This review will serve as input for the Strategic Advisory Group 
of Experts (SAGE) on immunisation, currently planned for late October 2015. 
The WHO and Centres for Disease Control and Prevention (CDC) acknowledged RIVM Luminex-
based serology (MIA) for measles and rubella seroprevalence in 2014 and intends to share and 
build this capacity in the WHO measles and rubella laboratory network. The specific aims for 
2015/2016 are to establish the MIA technique at CDC and validate the measles and rubella 
Surveillance and developments in 2014-2015   |  103
serology, and to subsequently transfer the technology to regional laboratories within the WHO 
Laboratory Network. The first agreement was reached at the WHO Labnet Meeting in Geneva 
on July 1, 2015.
6.7.5 International developments
During 2014, 3,616 measles cases were reported by 30 EU/EEA countries. Most cases were 
reported by Germany and Italy (59%). The highest notification rates were among infants under 
one year of age (38.1 cases per million population). Of the cases with known vaccination status 
(n=3240), 83% were unvaccinated. Compared with previous years, the number of reported 
cases in Europe was low [6].
6.7.6 Tables and Figures
Figure 6.7.1 Measles notifications by municipality from January 2014 to June 2015  
(n=139, one missing)
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Figure 6.7.2 Measles notifications by week of rash onset (n = 140), 1-1-2014 to 30-6-2015
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6.8  Rubella
N.A.T. van der Maas, W.L.M. Ruijs, N.Y. Rots, R. van Binnendijk, S. Hahné
6.8.1 Key points
• In the calendar year 2014 (n=2) and in 2015 up to week 25 (n=0), two rubella cases were 
reported. Those cases were not related.
• In 2013, a large rubella outbreak started in Poland. In 2014 and in 2015 up to week 25, 
this outbreak still continues, although reported numbers are decreasing.
6.8.2 Epidemiology
In the calendar year 2014 and in 2015 up to week 25, two rubella cases were reported. One case 
was an unvaccinated infant; the other was an unvaccinated male who contracted rubella in 
Indonesia.
6.8.3 Pathogen
The reported adult rubella case appeared to be infected with genotype 1E rubella virus and 
with a sequence type, which matches that of rubella viruses that were endemic in South-East 
Asia in 2014 and the epidemiological source (Indonesia). The source of infection in the infant case 
is unknown, the disease was confirmed by IgM serology; no genotyping results are available.
Genotype 2B, which is by far the most prevalent genotype reported in outbreaks on the 
European continent in recent years (according to genotype data extracted from the new  
WHO/HPA ‘Rubens’ genotype database.)
6.8.4 Research
A multidisciplinary Dutch expert group was convened to prepare a national guideline on 
rubella screening during pregnancy. In the Netherlands there is no uniform policy on rubella 
screening. Some midwives screen all pregnant women, some only risk groups and others do 
not screen at all. Given the high vaccination coverage and low incidence of rubella, screening 
of all pregnant women is not cost-effective [1]. Furthermore, there is increased discussion on 
the validity of rubella IgG tests to determine the immune status in vaccinated women, which 
needs to be further re-evaluated. The guideline is expected in 2015/2016.
6.8.5 International developments
In 2013, a large rubella outbreak started in Poland with more than 38,000 cases reported.  
The outbreak is ongoing, with over 4,500 cases reported in 2014 and 2015 up to June  
(http://ecdc.europa.eu/en/healthtopics/rubella/epidemiological-data/pages/epidemiological_data.aspx).
The WHO initiated a rubella IgG standardisation workgroup in 2013/2014, as it turns out that 
many of the currently applied commercial tests for rubella IgG screening during pregnancy no 
longer meet the criteria for providing the immune status of rubella and also because many 
women currently gain this immunity from MMR immunisation and not from natural infection. 
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Follow-up studies and recommendations for the use of serological tests for rubella are 
expected to be presented by this international group in 2015/2016.
6.8.6 Literature
1*. Lugner AK, Mollema L, Ruijs WL, Hahne SJ. A cost-utility analysis of antenatal screening to 
prevent congenital rubella syndrome. Epidemiology and Infection. 2010;138(8):1172-84.
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6.9  Meningococcal serogroup C disease
L. Mollema, H.E. de Melker, F.R.M. van der Klis, P. Kaaijk, N.Y. Rots, A. van der Ende, L. Spanjaard, S.P. Stoof, 
M.B. van Ravenhorst, E.A.M. Sanders, G.A.M. Berbers
6.9.1 Key points
• In 2014, 3 cases of meningococcal group C (MenC) disease were reported and in 2015 
(until June) 5 cases of MenC including one vaccine failure. 
• In the UK, the adolescent MenC conjugate vaccine currently recommended for 13-14 
year-olds will be replaced with the MenACWY conjugate vaccine in response to a 
continuous rise in cases of MenW since 2009. 
• In May/June 2015 there was a small outbreak of serogroup C meningococcal disease 
among men who have sex with men (MSM) in the Chicago metropolitan area.
• In France the high serogroup C invasive meningococcal disease (IMD) incidence caused 
by C:P1.5-1,10-8:F3-6:cc11 isolates and the persistence of cases linked to the men who 
have sex with men (MSM) community led to the MenC vaccination recommendation 
targeting MSM and individuals aged 25 years and older attending social venues 
associated with the gay community.
6.9.2 Epidemiology
Since the introduction of the conjugated MenC vaccine in 2002 at 14 months of age with a 
catch-up for 1-18 year-olds, the incidence of meningococcal serogroup C disease has decreased 
enormously from 1.38 per 100,000 in 2002 to 0.02 per 100,000 in 2014 (Figure 6.9.1). In 2014,  
3 cases of invasive meningococcal group C disease were reported: one male from Poland who 
was 24 years old with unknown vaccination status and two unvaccinated females of ages 
50 and 70 years. In 2015 up to June, 5 cases of invasive MenC disease were reported: four 
males aged 0, 22, 37 and 68 years and one female aged 75 years died due to the disease. It was 
unknown whether the 75-year-old female had an underlying disease. The male aged 22 years was 
vaccinated with NeisVac-C and therefore constitutes a case of vaccine failure. This is the fourth 
vaccine failure case to occur since the introduction of the conjugated MenC vaccine in 2002.  
Two of the patients involved in the vaccine failures were known to have had an immune deficiency.
6.9.3 Pathogen
See the first paragraph of Section 6.9.4.
6.9.4 Research
A retrospective study using Dutch surveillance data on IMD from June 1999-June 2011 was 
conducted to provide updated and representative information on the burden of IMD in the 
Netherlands and to assess the relationship between the clonal complex (CC) of the infecting 
strain and clinical manifestation, disease course and outcome [1]. Clinical information was 
retrieved from hospital records. Results showed that IMD mainly affects young and healthy 
individuals, most patients (48%) develop distinct meningitis and one-third of IMD patients 
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develop septic shock. The case-fatality rate (CFR) throughout the study was 8%, which was 
higher for adults than for children. Furthermore, this study showed that the disease course and 
outcome are mainly affected by age and clinical manifestation and much less by meningococcal 
clonal complex or serogroup. Underlying comorbidity, whether immunocompromising or not, 
has no effect on the disease course or outcome. Septic shock is the main determinant of the 
burden of IMD with higher percentages of intensive care unit (ICU) admittance, mortality and 
(severe) sequelae compared with meningitis or mild meningococcemia. 
Information on CC was available for 900 patients and categorised into six groups based on the 
prevalence of the different CCs. Most prevalent was CC41/44 (47%), followed by CC32 (16%), CC11 
(16%), CC213 (4%), CC269 (3%), with the remainder categorized as ‘other CCs’ (13%). CC11 was less 
prevalent among patients aged 0-4 years, compared with patients aged 10-64 years. The 
proportion of cases involving septic shock (with and without meningitis) did not differ between 
CCs. The CC of the infecting strain had no significant effect on CFR or the development of sequelae.
In a study by Stoof et al. [2], salivary antibody levels in adolescents were analysed in response 
to a meningococcal serogroup C conjugate booster vaccination nine years after priming in 
healthy 10, 12 and 15 year-olds. The parenteral MenC-TT booster vaccination induces a clear 
increase in salivary MenC-PS-specific IgG and IgA levels and the persistence of the highest 
levels correlates with age. Additionally, they showed that MenC-PS-specific IgG and IgA levels 
in saliva strongly correlate with the levels in serum. Therefore, saliva may offer an easy and 
reliable tool for future antibody surveillance.
Furthermore, preliminary results of the 3-year follow-up of this study indicate that, while a 
rapid decline of MenC-specific functional antibodies in serum was observed in the first year 
after the meningococcal conjugate C (MenCC) booster vaccination, a much slower decline was 
observed between the 1st and 3rd years. 
For a comparison between the monovalent and tetravalent meningococcal booster vaccines, 
410 healthy 10, 12 and 15 year-olds were enrolled between March and May 2014 and received a 
MenCC or a MenACWY conjugated vaccine 11 years after priming with MenCC vaccine. Blood 
and saliva samples were collected prior to vaccination, as well as 1 month and 1 year after 
booster vaccination. This study will provide important data for future considerations of a 
meningococcal booster vaccine in the Netherlands. Results are expected at the end of 2015.
In a nationwide surveillance study, MenC invasive disease between 1998 and the introduction 
of Meningococcal conjugate vaccines (MCC; 2002) was compared with the invasive MenC 
disease appearing from 2002 to 2012 in age groups eligible and not eligible for vaccination. In 
addition, the proportions of isolates from clonal complexes (ST-11 and ST-8) that are known to 
have a high expression rate of their polysaccharide capsule during nasopharyngeal carriage 
were compared between the pre-vaccination and post-vaccination periods. Results showed 
that there was a 99% decline in MenC disease in patients eligible for vaccination and a 93% 
decline in those not eligible. Furthermore, 36% of the overall MenC reduction had occurred in 
the unvaccinated population. The decline in MenC incidence was most pronounced among 
ST-11 and ST-8 complex serogroup C meningococci and therefore signalled a reduced carriage 
of these meningococci [3].
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6.9.5 International developments
By the end of May 2015, 170 MenW cases had been reported in the UK in the epidemiological 
year 2014/2015, compared with 88 and 46 cases for the same period in 2013/2014 and 
2012/2013, respectively. Because of the continuing rapid increase in MenW disease, the UK 
Departments of Health announced a rapid introduction of an adolescent MenACWY conjugate 
vaccine programme to begin in August 2015. The adolescent MenC conjugate vaccine currently 
recommended for 13-14 year-olds will be replaced by the MenACWY conjugate vaccine. Over 
the next two years, all remaining adolescents in the 13-18 year age groups will be offered 
MenACWY conjugate vaccine [4].
From May 12 to June 8, 2015, five cases of culture-confirmed serogroup C meningococcal 
disease among MSM were reported in the Chicago metropolitan area. Health care providers 
should consider the vaccination of at-risk MSM travelling to Chicago. Risk factors include
MSM, HIV infection and the use of online ‘hook-up’ apps to meet anonymous sexual partners. 
Based on case demographics, African American MSM appear to be at increased risk. In 
anticipation of the 46th Annual Chicago Pride (June 20-21, 2015) and Chicago Black Pride  
(July 2-5, 2015) events, CDC recommends increasing awareness of the signs and symptoms of 
meningococcal disease among MSM and suggests considering the vaccination of individuals 
travelling to Chicago who are (1) sexually active MSM infected with HIV and (2) MSM who have 
sex with anonymous partners or use online ‘hook-up’ apps to identify male sexual partners.
In the Netherlands, the subtype (P1.5-1, 10-8, F3-6), which had caused several outbreaks 
among MSM in past years, has occurred only once since 2010 (in 2013) in an unvaccinated 
young girl. In the period 2004-2009, this subtype occurred 5 times among males 16 years and 
older. These 5 patients lived in different cities and the time interval between cases ranged from 
6 weeks to 3 years [5]. Since January 2015, a question was added to the RIVM Osiris MenC 
questionnaire to discern whether the meningococcal case belongs to the MSM group. No cases 
belonging to MSM group were reported up to June 2015.
In France a national enhanced surveillance was established in response to the several 
outbreaks among MSM in past years in various countries. Since July 34 cases of serogroup C 
IMD have been notified in the Paris region. Of the 29 isolates, 14 were related to the genotype 
C:P1.5-1, 10-8:F3-6:cc11, of which nine isolates showed additional specific markers (similar to 
earlier outbreaks among MSM, such as in Germany). They corresponded to seven men (one 
aged 15-24 years and six aged 25-29 years) and two women (one aged 15-24 years and one in 
the age group 60 years and older). One additional male case (15-24 years-old) was 
epidemiologically linked to one of them (family cluster). These 10 cases were directly or 
indirectly linked to the MSM community, four cases of which, aged 25-29 years, self-identified 
as MSM. The four cases of serogroup C IMD among 25-29 year-old MSM (individuals older 
than 25 years are not targeted by the national vaccination programme) were 10 times greater 
than the expected number of men in this age group. In addition, the surveillance data 
highlighted that two family clusters of two cases each were also reported outside the Paris 
region in 2014, indicating that such isolates may spread all over the country and not only in the 
Paris region. Based on the above, the French public health authorities renewed the earlier 
recommendation of MenCC vaccination in November 2014 for one year and extended it 
beyond the Paris region to include the whole country, targeting MSM and all individuals aged 
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25 years and older attending social venues associated with the gay community. The observed 
increase in MenC IMD suggested a lack of vaccine-induced herd immunity caused by low 
vaccine uptake (56% at the age of two years and 17% among the 15 to 19 year-olds in 2013) [6].
Ishola et al. (2015) [7] had compared the immunogenicity and safety of either a CRM-conjugated 
or a TT-conjugated MenACWY vaccine in 93 teenagers (aged 16-19 years) who received either 
MCC-TT or MCC-CRM during a primary vaccination study 12-14 years earlier. A relatively greater 
proportion of those primed with MCC-TT had protective SBA titre, compared with the MCC-
CRM primed groups. Post-boosting both MenACWY vaccines induces protective SBA titres to 
all 4 serogroups in most participants (98% at 1 month and ≥90% by 9 months post boost).  
The highest MenC SBA titres were seen in those MCC-TT primed and MenACWY-TT boosted, 
followed by those boosted with MenACWY-CRM, irrespective of priming, and then those 
MCC-CRM primed and MenACWY-TT-boosted.
6.9.6 Tables and Figures
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Figure 6.9.1 Age-specific incidence of meningococcal C disease, 2001-2015 (*up to June) 
Source: NRBM
Table 6.9.1 Absolute numbers of invasive meningococcal C isolates, 2001-2015 (*up to June) 
Source: NRBM 
Age 
in yrs
20
01
20
02
20
03
20
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20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
*
0-4 73 52 17 2 0 1 2 2 2 2 0 2 1 0 1
5-9 27 30 0 1 0 0 1 0 0 0 0 0 0 0 0
10-19 105 73 1 0 0 0 1 0 0 2 0 0 0 0 0
20-39 31 32 12 6 1 1 1 3 2 2 1 0 1 1 2
40-64 27 20 7 4 2 1 5 3 1 0 0 1 0 1 0
65+ 14 15 5 4 1 1 0 3 4 0 2 0 4 1 2
Total 277 222 42 17 4 4 10 11 9 6 3 3 6 3 5
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6.10  Hepatitis B
S. Hofstraat, F. van Heiningen, B. van Benthem, I. Veldhuijzen, J. Cremer, K. Benschop, A.J. King, S. Hahné
6.10.1 Key points
• The incidence of acute hepatitis B virus (HBV) notifications in 2014 was 0.8 per 100,000 
of population, comparable to 2013.
• Among men, sexual contact with men remained the most frequently reported risk 
factor. For women, heterosexual contact was the most frequently reported risk factor.
• Molecular surveillance shows type A to be the dominant genotype among acute HBV 
cases, followed by type D. 
6.10.2  Epidemiology
In 2014, 1,224 cases of HBV infection were notified. Of these, 1,074 (88%) were chronic infections 
and 141 (12%) acute infections (9 cases unknown status). Compared with 2013 (145 cases), the 
number of notified acute HBV infections decreased slightly. The incidence of acute HBV 
notifications in 2014 was 0.9 per 100,000 of population (2013: 0.8/100,000), 1.2/100,000 among 
men and 0.4/100,000 among women. The HBV incidence, which has been decreasing for men 
and women since 2004, seems to have stabilised overall (Fig. 6.10.1). However, in the province of 
Friesland (Northern region of the Netherlands) a notable increase of acute HBV cases was found 
in 2014 (n=15), compared with 2013 (n=4). Similar clusters of acute cases in rural parts of the 
Netherlands have been identified by Soetens et al. [1] who described clusters of acute HBV cases 
in the south-western and north-eastern regions of the Netherlands in the period 2009-2013.
In 2014, most cases of acute HBV infection (57%) were acquired through sexual contact.  
For 31% of reports of acute HBV infection, the most likely route of transmission remained 
unknown, despite source tracing. Among men (104 cases), sexual contacts between men  
who have sex with men (MSM) accounted for 30% of acute infections and heterosexual 
transmission for 19%. Among women (37 cases), heterosexual contact accounted for 62%  
of the cases.
6.10.2.1 Chronic HBV epidemiology
Since 2009, the number of chronic HBV notifications has decreased by 41% (n=1820 in 2009 
and n=1074 in 2014). The reason for this decline is unknown, but as chronic hepatitis B is 
largely asymptomatic, it is likely to reflect changing testing practices. In 2014, more than half  
of the cases (56%) acquired chronic HBV infection through vertical transmission. Six per cent 
were infected by sexual contact. For 28% of the reports of chronic HBV infection, the most 
likely route of transmission was unknown. For the remaining 10%, transmission occurred via 
injecting drug use (IDU), needle stick injuries or via other routes. Eighty-two per cent of the 
chronic HBV patients were born abroad (with Turkey, China, Ghana, Vietnam and Suriname as 
the five most frequently reported countries of birth).
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6.10.3  Pathogen
Molecular sequencing and typing of 92 acute HBV cases (65%) was done in 2014. PCR 
amplification and sequencing gave results for 88 (96%) samples for the S-region. A minimum 
spanning tree based on S-region sequences is shown in Figure 6.10.2. This shows that the 
largest cluster of cases continues to be among genotype A cases, the most common genotype 
in the Netherlands.
6.10.3.1 Molecular typing
The molecular typing of notified acute HBV cases and of chronic HBV cases in the target groups 
for selective vaccination will continue in 2015. Besides molecular typing, molecular data can be 
used to analyse the circulation of genetic variants, such as possible immune escape variants 
and antiviral resistant variants [2], to assess the current vaccination campaigns and the impact 
of factors such as the influx of non-endemic strains and to gain insight into transmission 
networks in the Netherlands. For efficient analysis and surveillance of these variants, the 
Centre for Infectious Disease Control of the RIVM (RIVM/CIb) is working on implementing the 
molecular platform VIRO-TypeNed [3] of HBV, as well as the hepatitis C virus, of both acute and 
chronic cases. The platform aims to combine molecular data with epidemiological and 
transmission data to allow for a more efficient surveillance of HBV, source monitoring and 
detection of antiviral resistance and immune escape variants.
6.10.4  International developments
In March 2015, the WHO [4] issued its first hepatitis B guidelines: ‘Guidelines for the 
prevention, care and treatment of persons with chronic hepatitis B infection’. It focuses on  
the care and treatment of persons living with chronic hepatitis B infection, as well as existing 
recommendations for the prevention of HBV. These include infant hepatitis B vaccination, 
catch-up vaccination and other prevention strategies for high-risk populations (MSM, 
commercial sex workers), as well as the prevention of transmission in health care settings.
Jazwa et al. [5] performed an economic analysis of an overseas hepatitis B programme for 
refugees. They carried out a cost-benefit analysis comparing two strategies among refugees 
from 82 countries of origin coming to the United States of America who were at an increased 
risk of chronic HBV infection. One approach was a ‘screen, vaccinate or initiate management’ 
strategy and the other a ‘vaccinate only’ strategy. A cohort of 26,548 refugees who arrived in 
Minnesota and Georgia during 2005–2010 was evaluated to determine the prevalence of 
chronic HBV infection. The estimated six-year period-prevalence of chronic HBV infection was 
6.8% in the overall refugee population. While the up-front costs of the screening strategy were 
higher than ‘vaccinate only’, the ‘screen, vaccinate or initiate management’ proposal displayed 
a positive net benefit. The major benefit drivers for the screening policy are earlier medical 
management of chronic HBV infection and averted lost societal contributions from premature 
death.
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6.10.5  Tables and Figures
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Figure 6.10.1 Incidence of acute HBV infections (notifications) in men and women in the 
Netherlands between 1976 and 2014
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Figure 6.10.2 Minimum spanning tree based on the S-region sequence of acute HBV cases in 
the Netherlands in 2014 by reported risk factor (n=88)
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6.11  Pneumococcal disease
M.J. Knol, H.E. de Melker, E.A.M. Sanders, P. Kaaijk, N.Y. Rots, A.W.M. Suijkerbuijk, A. van der Ende,  
K. Elberse, G.A.M. Berbers
6.11.1  Key points
• Introduction of pneumococcal conjugate vaccination (PCV) led to a significant decrease 
in overall invasive pneumococcal disease (IPD), especially in the vaccine target group of 
children under 5 years and the elderly aged 65 and older, due to herd protection.
• Introduction of 7-valent PCV (PCV7) in 2006 decreased vaccine-type IPD from 7.4 per 
100,000 per year in 2004-2006 to less than 1 per 100,000 per year in 2013-2015.
• The switch to 10-valent PCV (PCV10) in 2011 reduced the number of IPD cases caused by 
the additional PCV10 serotypes (1, 5 and 7F) in the vaccine-eligible age groups.
• A decrease in incidence of IPD caused by the additional PCV10 serotypes in the adult 
age groups was seen in 2013-2015. This is probably due to herd protection as a result of 
PCV10 introduction for children, although longer follow-up is needed to establish this 
since natural fluctuations in time cannot be ruled out yet.
• The incidence of non-vaccine-type IPD increased after the introduction of PCV7. The 
increase in 2013-2015 was very small. This was mainly due to a decrease in serotype 
19A IPD. The decrease in 19A IPD probably reflects natural fluctuation, but may also be 
due to cross-protection by PCV10 or a new balance between serotypes over time.
6.11.2  Epidemiology
6.11.2.1 Vaccination schedule
In 2006, 7-valent pneumococcal conjugate vaccination (PCV7; including serotypes 4, 6B, 9V, 14, 
18C, 19F and 23F) was introduced in the NIP for children born on or after April 1, 2006. In 2011, 
PCV7 was replaced by PCV10 (with additional serotypes 1, 5 and 7F) for children born on or 
after March 1, 2011. The vaccination schedule changed from four to three doses of PCV10, given 
at 2, 4 and 11 months of age, in November 2013.
6.11.2.2 Overall IPD
Overall, IPD incidence decreased significantly by 11% since the introduction of PCV7 in 2006. 
The decrease was largest in the major affected age groups of children <5 years and the elderly 
aged 65 years and older (Figure 6.11.1).
6.11.2.3 Vaccine type IPD
In the last 2 years (period June 2013-May 2015), the overall incidence of IPD caused by PCV7 
serotypes was less than 1 per 100,000 per year, indicating a large and sustained effect of PCV7 
introduction in vaccinated and unvaccinated age groups (Figure 6.11.2). The switch to PCV10 in 
2011 decreased the incidence of IPD caused by the three additional serotypes in PCV10 in 
vaccine-eligible age groups. For example, there were 0 cases of serotype 1, 5 and 7F in the <2 years 
age group in the last 2 years in the sentinel surveillance (Figure 6.11.3). In the nationwide 
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surveillance, the number of cases in <2-year-olds clearly decreased after 2011 with only 1 case 
of serotype 1, 5 or 7F in 2014 and 1 case up to May 2015 (Figure 6.11.4). Figure 6.11.2 also shows 
a significant decrease in incidence of IPD caused by the additional PCV10 serotypes in the adult 
age groups in 2013-2015. This is probably due to herd protection as a result of a reduction in 
the carriage and transmission of the three additional serotypes in vaccinated children, 
although longer follow-up is needed to firmly establish these herd effects over time.
6.11.2.4 Non-vaccine type IPD
After the introduction of PCV7, the incidence of IPD caused by non-vaccine serotypes 
increased, especially in the older age groups (Figure 6.11.5 shows the increase in non-PCV10 
serotype IPD). In the last two years, there was no substantial increase any longer of non-
vaccine type IPD. This was partly due to a decrease in serotype 19A IPD (Figure 6.11.6). The 
decrease in 19A IPD was expected, since a decline in 19A carriage was also observed in 2011/12 
in children (Bosch et al., submitted), who are the key transmitters of pneumococcal infections 
in the population. The decline in carriage and subsequent disease may be due to cross-
protection by 19F in PCV10, a new balance between competitive serotypes over time or it may 
reflect natural fluctuation. In adults, the decline in 19A incidence probably reflects natural 
fluctuation, as we observed a substantially higher incidence in 2014-2015 (1.8 per 100,000) 
compared with 2013-2014 (1.2 per 100,000).
6.11.2.5 Hospitalisation due to IPD
The overall incidence of hospital admissions due to meningitis, sepsis and pneumonia caused 
by pneumococci has decreased since 2006 in the age groups targeted for pneumococcal 
vaccination (Figure 6.11.7). The incidence of hospital admissions in children above 5 years of 
age, adults and the elderly remained more or less stable.
6.11.2.6 Mortality of IPD
Clinical IPD surveillance showed that the case fatality rate of IPD significantly decreased from 
16% in 2004-2006 to 12% in 2008-2012. Together with a decline in IPD, the IPD mortality 
incidence decreased significantly from 2.4 per 100,000 per year in 2004-2006 to 1.7 per 
100,000 per year in 2008-2012. The case fatality rate and mortality incidence were highest 
among patients 65 years or older (17% and 8.3/100,000 respectively in 2008-2012). 
In 2014 and 2015, 70 IPD cases among children aged 5 years or younger were reported 
nationally. For 44 cases, the mortality status was known. Three of the 44 cases (6.8%) died. 
These three cases had non-vaccine type IPD (serotype 15C, 22F and 23A) and one had 
comorbidity.
6.11.2.7 Vaccine failure
Since the introduction of PCV7, there have been 43 cases of vaccine-type IPD among vaccine-
eligible children in the nationwide surveillance. Of these, 16 children (37.2%) were vaccinated 
with at least 2 doses (Table 6.11.1). Six of these children had serotype 19F IPD. In 2014 and 2015, 
there were two 7F vaccine failure cases. Serotype 7F is one of the three additional serotypes in 
PCV10 as compared with PCV7.
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6.11.3  Pathogen
Some changes in the characteristics of the pneumococcal strains isolated from IPD patients 
have been observed. For serotypes 1 and 12F there was a significant shift in clonal lineage 
within the serotype in the post vaccine era, compared with the years before the introduction of 
the vaccine. Isolates in the new clonal lineage within serotype 12F were significantly more 
associated with pneumonia than with other clinical syndromes. Therefore, not only serotype, 
but also clonal lineage may influence the clinical outcome.
6.11.4  Research
6.11.4.1 IPD in risk groups
Using clinical data on IPD cases from June 2008 – May 2012 and data on the prevalence of 
risk conditions from 2012, we calculated the incidence and case fatality of IPD in normal-risk, 
medium-risk and high-risk groups. IPD incidence in adults with immunocompromising 
conditions (high-risk group) and non-immunocompromising comorbidities (medium-risk 
group) were compared with the ‘normal-risk group’ without diagnosed comorbidities. 
Adults with a high-risk condition have a 18-fold and 3-fold higher risk for IPD at age 18-64 years 
and 65 years and older, respectively. In case of a medium-risk condition, the risk is 5-fold and 
2-fold higher in age groups 18-64 and ≥65 years old. Likewise, IPD patients with a high-risk or 
medium-risk condition have a higher case-fatality (after adjustment for age, 2-fold and 
1.4-fold, respectively). Several serotypes (e.g. 6A, 6B, 23A and 23B) are associated with a 
significantly higher propensity to cause disease in high-risk patients. The risk for IPD and death 
in the post-PCV7 era has remained considerably higher in adults and the elderly with 
underlying conditions. The identification of serotypes with a high propensity to affect risk 
groups is important for selecting (future) vaccine serotypes.
6.11.4.2  Increase in empyema
Clinical data of IPD cases from June 2004 – May 2012 showed that invasive pneumonia 
incidence increased in the 5-64 year-old age group from 4.92 to 5.58 cases/100,000/year (RR 
1.13, 95%CI 0.99-1.29). Empyema incidence significantly increased in the elderly 65 years and 
older, from 0.62 to 2.60 cases/100,000/year (RR 4.28, 95%CI 1.97-9.33), mainly due to serotype 
1. The incidence of other clinical syndromes, including meningitis and bacteraemia without or 
with other focus, decreased or stayed constant after PCV7 introduction. Serotype 1 is included 
in PCV10 and therefore the observed increase in empyema may decline again when herd 
effects of PCV10 occur.
6.11.4.3  Hospitalisations of pneumonia
Pneumonia remains an important cause of morbidity and mortality in all age groups. Until the 
mid-2000s, there was an increasing trend in hospitalisations due to pneumonia in the USA and 
Europe, which was also seen in the Netherlands. Although the aetiology of pneumonia is 
polymicrobial, Streptococcus pneumoniae is the leading cause of (bacterial) pneumonia, 
accounting for 20-60% of all cases.
To study the impact of infant PCV vaccination on hospital-treated primary pneumonia (HTPP) 
hospitalisations in all age-groups, inpatient discharge codes were collected from the National 
Medical Registration (LMR) for the years 1999-2005 (pre–PCV7) and 2008-2012 (post-PCV7). 
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HTPP was defined as a main discharge diagnosis for all-cause pneumonia, or meningitis, 
septicaemia or empyema together with pneumonia as a secondary discharge diagnosis. 
A notable, statistically significant decrease in the trend was seen for the age groups 0-6 
months, 6 months-1 year, 50-64 years and 65 years and older, in which the observed annual 
decrease was respectively 17.5% (95%CI 16.2-20.0%), 8.8% (95%CI 6.8-10.9%), 4.0% (95%CI 
3.9-4.0%) and 5.9% (95%CI 5.9-6.9%). A reduction in absolute number of hospitalisations due 
to HTPP was seen in all age groups in the last two observed epidemiological years, although 
these reductions were not statistically significant for the 0-6 year-olds and 50-64 year-olds in 
both epidemiological years and for those 65 and older in 2010/2011. For the entire post-PVC 
period, in comparison with the pre-PCV period, we observed a 30% reduction of the HTPP 
hospitalisation rate in children and a 6-16% reduction in adults, with only the result for the age 
group of 65 years and older reaching statistical significance. When vaccine-eligible children 
were compared with non-vaccine-eligible children, a significant reduction in HTPP 
hospitalisation was observed for 0-6 month-olds (IRR 0.68, 95%CI 0.64-0.73), 1-2 year-olds 
(IRR 0.85, 95%CI 0.80-0.89) and 2-3 year-olds (IRR 0.86, 95%CI 0.81-0.92), whereas no 
reduction was observed among 3-4 and 4-5 year-old children.
6.11.5  (Inter)national developments
6.11.5.1  Efficacy of PCV13 in elderly
In the Netherlands, a randomised, double-blind, placebo-controlled trial in 84,496 elderly ≥65 
years of age was conducted to determine the vaccine efficacy (VE) of 13-valent PCV (PCV13) [1]. 
The primary endpoint was the first episodes of vaccine-type pneumococcal community-
acquired pneumonia (VT-CAP) and the secondary endpoints were non-bacteremic/non-
invasive VT pneumococcal CAP (NB/NI VT-CAP) and VT invasive pneumococcal disease 
(VT-IPD). In the per-protocol analysis, the first episodes of VT-CAP occurred in 49 and 
90 subjects in the PCV13 and placebo group, respectively (VE 45.56%, 95.2%CI: 21.82-62.49);  
in 33 and 60 subjects for NB/NI VT-CAP (VE 45.00%, 95.2%CI: 14.21-65.31); and in 7 and 28 
subjects for VT-IPD (VE 75.00%, 95%CI: 41.43-90.78). All-cause CAP occurred in 747 and 787 
subjects in the PCV13 and placebo group, respectively (VE 5.08%, 95%CI: -5.05-14.24).
6.11.5.2  Cost-effectiveness
In the Netherlands, the cost-effectiveness of vaccinating older adults against pneumococcal 
disease with PCV13 was examined [2]. A probabilistic cohort model with a Markov-type process 
depicting the risk of clinical and economic outcomes of pneumococcal disease (IPD and CAP), 
as well as the expected impact of PCV13 vaccination in older adults, was developed. A base-
case scenario of PCV13 versus no vaccine was evaluated in adults aged 65-74 years (n=1.5 
million), assuming a 70.7% PCV13 uptake. The ICER for base-case PCV13 vaccination strategy 
was € 8,650/QALY (95%CI: 5,750-17,100). PCV13 vaccination of high-risk individuals aged 65-74 
years was most cost-effective (i.e. cost saving) and extension to medium-risk individuals aged 
65-74 years yielded an ICER of € 2,900.
In the UK, the cost-effectiveness of vaccinating the elderly and at-risk adults with the 
23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine 
was assessed [3]. A Markov model was used to track one UK-based cohort of individuals 
assuming PPSV23, PCV13 or no vaccination until death. The ICER was estimated at £8,413 when 
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PPSV23 was compared with no vaccination; PPSV23 dominated PCV13. Despite reductions in 
invasive pneumococcal diseases incidence in adults and a protection of vaccination of less than 
10 years, PPSV23 was the most cost-effective option.
Wu et al. conducted a review of economic evaluations, published since 2006, of conjugate 
pneumococcal vaccines in children [4]. At current prices, both PCV13 and PCV10 were judged 
preferable to PCV7. The uncertainty related to price differences, burden of disease, vaccine 
effectiveness, and indirect effects determine the preference base for either PCV10 or PCV13. 
The crucial assumptions and results also depended on which manufacturer sponsored the 
study. Therefore, decision-makers using these analyses should not rely solely on an analysis 
from a single manufacturer.
6.11.5.3  Correlates of protection
Andrews et al. performed a post-licensure assessment of serotype-specific vaccine 
effectiveness (VE) and immunogenicity in England, Wales and Northern Ireland to derive the 
correlates of protection for individual serotypes [5]. For the 706 cases of invasive 
pneumococcal disease included in the study, PCV13 vaccine effectiveness after two doses 
before age 12 months or one dose from 12 months on was 75% (95%CI: 58–84). VE was 90% 
(95%CI: 34–98) for the PCV7 serotypes and 73% (95%CI: 55–84) for the six additional serotypes 
included in PCV13. Protection was shown for four of the six additional PCV13 serotypes (VE for 
serotype 3 was not significant and no cases of serotype 5 infection occurred during the 
observation period). The VE for PCV13 and PCV7 was lower than predicted by the aggregate 
correlate of protection of 0.35 μg/mL used during licensing. Calculated serotype-specific 
correlates of protection were higher than 0.35 μg/mL for serotypes 1, 3, 7F, 19A and 19F, and 
lower than 0.35 μg/mL for serotypes 6A, 6B, 18C and 23F. Opsonophagocytic antibody titres of 
1 in 8 or higher did not predict protection. Although use of the aggregate correlate of 
protection of 0.35 μg/mL has enabled the licensing of effective new PCVs, serotype-specific 
correlates of protection vary widely.
6.11.5.4  Antibiotic prescriptions
A study in the Netherlands compared the use of respiratory antibiotics in the pre-PCV and 
post-PCV vaccination period [6]. They found that the proportion of respiratory antibiotic 
prescriptions fell by 4.9% (95%CI: 4.6-5.3) and 9.0% (95%CI: 2.8-14) after the introduction of 
the 7-valent vaccine in children aged three and four years, respectively. After the introduction 
of the 10-valent vaccine, a reduction of 13% (95%CI: 2.8-22), 20% (95%CI: 13-26), 17% (95%CI: 
3.1-28), 22% (95%CI: 3.7-37) and 24% (95%CI: 2.4-40) was observed in two, three, four, six and 
seven year-old children, respectively. These results indicate a reduction in respiratory antibiotic 
prescriptions in young children after the introduction of the pneumococcal vaccines, although 
it was an ecological study and other factors could have contributed to the reduction.
6.11.5.5  Next generation vaccines
The disadvantage of currently available vaccines, 23-valent pneumococcal polysaccharide 
vaccine (PPSV23) and PCVs, is that they are serotype-specific. Vaccines that provide broader 
protection, such as recombinant protein (Phase I), Protein-plus-conjugate (phase II) and 
inactivated whole-cell (Phase I) vaccines, are being developed.
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6.11.6 Tables and Figures
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Figure 6.11.1 Incidence of IPD caused by all serotypes, presented by age group and time 
period (’04-’06 = June 2004-May 2006, ’06-’08 = June 2006-May 2008, etc.) 
PCV7 was introduced in June 2006 and PCV10 in May 2011. Data of sentinel surveillance are used and extrapolated to the Dutch population. 
Source: NRBM
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Figure 6.11.2 Incidence of IPD caused by PCV7 serotypes, presented by age group and time 
period (’04-’06 = June 2004-May 2006, ’06-’08 = June 2006-May 2008, etc.) 
PCV7 was introduced in June 2006 and PCV10 in May 2011. Data of sentinel surveillance are used and extrapolated to the Dutch population.  
Source: NRBM
122  |   The National Immunisation Programme in the Netherlands
Figure 6.11.3 Incidence of IPD caused by additional PCV10 serotypes (1, 5 and 7F), presented 
by age group and time period (’04-’06 = June 2004-May 2006, ’06-’08 = June 2006-May 2008, etc.) 
PCV7 was introduced in June 2006 and PCV10 in May 2011. Data of sentinel surveillance are used and extrapolated to the Dutch population.  
Source: NRBM
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Figure 6.11.4 Cumulative number of IPD cases caused by the additional PCV10 serotypes  
(1, 5 and 7F) in children < 2 years of age  
PCV10 was introduced in March 2011. Data of nationwide surveillance are used.  
Source: NRBM
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Figure 6.11.5 Incidence of IPD caused by non-PCV10 serotypes, presented by age group and 
time period (’04-’06 = June 2004-May 2006, ’06-’08 = June 2006-May 2008, etc.) 
PCV7 was introduced in June 2006 and PCV10 in May 2011. Data of sentinel surveillance are used and extrapolated to the Dutch population.  
Source: NRBM
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Figure 6.11.6 Incidence of IPD caused by serotype 19A, presented by age group and time 
period (’04-’06 = June 2004-May 2006, ’06-’08 = June 2006-May 2008, etc.) 
PCV7 was introduced in June 2006 and PCV10 in May 2011. Data of sentinel surveillance are used and extrapolated to the Dutch population.  
Source: NRBM
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Figure 6.11.7 Age-specific incidence of hospitalisation due to pneumococcal disease  
(i.e. pneumococcal meningitis, pneumococcal septicaemia, pneumococcal pneumoniae and 
pneumoniae by Streptococcus)  
* For 2014, the hospitalisation data are preliminary and incomplete.  
Source: DHD
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Table 6.11.1 Children with vaccine type IPD who received at least 2 vaccinations based on 
nationwide surveillance data using data up to May 2015
Year of 
diagnosis
Age in 
months
Serotype Vaccine 
received
Number of 
vaccinations
Patient details if known
2008 3 9V PCV7 2 Diagnosis within 1 wk 
after 2nd dose
2008 3 6B PCV7 2 Diagnosis at least 2 wks 
after 2nd dose
2008 7 6B PCV7 3 ?
2009 29 19F PCV7 4 ?
2009 6 19F PCV7 3 -
2010 12 6B PCV7 4 ?
2011 59 19F PCV7 4 Nephrotic syndrome
2012 63 18C PCV7 4 -
2012 45 19F PCV7 4 Leukaemia
2012 54 9V PCV7 4 ?
2013 2 7F PCV10 2 Premature, diagnosis 
within 1 wk after 2nd 
dose
2013 73 19F PCV7 4 ?
2014 68 19F PCV7 4 CSF leakage, history of 
meningitis
2014 18 7F PCV10 4 -
2014 41 23F PCV10 4 Beta thalassemia  
with chronic blood 
transfusions
2015 13 7F PCV10 4 -
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6.12 Human papillomavirus (HPV) infection
R. Donken, T.M. Schurink-van ’t Klooster, A.J. King, P.J. Woestenberg, P. Rog, A.W.M. Suijkerbuijck,  
J.A. Bogaards, M.F. Schim van der Loeff, F.R.M. van der Klis, H.E. de Melker
6.12.1 Key points
• Incidences of human papillomavirus (HPV)-associated cancers and death related to  
HPV-associated cancers have slightly increased in the last decade in the Netherlands. 
• Vaccine effectiveness of the bivalent vaccine against incident and persistent infections 
in a cohort study was high up to four years post-vaccination. 
• Persistent HPV16/18 infections were found to have significantly higher baseline viral 
loads than clearing infections. 
• Antibody avidity after a two-dose schedule (0, 6 months) was not remarkably different 
from a three-dose schedule, indicating comparable quality of the antibody response.
6.12.2  Epidemiology
A persistent HPV infection with a high risk HPV (hrHPV) type is a necessary cause in the 
development of cervical cancer. It can also cause vaginal, vulvar, penile, anal, mouth/oral and 
oropharyngeal cancer. hrHPV infections are estimated to cause 88% of anal cancers, 70% of 
vaginal cancers, 43% of vulvar cancers, 50% of penile cancers and 39% of oropharyngeal 
cancers, including the tonsils and base of the tongue [1]. Figure 6.12.1 and Figure 6.12.2 present 
the incidences of HPV-associated cancers and deaths related to HPV-associated cancers, for 
absolute numbers of cervical cancers see Appendix 2. The non-oncogenic low-risk HPV (lrHPV) 
types 6 and 11 can cause genital warts (GW). In 2014, the number of GW diagnoses at sexually 
transmitted infections (STI) clinics was 2,029 [2]. The percentage of diagnoses of GW by the 
number of consults decreased from 2.9% in 2009 to 1.4% in 2014. The number of diagnoses of 
GW by GPs has slightly increased since 2009 and was estimated at 36,552 in 2013.
From 2014 onwards, all Dutch girls up to 14 years of age will receive the bivalent (HPV16/18) 
HPV-vaccine in a two-dose vaccination schedule (0, 6 months).
6.12.3  Pathogen
Besides genotyping, pathogen surveillance activities focus on intratype variation in the  
L1 protein of HPV16/18 viruses. Intratypic molecular variants of HPV16 and HPV18 exist. 
Long-term vaccination with the L1 protein could lead to shifts in the genetic diversity of the 
HPV16/18 virus population. In order to detect shifts in the genetic diversity, we have 
determined the genetic diversity at the start of vaccination through the molecular sequencing 
of the entire L1 gene of HPV16 and HPV18 virus strains isolated in 2009 and 2011. As HPV 
variants have been shown to differ in geographic origins, it was to be expected that European 
HPV16 and HPV18 variants were identified most frequently in the Dutch isolates. Indeed, the 
majority of our isolates concerned variant lineages, 93% and 86% for HPV16 and HPV18, 
respectively, similar to the European reference strain and the strains used in the vaccine.
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6.12.4  Research
6.12.4.1 HPV amongst vaccinated and unvaccinated adolescents (HAVANA)
A prospective cohort study, which was initiated in 2009 among vaccinated and unvaccinated  
14 to 16 year-old girls, is still ongoing. The primary aim is to monitor the effect of vaccination 
on HPV-type distribution amongst vaccinated and unvaccinated young women. Vaginal 
self-swabs collected in this cohort were tested for the presence of HPV DNA. Four years after 
vaccination, 1,244 swabs were tested, 27.3% were positive for any HPV and 19.9% were 
positive for a hrHPV type. Among vaccinated participants, HPV51, 56 and 58 were the most 
prevalent hrHPV types. Among unvaccinated participants HPV51, 52 and 16 were the most 
prevalent hrHPV types. VE against incident and persistent infections was determined. The 
bivalent vaccine is effective against HPV16/18/31/45 incident and persistent infections at least  
4 years post-vaccination (Table 6.12.1).
In addition, the long-term effectiveness and immunogenicity for alternate dosage schedules 
among participants of the HAVANA study was examined. Due to limited sample size, no hard 
conclusions could be drawn. GMCs for two doses at 0 and 6 months were comparable to three 
doses, although, due to the limited sample size, the non-inferiority comparison was incon-
clusive. Risk difference in infection rates was non-inferior for two doses, compared with three.
6.12.4.2 Genital warts among vaccinated and unvaccinated women (PASSYON)
Data from the UK [3] and from a vaccine trial [4] suggested that the bivalent vaccine, which is 
currently used in the Netherlands, might offer protection against GW. We investigated the 
effect of the bivalent vaccine on GW and genital HPV6/11 positivity, using data from a repeated 
cross-sectional study among 16 to 24 year-old STI-clinic visitors (PASSYON study) [5]. Of the 
385 female study participants who were eligible for vaccination in the NIP, 55.1% were reported 
to be vaccinated. Among the vaccinated women, 0.5% were diagnosed with GW and 11.8% 
tested positive for vaginal HPV6/11. Among the unvaccinated women, these figures were 2.3% 
and 13.3%, respectively. Although not statistically significant, the vaccinated women had lower 
odds of acquiring GW than the unvaccinated women (OR 0.2; 95%CI 0.02-1.8). No effect on 
HPV6/11 positivity was observed (OR 0.9; 95%CI 0.5-1.6). Adjustment for demographics and 
sexual behaviour did not change these effects. There are indications that the bivalent vaccine 
offers protection against GW, although we cannot draw definite conclusions due to the low 
incidence of GW.
6.12.4.3 Differences in development of sexual behaviour among HPV vaccinated and unvaccinated girls
This longitudinal observational study asks both vaccinated and unvaccinated girls about their 
knowledge of HPV and about their sexual behaviour and examines whether this changes 
differently over time. General knowledge of HPV and of HPV transmission increased for both 
the vaccinated and unvaccinated participants. The vaccinated girls were more likely to have 
stated that (offering) HPV vaccination had changed their sexual behaviour. The vaccinated girls 
were more likely to be sexually active at the start of the study. The proportion of those sexually 
active increased to a greater degree over time among the vaccinated girls than it did among 
the unvaccinated girls, although there were no large differences in the number of casual or 
steady partners.
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6.12.4.4 HPV16/18 Viral Load
The HPV viral load is a marker for the productivity of an infection at a specific time point. High 
viral load has been associated with persistent infections. HPV vaccination is expected to have 
effects on vaccine types HPV16 and HPV18 in the Netherlands. The vaccine has been shown to 
prevent persistent infection, but not necessarily transient infections. It can therefore be 
expected that vaccination will reduce the average HPV16/18 viral load in vaccinated girls. 
Monitoring changes in viral load values could lead to further insights into infection 
development.
To detect a possible change in viral load, highly sensitive quantification assays targeting 
HPV16/18 L1 have been implemented. The sensitivity of these real-time (RT) PCRs has been 
found to approach that of the SPF10-DEIA-LIPA25 platform used for HPV detection.
The assay has been applied in the Chlamydia trachomatis Screening and Implementation (CSI) 
study. Persistent HPV16/18 infections were found to have significantly higher viral loads than 
clearing infections (p=0.015 for HPV16 and p=0.018 for HPV18). Furthermore, an infection of 
HPV16 simultaneously with another HPV type was found to have a significantly higher viral 
load than HPV16 alone (p=0.003), for HPV18 the viral load was not influenced by co-infections 
(p=0.138). Predicting persistent infections based on single viral load measurements proved 
elusive, even when integrating both viral load and HPV co-infection status into a model. 
However, every log-unit increase of viral load led to higher odds of infections persisting 
(OR=1.29, 95%CI=1.11-1.51 and OR=1.26, 95%CI=1.06-1.51 per log-unit for HPV16 and HPV18, 
respectively). In addition, a trend was observed for participants with HPV co-infections other 
than HPV16. These participants were more likely to have a persistent infection (OR=1.58, 
95%CI=0.87-2.89, p=0.135). For HPV18, this trend was not observed (OR=1.62, 95%CI=0.54-
4.85, p=0.392).
6.12.4.5 HPV16/18 Whole Genome Sequencing
HPV is a highly conserved double stranded (ds) DNA virus, in which minimal variation occurs as 
a result of evolution. Comparing sequences from longitudinal study samples could therefore 
provide enough resolution to discriminate between true persisting infections and same-type 
reinfection events. Samples were obtained from the CSI study, which has up to four sample 
rounds per participant. HPV16 and HPV18 whole genome Sanger sequencing assays were 
developed at the RIVM. Full sequence coverage is required to be able to compare sequences 
obtained from different rounds. Preliminary results indicated that most infections were truly 
persistent. The HPV16 genome variants were identical through round one and two for all but 
one participant. The diverging participant was infected with a European HPV16 variant in 
round one and an Asian-American variant in round two. Sequencing of data from round three 
and four is in process.
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6.12.4.6 Monitoring the implementation of the two-dose schedule (HPV-2D)
For monitoring the change from a three-dose to a two-dose vaccination schedule, a study 
which consists of two parts was set up. Firstly, a retrospective cross-sectional serological 
evaluation was performed among girls who had received three doses or two doses (at least  
5 months apart) of the bivalent HPV vaccine (birth cohorts 1997-2000). For vaccine types 
HPV16 and HPV18, seroprevalence was 100% up to 4 ½ years after the first dose, irrespective 
of the schedule. GMCs for vaccine types after a two-dose schedule were not non-inferior (NI 
margin for GMC ratio 2.0) to a three-dose schedule at all-time points, except for HPV18 at two 
to three years after the first dose. For the antibody avidity of vaccine types, non-inferiority 
could not be concluded, mainly based on inconclusive non-inferiority comparisons, except for 
HPV16 at three to four years after the first dose, for which non-inferiority could be concluded. 
Although the non-inferiority of antibody avidity could not be concluded, no remarkable 
differences were found. Secondly, this study consists of a still ongoing cohort study being 
conducted among the first birth cohort that was eligible for vaccination with a two-dose 
schedule, i.e. birth cohort 2001. For at least one and a half years, these girls will be monitored 
for the quality and quantity of the generated immune response.
6.12.4.7 Systematic review of a comparison between two-dose and three-dose immunogenicity
In a systematic review and meta-analysis, the comparability of antibody levels between and 
within different age groups was evaluated. For both the bivalent and quadrivalent vaccine, a 
two-dose immunisation of girls yielded non-inferior GMCs relative to a three-dose schedule in 
young women up to, respectively, 48 and 36 months of follow-up. Pooled GMC ratios for the 
bivalent vaccine within girls showed the two-dose schedule becoming inferior to the three-
dose schedule in girls for HPV16 at approximately two years after the first dose. For the 
quadrivalent vaccine, antibody responses for HPV18 became inferior from 18 months of 
follow-up onwards when comparing the two-dose schedule with the three-dose schedule 
within girls. The implementation of two-dose HPV vaccination needs to be monitored closely.
6.12.4.8 Tolerability of the two-dose schedule
After the implementation of the two-dose schedule in the Netherlands, tolerability following 
this new schedule was monitored by the RIVM. Local and systemic AEs occurring within the 7 
days following each dose were obtained by online questionnaires. We also obtained online 
questionnaires on symptoms occurring in the week before vaccination. A local reaction was 
reported by 86.1% and 81.9%, respectively, after the first and second doses. A general 
symptom was reported by 73.0% and 71.6% following the first and second doses, respectively. 
The most reported local reactions were pain (1st dose: 71.7% and 2nd dose: 74.9%) and 
reduced use of the arm (1st dose: 63.0% and 2nd dose: 52.3%). With respect to the general 
symptoms, myalgia (1st dose: 60.7% and 2nd dose: 56.8%), fatigue (1st dose: 19.3% and 2nd 
dose: 25.9%) and headache (1st dose: 21.1% and 2nd dose: 17.7%) were the most reported. But 
general symptoms in the week before vaccination occurred just as often, or sometimes even 
more often, as they did after vaccination. The tolerability of the first dose of the two-dose 
schedule was more favourable compared with the first dose of the former three-dose 
schedule. For the dose at six months, the tolerability was comparable for both schedules.
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6.12.4.9 HPV and HIV (H2M)
In cross-sectional studies, HPV prevalence is consistently higher among HIV-infected people. 
Few studies have been done to establish the incidence and clearance rates of hrHPV infections 
in relation to HIV. The HIV and HPV in MSM (H2M) study is a prospective cohort study in which 
approximately 750 HIV-negative and HIV-infected MSM aged 18 years or older were tested 
every half year for anal and penile HPV DNA. The study was conducted in Amsterdam between 
2010 and 2013, and the follow-up for each participant lasted 24 months.
The incidence of hrHPV was high in this sexually active population: the incidence rate of anal 
HPV-16 infection was 9.1 per 1,000 person-months in HIV-infected men and 4.7 per 1,000 
person-months in HIV-uninfected men. The incidence of hrHPV was consistently higher  
among the HIV infected men (<0.001). Although the clearance rate of those men with an anal 
infection was high, a substantial proportion of those with hrHPV at baseline were still infected 
24 months later (e.g. for HPV18: 46% and 37%, respectively). The results indicate that the 
prevalence of anal hrHPV among HIV-infected men is high, because both the incidence is 
higher and the clearance rate is lower [6, 7].
6.12.4.10 Serology
The serological assay measuring antibodies against seven hrHPV types is based on the 
recognition of the antibodies to epitopes on distinct virus-like particles (VLPs). It is key to 
ensure the supply of the VLPs for future research, which is mainly in hands of the vaccine 
production companies. In addition to the seven hrHPV types, it is desirable to include HPV6 
and HPV11 as well, which would enable us to monitor the seroprevalence against these 
GW-related HPV types.
6.12.4.11 Modelling
We extended the means to model the sero-epidemiology of HPV16 by a mixture model in two 
ways: first, by incorporating serological measurements on another HPV type in a so-called 
bivariate mixture model; and second, by informing the rate of transition from seronegative to 
seropositive by the force of infection from a transmission model. The first extension showed 
that the classification of individuals with antibody concentrations around the laboratory 
cut-off for seropositivity can be improved in a bivariate relative to the univariate mixture 
model. It also suggested that the seroprevalence of HPV16 might be somewhat 
underestimated in a univariate model. This supposition was also borne out by linking the 
serological mixture model to a transmission model for HPV16. In doing so, we estimated 
around 75% of women seroconvert after an incident HPV infection, and that seropositivity is 
naturally lost at a rate of around 2% per year. These estimates imply that univariate 
seroprevalence estimates offer a lower boundary for the proportion of women who have been 
in contact with HPV16 [8].
We also assessed the reduction in the vaccine-preventable burden of cancer in men if boys  
are vaccinated along with girls against oncogenic HPV types 16 and 18 by means of Bayesian 
evidence synthesis. We evaluated the impact of vaccination against HPV types 16 and 18 on  
the burden of anal, penile and oropharyngeal carcinomas among heterosexual men and MSM. 
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We estimated that before HPV vaccination, around 15 QALYs per thousand men were lost to 
vaccine-preventable cancers associated with HPV in the Netherlands. Assuming that 
vaccination also prevents secondary transmission, this burden would be reduced by 37% if the 
vaccine uptake among girls remains at the current level of 60%. To prevent one additional case 
of cancer among men, 795 boys would need to be vaccinated; with tumour-specific numbers 
for anal, penile and oropharyngeal cancer of 2,162, 3,486 and 1,975, respectively. The burden of 
HPV-related cancer in men would be reduced by 66% if vaccine uptake among girls increased to 
90%. In such an event, 1,735 boys would need to be vaccinated to prevent an additional case; 
with tumour-specific numbers for anal, penile and oropharyngeal cancer of 2,593, 29,107, and 
6,484, respectively. The incremental benefit of vaccinating boys when vaccine uptake among 
girls is high is driven by the prevention of anal carcinomas, which underscores the relevance of 
HPV prevention efforts for men who have sex with men [9].
6.12.5  International developments
6.12.5.1 Effectiveness
A systematic review and meta-analysis to assess population-level consequences and herd 
effects after female HPV vaccination (both bivalent and quadrivalent vaccine) programmes 
showed a significant decrease in HPV16 and HPV18 infections between pre-vaccination and 
post-vaccination periods of 68% (RR 0.32 95%CI 0.19-0.52). Additionally, a reduction was also 
seen for HPV31, HPV33 and HPV45, which indicates cross-protection. Among countries using 
the quadrivalent vaccine, a decrease in GW in girls eligible for vaccination was seen, but also in 
older women and boys younger than 20 years of age, which indicates herd effects. In countries 
with vaccine coverage below 50%, indications for cross-protection or herd effects were absent, 
although this could be due to the indirect nature of the inferences in this study [10]. The final 
event-driven analysis of the PATRICIA trial, with a mean follow-up of 39 months, shows that in 
the HPV naïve group vaccine efficacy against cervical intraepithelial neoplasia (CIN) 1+, CIN2+ 
and CIN3+ associated with HPV16 or HPV18 were, respectively, 96.5% (95%CI 89.0-89.4%), 
98.4% (95%CI 90.4-100%) and 100% (95%CI 64.7-100%). So vaccinating adolescents before 
sexual debut has a substantial impact on the incidence of high-grade cervical abnormalities [11].
6.12.5.2 Cost-effectiveness
Two studies, in Canada and the UK, were conducted to evaluate the cost-effectiveness of a 
two-dose HPV vaccination schedule [12, 13]. The studies concerned men and women and also 
took non-cervical cancers into account. Both studies concluded that a two-dose schedule is 
likely to be the most cost-effective option if protection lasts for at least 20 years. As the precise 
duration of protection provided by two-dose schedules may not be known for decades, 
cohorts given two doses should be closely monitored.
Olsen et al. assessed the cost-effectiveness of extending the universal HPV vaccination to both 
girls and boys in Denmark, including the prophylactic effects on all potentially vaccine 
preventable HPV-associated diseases in males and females [14]. The ICER of vaccinating girls 
only was estimated to be € 3,583 per QALY gained in a 3-dose regime. The ICER of vaccinating 
girls and boys compared with girls only was € 28,031 and € 41,636 per QALY gained, in a two-dose 
and three-dose regime, respectively. Given a cost-effectiveness threshold of € 50,000 per QALY 
gained in Denmark, the vaccination of boys and girls was valued to be cost-effective.
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6.12.5.3 Males
In 2011, the USA was the first country that recommended the HPV vaccine for males for routine 
administration. Since that date, several countries have followed, such as Austria, Australia and 
several provinces of Canada. In the USA, the uptake of HPV vaccination in 2014 among males 
was 41.7% [15].
6.12.5.4 Nonavalent vaccine
In March 2015, the EMA adopted a positive opinion for the marketing authorisation of a 
nonavalent HPV vaccine (Gardasil 9, Merck and Co., Inc) [16]. This nonavalent vaccine is 
indicated, in a three-dose schedule (0, 2, 6 months), for the active immunisation of females 
and males from the age of 9 years against the following HPV diseases: i) premalignant lesions 
and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types 16, 18, 31, 
33, 45, 52 and 58; ii) genital warts caused by HPV types 6 and 11. 
Joura et al. investigated the efficacy and immunogenicity of the nonavalent HPV vaccine in 
women aged 16 to 26 years [17]. In this study an efficacy of 96.7 (95%CI 80.9-99.8) against 
high-grade cervical, vulvar, and vaginal disease related to HPV types 31, 33, 45, 52 or 58 was 
estimated in the per-protocol population. Antibody levels for HPV6/11/16/18 were, at one 
month after the third dose, non-inferior compared with the levels after the quadrivalent 
vaccine. A higher number of injection-site-related AEs were reported after the nonavalent 
vaccine (90.7% of participants) than were reported after the quadrivalent vaccine (84.9% of 
participants), and events with severe intensity were also more common after the nonavalent 
vaccine [17, 18]. Serious AEs related to the vaccine were rare [19].
Since February 2015, the Advisory Committee on Immunization Practices (ACIP) has 
recommended the nonavalent HPV vaccine as one of the three vaccines that can be used for 
routine HPV vaccination in the US [20]. In the US, the nonavalent vaccine was estimated to 
potentially prevent from 4.2% to 18.3% of the invasive cervical, anal, oropharyngeal and 
vaginal cancers in addition to the current vaccines for both males and females [21]. Serrano et 
al. estimated a potential additional impact of the nonavalent HPV vaccine compared with the 
current vaccines of 12 to 19% on HPV-related invasive cervical cancer in Brazil, Mexico, India 
and China [22]. In France, the additional impact of the nonavalent vaccine compared with the 
quadrivalent vaccine was potentially 9.9 to 15.3% for invasive cervical cancer, 24.7 to 33.3% for 
high-grade cervical neoplasias, 12.3 to 22.7% for low-grade squamous intraepithelial lesions 
and 8.5 to 10.4% for anal cancer [23]. A low efficacy benefit of 2.1 to 5.4% was found for genital 
warts and of 0.0 to 1.6% for oropharyngeal carcinoma, which could be explained by the fact 
that these conditions are almost exclusively associated with HPV types targeted by the 
quadrivalent vaccine. 
Kiatpongsan et al. determined the vaccine costs for which the nonavalent HPV vaccine would 
be cost-effective compared with the current bivalent and quadrivalent vaccines in Kenya and 
Uganda [24]. They estimated that the nonavalent vaccine would be very cost-effective if the 
added cost per vaccinated girl is between 5.2 (worst-case scenario) and 16.2 (best-case 
scenario) International dollars in Kenya and between 4.5 (worst-case scenario) and 13.7 
(best-case scenario) International dollars in Uganda.
Kosalaraksa et al. evaluated the immunogenicity and safety of the nonavalent vaccine when 
administered concomitantly with REPEVAX (a diphtheria, tetanus, pertussis and poliomyelitis 
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vaccine) in females and males 11-15 years of age [25]. Concomitant administration of the 
vaccines was generally well-tolerated. For all types of the nonavalent HPV vaccine,  
non-inferiority of GMC (non-inferiority margin GMC ratio 0.5) and seroconversion rates 
(non-inferiority margin difference -5%) for the concomitant versus the non-concomitant 
group was demonstrated.
6.12.5.5 Safety
Both the EMA and Lareb have announced a review of the current notifications of complex 
regional pain syndrome and postural orthostatic tachycardia syndrome in relation to HPV 
vaccination; former reports on these conditions among women who had received the HPV 
vaccine, in which a causal link was not established, were considered by the EMA.
6.12.6  Tables and Figures
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Figure 6.12.1 Incidence / 100,000 (standardised by the European standardised rate) of new 
cervical, anogenital, mouth/oral and pharynx/pharyngeal cancer cases in the Netherlands 
2000-2014, by cancer type (the Netherlands Cancer Registry (NKR)) 
*Preliminary figures
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Figure 6.12.2 Incidence / 100,000 of deaths related to cervical, anogenital, mouth, oropharynx and 
pharynx cancer cases in the Netherlands 2000-2013 by cancer type (Statistics Netherlands (CBS)) 
* Number of deaths due to pharynx cancer includes the number of oropharynx cancer deaths. 
** Preliminary figures. In 2013, CBS started to use international software for automatically coding the causes of death. This makes the number more 
reproducible and internationally comparable. Due to this change, there have been some significant shifts seen in the causes of death.
Table 6.12.1 Vaccine effectiveness (VE) up to four years post-vaccination 
Crude VE 95% CI Adjusted VE* 95% CI
Incident infections
HPV16 and 18 69% (50%-81%) 70% (52%-82%)
HPV16,18,31,45 73% (60%-82%) 72% (58%-82%)
Persistent infections
HPV16,18 (#) 100% ## 100% ##
HPV16,18,31,45 (#) 76% (-16%-95%) 86% (58%-95%)
HPV16,18 65% (25%-84%) 75% (44%-89%)
HPV16,18,31, 45 62% (27%-80%) 69% (39%-84%)
 
HPV = human papillomavirus;
* Adjusted for the following baseline characteristics: age, urbanization degree, education, ethnicity, ever smoked, currently smoking, 
contraception use, ever had sexual intercourse, age of partner, lifetime number of sexual partners
# Negative for one of these types at baseline
## Model does not converge
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7.1  Rotavirus infection
P. Bruijning-Verhagen, E. Duizer, W. van Pelt, J.M. Kemmeren, H.E. de Melker, W. Luytjes, I.H.M. Friesema
7.1.1 Key points
• In 2014, the rotavirus season was exceptional low.
• G9P[8] was the most prevalent genotype in 2014. 
• The relative prevalence of G2P[4] shows a slight, but steady increase since 2011.
7.1.2 Epidemiology
The Working Group Clinical Virology reports the number of rotavirus positive results weekly. In 
2014, the rotavirus season was exceptionally low and delayed in the winter/spring in the 
Netherlands (Figure 7.1.1). In total, 607 diagnoses were reported in 2014, compared with 1,487 
diagnoses in 2013 and 1,287 in 2012 (Table 7.1.1). After the low season of 2014, an extra high 
season was expected in the winter of 2014-2015. However, up to July 2015, the season was 
comparable to 2012, which had been a low season (see Figure 7.1.1). All-cause gastroenteritis in 
children under the age of 5 was examined using routine health record data from general practices 
in the Nivel Primary Care Database for comparison with the weekly rotavirus reports [1]. These 
data correlated well with the weekly number of rotavirus positive results, with a significant 
decrease occurring between August 2013 and August 2014. The cause of this drop in rotavirus in 
the Netherlands in 2014 is unknown. Some potential contributing mechanisms mentioned in the 
literature are the mild winter of 2013/2014, the relatively high rotavirus epidemic season of the 
winter of 2012/2013, declining birth rates over the years, thus decreasing the group of susceptible 
individuals, and rotavirus vaccination programmes in neighbouring countries [1-4]. 
Recent studies suggest that there is a slight increase in the risk of intussusception among 
babies after receiving the first dose of rotavirus vaccine [5-9]. After the second and third doses, 
this risk is marginally elevated. As a result of these findings, baseline incidences of 
intussusception are calculated for the Netherlands to observe a possible increase after the 
introduction of rotavirus vaccination (see Chapter 5, Table 5.3 and Table 5.4).
7.1.3 Pathogen
IDS/RIVM received 137 faeces samples that tested positive for rotavirus in peripheral 
laboratories, 130 of these samples could be typed (Table 7.1.1). G1P[8] was no longer the most 
prevalent genotype in 2014. The most prevalent genotype in 2014 was G9P[8]. Worthy of note 
is the slight, but steady increase of relative prevalence of G2P[4] since 2011 (Figure 7.1.2). Mixed 
rotavirus infections are known to occur in approximately 5% of the cases, but will not readily 
be detected by this sequence-based method.
7.1.4 Research
IDS/RIVM participates, together with 14 other countries, in EuroRotaNet. This European 
Rotavirus Network was established in January 2007; IDS joined the project in June 2008. 
Within this project, Dutch microbiological laboratories can send rotavirus-positive faeces 
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samples to IDS for typing using sequencing. EuroRotaNet combines the results of the 
participating countries to create an overview of circulating serotypes of rotavirus in 
consecutive rotavirus seasons in Europe. The results for the Netherlands for 2009-2014 are 
given in Section 7.1.3 and Figure 7.1.2.
This multicentre study, Risk-Group Infant Vaccination Against Rotavirus (RIVAR), started in 
December 2014. This Phase IV study assesses the effectiveness, impact and feasibility of a 
rotavirus vaccination programme organised through secondary paediatric care and targets 
high-risk infants, including children born prematurely, with low birth weight or severe congenital 
pathology. The study pilots implementation of the RIVAR programme in several hospitals in a 
step-wedged design, combined with an observational before-after cohort study of high-risk 
infants. Enrolment of implementation across several hospitals covers a period of 3 years. 
The mechanisms contributing to the rotavirus epidemic pattern and explaining the 
unanticipated drop in detected rotavirus cases in the 2014 season are further explored in a 
project initiated by the Epidemiology and Surveillance Department of the RIVM on temporal 
associations between rotavirus detections, birth rate and weather conditions.
7.1.5 International developments
As of April 1st 2015, 77 countries worldwide have implemented universal rotavirus vaccination, 
including 12 European countries (Armenia, Austria, Belgium, Estonia, Finland, Georgia, 
Germany, Latvia, Luxembourg, Moldavia, Norway and the United Kingdom) [10]. Several other 
countries are at various stages of issuing national recommendations or integrating rotavirus 
vaccination into their national immunisation programmes. In the Netherlands, a 
recommendation by the Health Council about including rotavirus vaccination in the NIP is 
expected at the end of this year. In France, however, because of three infant deaths and many 
serious side effects, rotavirus vaccines are no longer recommended for routine childhood 
immunisation (see Chapter 5) [11].
Both the orally administered live monovalent Rotarix vaccine and the orally administered live 
pentavalent Rotateq vaccine are marketed internationally. The monovalent live attenuated 
vaccine Rotavac is currently only licensed for the Indian market. Local development of other 
rotavirus vaccines is ongoing in the USA, Finland, India, Brazil, Australia and Vietnam [12]. 
These include other live (neonatal) rotavirus vaccines, as well as inactivated (subunit) rotavirus 
vaccines suitable for intramuscular or intradermal administration.
Post-implementation studies on the real-world impact of rotavirus vaccination now include 
data covering up to 7 years post-implementation. A systematic review summarised the impact 
of universal rotavirus vaccination in European countries and reported an effectiveness of 
between 68 and 98% and reductions in rotavirus-related hospitalisations of between 65 and 
84% [13]. Another meta-analysis assessed strain-specific effectiveness in high and middle-
income countries globally and the impact on rotavirus strain distribution using data covering 
up to 6 years post-implementation [14]. In high-income settings, the effectiveness of Rotarix 
and Rotateq was comparable, ranging from 83% to 94% for fully homotypic strains and from 
71% to 87% for partly or fully heterotypic strains. Prevalent strains in countries using Rotarix 
were G2P[4] (2,198 of 4,428, 50%) and G1P[8] (953, 22%), and prevalent strains in countries 
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using Rotateq were G1P[8] (1,280 of 3,875, 33%) and G2P[4] (1,169, 30%). Sustained 
predominance of a single strain was not recorded. The US reported sustained reductions in 
rotavirus detections up to 7 years post-implementation in the CDC passive laboratory 
reporting system, the National Respiratory and Enteric Virus Surveillance System (NREVSS) [15]. 
The decline compared with pre-vaccination ranged between 58% and 90% in each of the 7 
post-vaccine years. The biennial pattern of rotavirus activity that emerged in the post-vaccine 
era in the US was sustained, with years of low activity and highly erratic seasonality alternating 
with years of moderately increased activity and seasonality similar to that seen in the pre-
vaccine era. Annual rotavirus-coded hospitalisation rates in the US also declined by 63-94% in 
the post-vaccine years 2008-2012 [16].
The European Society for Paediatric Infectious Diseases updated their consensus 
recommendations for rotavirus vaccination in Europe [17]. The recommendation to vaccinate 
all infants against rotavirus and that the first dose of oral rotavirus vaccine should be given 
between 6 and 12 weeks of age has been sustained, but with an emphasis toward the lower 
range of the recommended age, that is, preferably between 6 and 8 weeks of age in order to 
minimise the risk of rotavirus vaccination induced intussusception. An update of literature on 
intussusception and other AEs of rotavirus vaccination is given in 5.3.2.5.
7.1.6 Tables and Figures
Table 7.1.1 Number of reported laboratory diagnoses of rotavirus, and number of positive 
samples sent to and typed at the RIVM, 2009-2014
Laboratory
diagnoses
Samples at RIVM Samples typed at RIVM
Year N
% of 
diagnoses N
% of samples  
at RIVM
2009 1,935 869 44.9 830 95.5
2010 2,180 578 26.5 547 94.6
2011 1,504 414 27.5 400 96.6
2012 1,287 276 21.4 265 96.0
2013 1,487 299 20.1 280 93.6
2014 607 137 22.6 130 94.9
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Figure 7.1.1 Reported laboratory diagnoses of rotavirus per month, 2009-2014
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Figure 7.1.2 Rotavirus types as genotyped at the RIVM, 2009-2014
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7.2  Varicella zoster virus (VZV) infection
E.A. van Lier, A.W.M. Suijkerbuijk, M. Nielen, A.K. Lugnér, M. van Boven, P. Jochemsen, W. Luytjes,  
H.E. de Melker
7.2.1 Key points
• The VZV epidemiology (incidence of GP consultations, hospitalisations and deaths) is 
comparable to previous years.
• It has been hypothesised by Hope-Simpson that exogenous immune boosting in 
latently infected persons by contact with varicella patients reduces the probability of 
herpes zoster. If true, universal varicella vaccination may increase herpes zoster 
incidence due to reduced varicella zoster virus circulation.
• The cost-effectiveness of varicella vaccination is strongly affected by its impact on 
herpes zoster and the time horizon for economic assessment: in the absence of 
exogenous immune boosting, varicella vaccination with high coverage is expected  
to be cost-effective and may even be cost saving, while it is not expected to be 
cost-effective on reasonable time scales if immune boosting is present. Results by  
birth cohort show that varicella vaccination may result in inequalities of the health 
effects between generations.
7.2.2 Epidemiology
According to a new, more precise method for estimating morbidity rates used by NIVEL from 
2012 onwards, the incidence of herpes zoster is higher than it was according to the old method 
(Table 7.2.1) [1, 2]. The new method uses constructed episodes of illness (episodes are closed 
after 4 and 16 weeks without an encounter for varicella and herpes zoster, respectively), based 
on an algorithm instead of the recorded ‘raw’ episodes of care in the old method. Because of 
these changes, the incidence for 2010-2012 was recalculated. In the period 2010-2013, 2.2% of 
the patients with a new varicella episode had more than one new episode in the same year, for 
herpes zoster this was 2.5%. The incidence of varicella episodes per 100,000 of population is 
highest in the age groups below five years, whereas the incidence of herpes zoster episodes is 
highest in the age groups above 50 years (Figure 7.2.1). The incidence of hospitalisations due to 
varicella is highest among new-borns, while the incidence of hospitalisations due to herpes 
zoster is highest among the oldest age groups (Figure 7.2.2 and Table 7.2.2). 
Mahamud et al. found that national death certificate data tend to overestimate the number of 
deaths in which herpes zoster is the underlying or contributing cause of death [3]. If we apply 
their rate of deaths in which herpes zoster was validated as the underlying cause of death (0.25 
(range 0.10–0.38) per 1 million population) on the Dutch population in 2014, we would expect 
4.2 deaths (range 1.7–6.4) instead of the 26 deaths that were reported in 2014 (Table 7.2.3).
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7.2.3 Pathogen
In 2015, an overview has been published concerning the current progress towards 
understanding the molecular mechanisms that account for the reduced virulence of vaccine 
virus [4]. A complicating factor in research into genetic factors that contribute to a lower 
pathogenicity of the OKA vaccine strain is the fact that the strain contains a mixture of 
genetically distinct haplotypes (i.e. not all genomes contain the vaccine changes at all 
positions). The three commercial vaccine strains differ in their sequence and genetic 
heterogeneity is observed between vaccine lots from the same manufacturer. Depledge et al. 
describe how the haplotype of Varivax is different in every skin lesion [5]. Rash-forming 
haplotypes are not completely representative of the virus population. They found no 
significant differences in allele frequencies between viruses directly causing rash after 
vaccination and those that cause a zoster-rash following a period of latency and reactivation.
7.2.4 Research
In 2015, a cost-effectiveness analysis of varicella vaccination in the Netherlands, including its 
effects on herpes zoster, has been finalised [6]. The effects of varicella vaccination were 
simulated using a dynamic transmission model, parameterised with varicella zoster 
prevalence [7] and herpes zoster incidence data [8], and linked to an economic model. In this 
study, a two-dose varicella vaccination programme with a first dose at 12 months and a second 
dose at 4 years of age was simulated starting on January 1, 2020 under various vaccination 
coverages. It has been hypothesised by Hope-Simpson [9] that exogenous immune boosting in 
latently infected persons by contact with varicella patients reduces the probability of herpes 
zoster. If true, universal varicella vaccination may increase herpes zoster incidence due to 
reduced varicella zoster virus circulation in the population. Furthermore, the varicella vaccine 
contains a live attenuated virus, which itself can cause reactivation. However, there is limited 
quantitative evidence on the frequency of herpes zoster among varicella vaccinees, especially 
over the long term [10]. We therefore considered four vaccination scenarios (labelled A-D) that 
differ by whether or not they include exogenous immune boosting and whether or not 
reactivation of vaccine virus is included (see Table 7.2.4). 
The impact of vaccination on the incidence of varicella and herpes zoster by birth cohort is 
shown in Figure 7.2.3. The four scenarios yield identical results for varicella and differ 
substantially for herpes zoster. Specifically, in scenario B (no boosting, no reactivation of 
vaccine virus), both varicella and herpes zoster incidence decrease with increasing vaccination 
coverage in vaccinated cohorts; the incidence of varicella and herpes zoster in unvaccinated 
cohorts is marginally affected. In contrast, in scenario A (immune boosting, no reactivation of 
vaccine virus), the incidence of herpes zoster increases in comparison with scenario B not only 
in the vaccinated cohorts but also in unvaccinated cohorts. This is due to the reduced immune 
boosting in latently infected persons, which has a profound impact, especially when 
vaccination coverage is high. In scenario C (immune boosting, reactivation of vaccine virus) the 
situation is even more extreme because, in this scenario, even all vaccinated cohorts have a 
high lifetime risk of herpes zoster if vaccination coverage is high. In the scenarios that include 
boosting (scenarios A and C), the effect of vaccination on varicella and herpes zoster is much 
smaller in case of low to intermediate vaccination coverage (25% or 50%).
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The full impact of vaccination on reducing the incidence of varicella is observed within 5 to 10 
years into the vaccination programme (Figure 7.2.4). In contrast, the potential increase in 
herpes zoster incidence (scenarios A and C with immune boosting) occurs on a much longer 
timescale of 20-60 years after the start of vaccination. 
Figure 7.2.5 shows a stylised overview of the cost-effectiveness analyses at high vaccination 
coverage (95%). In models without immune boosting (scenarios B and D), vaccination at high 
coverage is expected to be cost-effective (scenario D) or even cost saving (scenario B). In 
contrast, in models with boosting (scenarios A and C), vaccination at high coverage is either 
not cost-effective within 180 years (scenario C) or is cost-effective only in the very long term 
(>130 years; scenario A), with exception of the first ten years after the start of vaccination when 
varicella incidence is low and herpes zoster incidence has not yet increased. In these scenarios, 
disadvantages for unvaccinated birth cohorts (i.e. health loss due to increased herpes zoster) 
out-weigh health benefits for vaccinated cohorts. 
These analyses show that the health effects and cost-effectiveness of varicella vaccination 
depend crucially on its impact on herpes zoster and the time horizon for economic analysis.  
In the absence of exogenous immune boosting, vaccination with high coverage is expected to 
be cost-effective and may even be cost saving, while it is not expected to be cost-effective on 
reasonable timescales if immune boosting is present. Results by birth cohort further reveal 
that varicella vaccination may result in inequalities of the health effects between generations. 
Specifically, in scenarios with immune boosting, the benefits of vaccination accrue in 
vaccinated birth cohorts, while the burden and costs are largely due to herpes zoster in 
unvaccinated persons. Cohorts born just before the introduction of vaccination, especially, are 
expected to pay the price for the health gain in vaccinated cohorts. These results reveal an 
ethical dilemma for policymakers, as groups not included in the vaccination programme may 
be exposed to a substantially increased health hazard. In conclusion, optimal decision-making 
on varicella vaccination will involve judicious and repeated weighing of the various scenarios 
as more evidence comes in from countries with vaccination programmes already in place.  
The results of these analyses can be used by the Dutch Health Council, which is preparing a 
recommendation on herpes zoster vaccination (and, in the longer run, on varicella vaccination) 
in the Netherlands.
7.2.5 International developments
Besides the guidance of ECDC on varicella vaccination [11], which was finalised in 2015, the 
WHO published a position paper on varicella and herpes zoster vaccines [12]. The WHO 
acknowledges that the public health value of varicella vaccination in lowering the varicella 
disease burden is well-established. It advises countries before deciding on the introduction of 
varicella vaccination to set up adequate disease surveillance and especially to pay attention to 
vaccination coverage and its possible impact on herpes zoster. Countries deciding on herpes 
zoster vaccination should take into account the age-dependent burden of disease, vaccine 
effectiveness, the duration of protection and cost-effectiveness to determine the optimal age 
and dosing schedule.
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Continuous surveillance of varicella and herpes zoster is important since it remains difficult to 
draw definite conclusions on a possible effect of varicella vaccination on herpes zoster 
incidence [13]. Russell et al. found declining rates of herpes zoster in Alberta, Canada among 
persons ≤10 years, consistent with an impact of varicella vaccination. They state that the trend 
of increasing herpes zoster among older persons began prior to start of universal varicella 
vaccination in 2002 [14]. Humes et al. also detected declining rates of herpes zoster 
hospitalization in Connecticut, USA among persons ≤14 years [15]. They state that there are at 
least two possible explanations – a vaccine-induced reduction in the number of persons with 
latent wild varicella infection and a reduction in the prevalence of underlying conditions that 
are associated with a higher risk of HZ, such as HIV infection. Baxter et al. found a major 
reduction in varicella incidence and hospitalisation with no evidence of a shift to older age 
groups in the 15 years after the introduction of vaccination against varicella [16]. Kelly et al. 
showed decreased varicella and increased herpes zoster incidence in a setting of increasing 
varicella vaccine coverage in Victoria, Australia through an ecological study [17]. Severe 
varicella (as measured by hospitalisation) also decreased after the implementation of varicella 
vaccination in Spain, while the hospitalisation rate of herpes zoster slightly increased [18]. 
From 1 September 2013, routine vaccination against herpes zoster at 70 years of age was 
introduced in the UK [19].
Recently, two European economic evaluations and three reviews have been published 
regarding universal varicella vaccination and herpes zoster vaccination for the elderly. Péraud 
et al. assessed the cost-effectiveness of a herpes zoster vaccination programme in Germany 
using a Markov Model [20]. From a societal perspective, vaccinating 20% of people ≥60 years 
would result in an ICER of € 37,417 per QALY gained, whereas vaccinating 20% of people ≥50 
years would lead to more favourable results: € 32,848 per QALY gained. Kawai et al. reviewed 
the cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia and 
concluded that most of the 15 included studies showed that vaccination against herpes zoster 
is likely to be cost-effective [21]. De Boer et al. also reviewed the cost-effectiveness of 
vaccination against herpes zoster [22]. They concluded that the vast majority of the fourteen 
included studies showed that the vaccination of 60 to 75 year-olds was cost-effective when the 
duration of vaccine efficacy was longer than 10 years. Another study aimed to assess the 
cost-effectiveness of adding routine varicella vaccination through MMRV, using different 
vaccination strategies in France, based on a dynamic transmission model [23]. Routine MMRV 
vaccination is expected to be a cost-effective option, considering a cost-effectiveness 
threshold of € 20,000 per QALY gained; routine vaccination was cost saving from a societal 
perspective. Results were driven by a large decrease in varicella incidence, despite a temporary 
initial increase in the number of zoster cases due to the assumption of exogenous boosting. 
Damm et al. reviewed 38 modelling studies that assessed the cost-effectiveness of routine 
varicella and herpes zoster vaccination [24]. They also concluded that vaccination against 
herpes zoster is mostly considered to be cost-effective, while the cost-effectiveness of varicella 
vaccination depends on the inclusion or exclusion of exogenous boosting in the model. 
Therefore, a clarification concerning the role of exogenous boosting is crucial for decision-
making regarding varicella vaccination, as was also pointed out in our national cost-effectiveness 
analysis described in Paragraph 7.2.4.
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A recent study of Morrison et al. showed that the long-term persistence of zoster vaccine 
(Zostavax®) efficacy is limited and depends on the outcome measure: vaccine efficacy for 
herpes-zoster-related burden of illness (a severity-by-duration measure of herpes zoster pain 
and discomfort) persisted into year 10 post-vaccination, whereas vaccine efficacy for herpes 
zoster incidence persisted only through year 8 [25].
A phase III study with a follow-up period of, so far, 3.2 years among older adults (≥50 years) in 
18 countries, showed that the efficacy of a new adjuvanted recombinant subunit vaccine 
against herpes zoster (two doses two months apart) is high at 97.2% (95%CI: 96.6-97.9%) and 
does not depend on the age of administration (as was seen for Zostavax®) [26]. Although this 
new vaccine would, in principle, also be suitable for people with immunosuppression, efficacy 
and safety within this group were not studied. 
A phase II study showed that three different formulations of the vaccine were immunogenic 
and well-tolerated in adults ≥60 years [27]. At this moment it is unknown when this new 
vaccine against herpes zoster might become available on the Dutch market or whether the 
vaccine efficacy will be long-lasting.
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7.2.6 Tables and Figures
Table 7.2.1 Estimated incidence per 100,000 of population of episodes of varicella  
(ICPC-code A72) and herpes zoster (ICPC-code S70), based on NIVEL-PCD, using the old 
method (2005-2011) and the new method (2010-2013) (rounded off to tens)
Syndrome 2005 2006 2007 2008 2009 2010 2011 2012 2013
Varicella* 190 300 210 (160) (110) (180) - -
Varicella** 130 260 230 290 180 210 230 -
Varicella*** 310 270 250 280
Herpes zoster** 350 370 310 340 360 360 360 -
Herpes zoster*** 480 490 510 510
*  Dutch Sentinel General Practice Network (CMR) [28]; starting in 2008, this network has changed from registration on paper to electronic 
reporting, which may have resulted in under-reporting of the weekly number of varicella patients. We therefore used data from NIVEL-PCD 
from 2008 onwards.
**  NIVEL-PCD, old method [8].
*** NIVEL-PCD, new method from 2012 onwards [1]; 2010-2012 recalculated.
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Figure 7.2.1 Estimated incidence per 100,000 of population of episodes of varicella (ICPC-code 
A72) and herpes zoster (ICPC-code S70) in 2013 versus mean 2010-2012 by age group [1] 
Note: Varicella cases in people older than 49 are only sporadically reported by GPs and are therefore not included.
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Table 7.2.2 Incidence per 100,000 of population of hospitalisations due to main diagnosis of 
varicella (ICD-10 code B01) and herpes zoster (ICD-10 code B02), 2005–2014 [29]
Syndrome 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014*
Varicella 1.5 1.9 1.4 1.7 1.5 1.9 1.7 1.5 1.7 1.9
Herpes zoster 2.2 1.9 2.0 2.0 2.4 2.1 2.2 2.1 2.1 2.7
 
Note: In 2006/2007 a number of hospitals stopped their registration, causing an underestimation of hospital admissions from 2006 onwards  
 (see Appendix 1).
Note: Admissions for one day have been excluded.
Note: The number of admissions can be higher than the number of hospitalised patients reported here because some patients are admitted  
 more than once within the same year.
* For 2014, the hospitalisation data are preliminary and incomplete. 
Source: DHD
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Figure 7.2.2 Incidence per 100,000 of population of hospitalisations due to main diagnosis  
of varicella (ICD-10 code B01) and herpes zoster (ICD-10 code B02) in 2014 versus mean 
incidence in 2000-2013 by age group [29]. 
Note: For 2014, the hospitalisation data are preliminary and incomplete.  
Source: DHD
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Table 7.2.3 Absolute number of deaths with main cause varicella (ICD-10 code B01) and 
herpes zoster (ICD-10 code B02), 2005–2014 [30]; data for 2013-2014 are preliminary 
Source: CBS 
Syndrome 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Varicella 1 3 5 0 1 2 1 2 1 2
Herpes zoster 15 24 21 14 20 25 20 21 21 26
 
Table 7.2.4 Overview of the four main vaccination scenarios implemented in the dynamic 
transmission model based on different assumptions about the effects of immune boosting  
on herpes zoster and vaccine VZV reactivation, and with various vaccination coverages
Vaccination scenariosa
Assumptions A B C D
- Boostingb Yes No Yes No
- Vaccine VZV reactivationc No No Yes Yes
- Vaccination coverage (%)d 0/25/50/95 0/25/50/95 0/25/50/95 0/25/50/95
 
a General assumptions for all scenarios:  
 - two-dose varicella vaccination programme (first dose: 12 months, second dose: 4 years of age), starting on January 1, 2020;
 - vaccine effectiveness of 90% after one dose, 95% after two doses;
 - probability of breakthrough in varicella after one dose: 10% per infectious contact (relative infectiousness after one dose 50%), no 
breakthrough in varicella after two doses.
b Yes = exogenous immune boosting has an effect on the probability of VZV reactivation,  
No = no effects of immune boosting.
c Yes = vaccine VZV is able to reactivate at the same rate as wild type VZV,  
No = no reactivation of vaccine VZV.
d 0%: baseline without varicella vaccination, 25%: conservative coverage because of expected limited acceptance of varicella vaccination due to 
the perceived low severity of varicella, 50%: intermediate coverage, 95%: highest coverage based on regular Dutch vaccination coverage data.
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Figure 7.2.3 Impact of varicella vaccination by birth cohort on the occurrence of varicella and 
herpes zoster
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Figure 7.2.4 Impact of varicella vaccination over time on the occurrence of varicella and herpes 
zoster
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Figure 7.2.5 Stylised overview of the cost-effectiveness of high-coverage (95%) varicella 
vaccination programme over time; incremental cost-effectiveness ratio (ICER) threshold is set 
at € 20,000 per QALY
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7.3  Hepatitis A
I.H.M. Friesema, A.W.M. Suijkerbuijk, W. Luytjes, E. Duizer
7.3.1 Key points
• In 2014, the number of reported hepatitis A patients (105 cases) remained low, as in 
recent years. 
• More than half of these patients were younger than 20 years and clusters occurred 
almost only amongst these cases. 
• Fifty-three per cent of the Dutch cases were reported to be travel-related, almost half 
of them in Morocco.
7.3.2 Epidemiology
In 2014, 105 cases of hepatitis A were reported in the Netherlands, corresponding to 0.6 cases per 
100,000 inhabitants. This is comparable to 2013 (110 cases) and the lowest number since hepatitis 
A became notifiable in 1999 (Figure 7.3.1 / Appendix 2). No mortality due to hepatitis A was 
reported. The age distribution over the years 2005-2014 is given in Figure 7.3.2. This is the first 
time since 2006 that more than half of the patients were younger than 20. Of the 23 patients 
hospitalised (22%), only 3 (13%) were younger than 20 years (5, 16 and 18 years), compared with 
27% of patients hospitalised in 2013, with 13% younger than 20. Sixteen epidemiologically linked 
clusters with a total of 38 of the 105 cases could be deduced from the reports, only 4 clusters of 
which included an adult. 
The percentage of travel-related cases was 53% in 2014 (Figure 7.3.1). Morocco (23/56; 41%) 
was reported most frequently; all other countries were reported a maximum of four times. 
Half of the clusters (8/16) were at least partly travel-related, mostly from Morocco (4 clusters). 
The consumption of food or water was reported as the source of the infection in 32% of the 
cases, 30/34 (88%) of which were consumed in an endemic country.
7.3.3 Pathogen
In 2014, from 89 (85%) cases samples were sent in for virus typing and from 73 (70%) cases the 
samples were positive by PCR and could be sequenced. Out of all cases and contacts, a total of 
153 serum and faecal samples were tested. HAV RNA was detected in 79 (52%) and 78 (99%) 
could be typed, which resulted in 40 unique sequences, 12 of which were detected in clusters of 
2-14 cases. Since 2011, there seems to have been a slight, but steady increase in the fraction of 
HAV 1A strains (Figure 7.3.3), mostly originating from Morocco.
7.3.4 Research
Initially, the typing of IgM-positive samples by IDS was done for a period of two years, but is 
now being continued because it adds valuable data for the detection and follow-up of clusters 
and outbreaks. The results are linked to the notifications, where possible, to combine the 
available information about microbiology and epidemiology. In cases involving a molecular 
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cluster of cases with an unknown source within the Netherlands, or an international molecular 
cluster of cases, a source-tracing investigation is usually initiated.  
The RIVM coordinated the HAV NET database, which was built to help identify the source of 
food-related clusters and outbreaks. As of 2015, 32 institutes from 27 countries all over the 
world have admission to the database and 18 institutes have actively submitted data. The HAV 
NET database currently contains a total of 6,935 sequences (HAV NET (N=2568) and Genbank 
(N=4367)) for the period 1957-2015. Data submitted by HAV NET partners include HAV strain 
sequences with additional information: case identification and immune status, possible 
transmission route (e.g. travel related), typed region and length of the fragment, geographic 
information of the sequence, and level of endemicity. In the HAV NET database, Genotype IA 
(60%) is the most prevalent; Genotype IB (19.5%) is more prevalent in Africa and the Middle 
East and Genotype IIIA (19.7%) is the most prevalent in Asia (India, Afghanistan). Available 
sequences have made it possible to identify and link outbreaks and their geographic origin 
internationally. The currently available HAV NET database contains information from most 
continents and genotypes, but resolution in some geographic areas is limited by the number 
and the length of sequences. It does, however, allow for estimating the most likely origin of 
the infecting strain in >90% of the cases.
7.3.5 International developments
Greece, Catalonia (Spain) and Israel reported an evaluation of the effect of routine vaccination 
against hepatitis A in children. Greece is the only European Union member state that in 2008 
included hepatitis A vaccine in the routine national childhood immunisation programme. 
Mellou et al. [1] identified a decreasing trend in the HAV notification rate over the years 
1982-2013. However, universal vaccination (~80% vaccine coverage of children) had no 
significant effect on the annual number of reported cases. In the last decade, one-third of all 
reported cases were Roma and, in 2013, three outbreaks including Roma cases were recorded. 
Contributing factors mentioned are a low vaccination coverage for this group, low 
socioeconomic conditions and poor hygiene. The authors suggest that universal vaccination 
may need to be reconsidered given the limited resources allocated to public health in Greece. 
Probably a more cost-effective approach would be to implement a programme that included: 
a) vaccination of high-risk groups, b) universal vaccination of Roma children and improving 
conditions at Roma camps, c) education of the population and travel advice, and d) 
enhancement of the control measures related to hepatitis A. In Catalonia, children have been 
vaccinated against hepatitis A at the age of 12 years since 1999 [2]. Attack rates declined and 
were as low as 1.5 per 100,000 inhabitants in the 2010-2013 period. Vaccine failures occurred at 
a very low rate. More striking was the increase of symptomatic infections among young 
children under 6 years of age. The authors hypothesize that genotype IIIA strains may produce 
more clinical cases in these young children than anticipated. They conclude that it would be 
better to vaccinate at an earlier age than is done now. In Israel, vaccination against hepatitis A 
was started in 1999 with a mean vaccine coverage of 92% for the first dose (given at 18 months 
of age) and 88% for the second dose (given at 24 months of age) [3]. In the pre-vaccination 
period (1993-1998), the average annual incidence was 50.4 per 100,000 inhabitants, which 
declined to an average of less than 1.0 per 100,000 inhabitants per year in 2008-2012. The 
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decrease was also seen in the unvaccinated populations. Of the cases reported between 2002 
and 2012, 2% were reported to be vaccinated with one dose and less than 1% had received 2 
doses (3 cases). 
Espul et al. [4] reported the results of 5 years of follow-up of immune response after 1 or 2 
doses of inactivated hepatitis A vaccine (Avaxim 80U Pediatric) given at 11-23 months of age in 
the Mendoza Province, Argentina. Most of the 411 children that were evaluable at year 5 had 
received 1 dose (n=318) and 85 had received 2 doses. Seroprotection after 5 years was 99.7% in 
the group with 1 dose and 100% in the group with 2 doses. The highest anti-HAV antibody 
concentrations were found in the children who had received 2 doses. The children who became 
seronegative received a booster dose. Results of an open Phase II study conducted at 2 centres 
in Belgium was published in 2015, reporting the immunogenicity of 2 doses of Epaxal® Junior 
compared with Epaxal® and Havrix® Junior in children 1-17 years, 5.5 years after the second 
dose [5]. Seroprotection at 5.5 years of follow-up was 100% for all 3 vaccines. GMCs were 
overall higher for Epaxal®. No statistically significant differences in GMCs were seen between 
Epaxal® Junior and Havrix® Junior. In addition, GMCs decreased more rapidly in younger 
children than in older children.
A study in Brazil involving 22 healthy adults and 20 outpatients with self-limited acute 
hepatitis A showed that the first vaccine dose induced HAV-specific cellular response similar to 
that found in an initial natural infection. [6]
Finally, Hens et al. [7] used the data from two clinical trials with results of hepatitis A vaccine-
induced antibodies measured up to 17 years after the first dose to review the results of existing 
statistical models of the long-term persistence of antibodies. Based on these models and the 
available data, they predicted a duration of protection of at least 25 years in at least 95% of the 
vaccinees. These results are comparable to long-term estimates based upon shorter follow-
up. The different models run by the authors were not consistent in the estimation of the 
maximum duration of protection, varying from a drop in protection after 25 years to 
protection of up to at least 40 years after vaccination.
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7.3.6 Tables and Figures
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Figure 7.3.3 HAV genotype distribution of HAV strains detected in the Netherlands in 2011-2014
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7.4  Meningococcal serogroup B disease
L. Mollema, H.E. de Melker, F.R.M. van der Klis, P. Kaaijk, N.Y. Rots, G.A.M. Berbers, L. Spanjaard,  
M.B. van Ravenhorst, E.A.M. Sanders, A. van der Ende
7.4.1 Key points
• In 2014, a decrease in meningococcal serogroup B (MenB) disease was seen (60 cases in 
2014, compared with 88 in 2013). In 2015, up to June, there were 32 MenB cases.
• In September 2015, UK babies born on or after 1 July 2015 will be offered the 4CMenB 
Bexsero® vaccine (at 2, 4 and 12 months of age) alongside their other routine immunisations. 
7.4.2 Epidemiology
In 2014, 73% of all meningococcal cases were caused by MenB and 40% of the MenB disease 
cases concerned children younger than five years. From 2001 to 2012, the number of patients 
with meningococcal B disease decreased from 422 to 76. In 2013, a slight increase to 88 cases 
was observed, after which it decreased again to 60 cases in 2014. In 2015, up to June, there 
were 32 MenB cases. The incidence among 0-4 year-olds and 40-64 year-olds had decreased 
from 3.9 per 100,000 to 2.7 per 100,000 and from 0.3 per 100,000 to 0.1 per 100,000 in 2013 
and 2014, respectively. The incidence among 5-9 year-olds increased from 0.6 per 100,000 in 
2013 to 0.9 per 100,000 in 2014 (Figure 7.4.1).
7.4.3 Pathogen
Among others, Bijlsma et al. (2014) [1] described the epidemiology of PorA serosubtypes of 
serogroup B invasive meningococcal cases for the period 1960 to 2012. The most common 
PorA serosubtype during the first decade of the hyper-endemic period (1982-91) was P1.4, 
followed by P1.16 and P1.2. During the second decade (1992-2001), the most common 
serosubtypes were P1.4, P1.10 and P1.16. PorA finetype was available during the last decade 
(2002-2012), the most common finetypes were P1.7-2,4, P1.22,14 and P1.5-2,10.
7.4.4 Research
A large carriage study was conducted in the Netherlands during the epidemiological years 
(from July 1st to June 30th) 2013 and 2014. The preliminary results of this study showed an 
overall carriage prevalence of 16% in adolescents and young adults aged 13-22 years and 
serogroup B was the most frequently carried serogroup (27%).
7.4.5 International developments
In March 2015, it was announced that all babies in the UK will soon be vaccinated against 
MenB disease as part of the national childhood immunisation programme using the 4CMenB 
vaccine, Bexsero®. 
In September 2015, UK babies born on or after 1 July 2015 will be offered the vaccine alongside 
their other routine immunisations (http://www.meningitis.org/menb-vaccine). In addition, babies 
born between 1 May and 31 May 2015 will be offered the 4CMenB vaccine at 4 and 12 months 
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and babies born between 1 June and 30 June 2015 will be offered the 4CMenB vaccine at 3, 4 
and 12 months (http://www.immunisationscotland.org.uk/vaccines-and-diseases/menb.aspx#menbcatchup).
The National Immunisation Advisory Committee (NIAC) in Ireland has recommended that the 
4CMenB vaccine should be made routinely available to infants as part of the Primary 
Childhood Immunisation Schedule (subject to cost-effectiveness), but a decision has yet to be 
made by the Department of Health. 
In the following countries there is a recommendation for 4CMenB vaccination for infants and 
children: Australia, Austria, Canada, the Czech Republic, Germany, Greece, Hungary, Italy, 
Poland, Portugal, Spain and the UK. In Canada and Portugal, there is also a recommendation 
for adolescents. No routine programme of 4CMenB in adolescents/young adults only has yet 
been implemented or announced [2]. However, on February 26, 2015, the Advisory Committee 
on Immunization Practices (ACIP) in the USA recommended the use of 4CMenB vaccines 
among certain groups of persons aged ≥10 years who are at increased risk for serogroup B 
meningococcal disease (http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm6422a3.htm). In the USA, 
two meningococcal serogroup B vaccines have been licensed, i.e. Bexsero® and Trumenba® 
(Pfizer, containing two variants of the outer membrane lipoprotein factor H binding protein 
(FHbp, also referred as rLP2086 in this vaccine)), both for use in individuals aged 10-25 years 
old (and thus not for infants). In Europe, only Bexsero® has been licensed, where it is indicated 
for individuals aged 2 months and older (thus including infants). 
Read and colleagues [3] reported a phase 3, observer-blind, randomised, controlled trial that 
assessed the effects on the carriage of meningococci in 2,954 students (aged 18-24 years). The 
students received two doses of 4CMenB, one dose of MenACWY-CRM, plus one dose of 
placebo, or two doses of Japanese encephalitis virus vaccine (control vaccine) in a 1:1:1 ratio, 
followed-up for 12 months. For both vaccines, significantly lower carriage prevalence were 
recorded versus the control group for any N. meningitidis strain. Although 4CMenB is 
characterised as a MenB vaccine, antigens in the vaccine are also present and able to induce 
bactericidal antibodies against non-serogroup B strains as well. No impact of 4CMenB only on 
capsular group B strains was observed. This may be due to the low number of capsular group B 
carriage acquisitions during the study, in addition to the observation that most acquisition 
events occurred after the first vaccine dose and before the second. 
The potential coverage offered by the 4CMenB vaccine has been assessed retrospectively 
during MenB outbreaks worldwide since the mid-1970s [4]. Four hyper invasive lineages  
(CC32, CC41/44, CC269 and CC162) have dominated during outbreaks of serogroup B invasive 
meningococcal disease worldwide since the 1970s. For the 21 isolates from these four clonal 
complexes evaluated using both human Serum Bactericidal Assay and the Meningococcal 
Antigen Testing System (MATS), the coverage ranged from 67% (2/3 strains belonging to 
CC269) to 100% (8/8 strains belonging to CC32, 9/9 strains belonging to CC41/44 and 1/1 strain 
belonging to CC162). 
Ladhani et al. [5] studied the potential use of the 4CMenB vaccine in addition to antibiotic 
chemoprophylaxis for preventing secondary cases. They estimated the numbers needed to 
vaccinate (NNV) with the 4CMenB vaccine to prevent a secondary case in household and 
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educational settings. Most secondary cases occur within a few days of diagnosis in the index 
case. Unlike conjugate vaccines, early protection offered after a single dose of the 4CMenB 
vaccine is likely to be low, particularly in young children, who are at a higher risk of secondary 
infection. The NNV is dependent on predicted meningococcal strain coverage, estimated onset 
of protection after one 4CMenB vaccine dose and estimated vaccine efficacy. In the most 
favourable scenario, in which they assumed the vaccine is administered within 4 days of the 
index case and prevents 90% of cases occurring after 14 days, the NNV for household contacts 
was more than 1,000. The NNV in educational settings was much higher. The authors 
concluded that the 4CMenB vaccine may have a protective role only in clusters and outbreaks 
and would not prevent secondary cases of index cases in household or educational settings. 
McIntosh et al. [6] reviewed all 4CMenB studies. The studies found 4CMenB to be highly 
immunogenic, inducing protective antibody levels against serogroup B strains expressing 
vaccine antigens in >95% of vaccinated cohorts. When antibody levels waned, all tested 
groups (infants, toddlers, adolescents and adults) demonstrated booster responses. The MATS 
technique predicts that global coverage of 4CMenB against all serogroup B strains is in the 
range of 66% (Canada) to 91% (USA). Regarding the safety profile, local and systemic reactions 
and, notably, fever in infants increased following concomitant administration of 4CMenB with 
routine vaccines. Prophylactic paracetamol significantly decreased the frequency and severity 
of reactions in infants, with no clinically significant impact on the immunogenicity of 4CMenB 
or concomitant routine vaccines. 
Rollier et al. [7] presented immunogenicity and safety data, which was published in peer-
reviewed literature between 2004 and 2014, in the context of the recent recommendation for 
the use of the 4CMenB vaccine in infants in the UK. Despite the wealth of data on 4CMenB 
(already summarized in the paragraphs above), they also discussed the fact that a number of 
questions remain unanswered. It is not clear whether this vaccine will include herd protection. 
To provide this critical information, carriage studies should be conducted in all populations 
where the vaccine is introduced. Furthermore, vaccine effectiveness in the field is unknown. 
The vaccine will protect against strains that express sufficient levels of the specific variants of 
the vaccine antigens on the surface, but protection against other strains is not known. 
Carefully conducted surveillance post-vaccine implementation is needed. As this vaccine will 
not eliminate all capsular group B meningococcal disease, it is important that research into 
improved meningococcal vaccines continues. Currently, another vaccine with a potential to 
provide broad protection is in clinical development: a MenABCWY conjugate vaccine 
combining 4CMenB with the MenACWY conjugate vaccine, which is in a Phase II clinical trial. 
In a review, Esposito et al. [8] discussed the immunogenicity, safety and tolerability of the 
4CMenB vaccine in infants and toddlers, and the efficacy of different vaccination strategies. 
They state that, with the availability of the bivalent rLP2086 vaccine (Trumenba®) for the 
adolescent age, it will be important to compare vaccination strategies that cover different age 
groups and to understand the impact of the two vaccines against IMD overall, meningococcal 
disease due to serogroups different from MenB and meningococcal carriage in the 
nasopharynx.
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Medini et al. [9] described the public-private cooperation in which the MATS assay platform 
was made available to meningococcal reference laboratories. So 4CMenB coverage can be 
estimated in countries around the world. They also discuss the potential use of MATS for 
post-implementation surveillance.
7.4.6 Tables and Figures
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Table 7.4.1 Absolute numbers of invasive MenB isolates per age-category from 2001-2015* 
(*up to June 2015) 
Source: NRBM
Age 
in yrs
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
*
0-4 210 180 137 120 96 70 77 59 65 52 37 41 36 24 12
5-9 54 53 36 22 27 20 18 17 17 12 3 3 6 8 3
10-19 88 72 49 40 38 28 27 17 18 13 10 10 11 9 6
20-39 32 19 27 12 20 16 14 7 11 13 10 9 12 6 5
40-64 24 31 28 22 16 11 11 15 7 12 10 6 17 8 1
65+ 14 20 16 15 12 10 12 13 8 10 5 7 6 5 5
Total 422 375 293 231 209 155 159 128 126 112 75 76 88 60 32
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7.5  Meningococcal non-serogroup B and C types
L. Mollema, H.E. de Melker, F.R.M. van der Klis, P. Kaaijk, N.Y. Rots, G.A.M. Berbers, L. Spanjaard,  
M.B. van Ravenhorst, E.A.M. Sanders, A. van der Ende
7.5.1 Key points
• In 2014, 19 (23%) meningococcal cases were caused by non-serogroup B or C types out 
of a total of 83 cases. In 2015, up to June, 10 out of 45 cases were caused by non-
serogroup B or C types.
• Most non B and C meningococcal cases were caused by serogroup Y, with 12 and 5 
cases in 2014 and 2015, respectively, up to June.
• In March 2015, the British JCVI (Joint Committee on Vaccination and Immunisation) 
advised offering a MenACWY conjugate vaccine to 13-18 year-olds due to a continuous 
rise in cases of MenW since 2009. 
7.5.2 Epidemiology
7.5.2.1 Meningococcal serogroup W
Since 2001, the number of meningococcal serogroup W (MenW) cases decreased to 1-7 cases 
each year. In 2014, the number of MenW cases amounted to 2 and in 2015, up to June, there 
were 4 MenW cases (Figure 7.5.1 and Table 7.5.1).
7.5.2.2 Meningococcal serogroup Y
From 2001 to 2006, the number of MenY cases amounted to 4-7 cases each year. In 2007, the 
number of MenY cases had increased to 11, after which it decreased again to 7 in 2008 and 2009. 
From 2010 to 2014, the number of MenY cases ranged from 12 to 15 cases each year, with most 
cases (5 out of 12) occurring among individuals aged 65 years and older. In 2015, up to June,  
there were 5 MenY cases, four of which were in the age group 65+ (Figure 7.5.1 and Table 7.5.1).
7.5.2.3 Other meningococcal serogroups
In 2014, one Men29E, one MenX and 2 non-groupable Men were reported. In 2015, up to June, 
no cases with a meningococcal serogroup other than MenW or MenY were reported.
7.5.3 Pathogen
There are no indications that the proportions of non-serogroup B or C strains isolated from 
patients with invasive disease in the Netherlands have changed.
7.5.4 Research
As mentioned in the MenC chapter, a large prospective study was conducted to compare a MenCC 
and MenACWY conjugate booster vaccine 11 years after priming in healthy 10, 12 and 15 year-olds. 
This study also aims to investigate, for serogroup A, W and Y, possible differences in age in 
MenAWY-specific SBA titres at baseline, 1 month and 1 year after priming. Results are expected at 
the end of 2015.
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7.5.5 International developments
Public Health England conducted enhanced national surveillance of invasive meningococcal 
disease in England and Wales [1]. Detailed clinical information was obtained for all laboratory-
confirmed MenW cases diagnosed during 3 epidemiological years (2010-2011 to 2012-2013) and 
whole genome sequencing analysis of the clinical isolates was performed. A year-on-year 
increase in invasive MenW disease was shown across all age groups since 2009-2010, which 
was due to rapid endemic expansion of a single clone belonging to the sequence type 11 
complex (cc11). In the 129 MenW cases diagnosed, most patients were previously healthy, had 
not travelled abroad prior to the illness and the majority of cases presented with septicaemia. 
Thirty-seven per cent required intensive care and 12% died. There was no association between 
the infecting strain, clinical disease or outcome. 
By the end of May 2015, 170 MenW cases had been reported in the UK in the epidemiological 
year 2014/2015, compared with 88 and 46 cases for the same period in 2013/2014 and 
2012/2013, respectively. MenW is responsible for 25% of all IMD cases in 2014/2015, compared 
with 15% in 2013/2014 and 7% in 2012/2013. Because of the continuing rapid increase in MenW 
disease, the UK Departments of Health announced a rapid introduction of an adolescent 
MenACWY conjugate vaccine programme to begin in August 2015. The adolescent MenC 
conjugate vaccine currently recommended for 13-14 year-olds will be replaced by the 
MenACWY conjugate vaccine [2]. 
Also, in some other European countries, a small increase in MenW disease has been noticed.  
In the Netherlands, the number of MenW cases has been consistently low since 2001 and there 
are no signs of an increase in the number of cases.
7.5.6 Tables and Figures
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Figure 7.5.1 Absolute number of meningococcal non-serogroup B or C isolates (e.g. A, 29E,  
W, X, Y, Z, non-groupable), 2001-2015*  
(*up to June 2015) 
Source: NRBM
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Table 7.5.1 Absolute number of invasive MenW isolates per age category, 2001-2015*  
(*up to June 2015) 
Source: NRBM 
Age 
in yrs
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
*
0-4 5 1 3 0 1 2 2 1 1 1 0 0 1 0 0
5-9 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0
10-19 0 1 1 0 1 0 1 0 1 1 1 0 1 0 0
20-39 4 1 0 0 0 1 1 1 1 0 0 1 0 0 1
40-64 3 2 0 1 0 0 0 1 1 0 0 1 0 2 2
65+ 1 1 2 3 1 0 1 1 1 2 0 1 4 0 1
Total 14 7 6 4 3 3 5 4 5 5 1 3 6 2 4
Table 7.5.2 Absolute number of invasive MenY isolates per age category, 2001-2015*  
(*up to June 2015) 
Source: NRBM
 
Age 
in yrs
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
*
0-4 0 0 1 0 0 0 0 0 1 1 0 2 2 1 0
5-9 0 0 0 1 0 0 1 0 0 0 1 3 0 1 0
10-19 0 1 1 2 0 0 1 0 0 2 5 1 1 2 0
20-39 1 2 1 0 0 0 1 1 1 3 2 2 0 2 0
40-64 1 0 1 1 2 0 2 2 2 3 3 3 3 1 1
65+ 2 4 1 2 3 4 6 4 3 3 4 2 8 5 4
Total 4 7 5 6 5 4 11 7 7 12 15 13 14 12 5
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N.Y. Rots
8.1 Vaccines under development
An update of information with regard to vaccines for infectious diseases in development that 
have reached the clinical testing phase and are relevant for the Netherlands is given in Table 
8.1. Relevant developments of combination vaccines are described in earlier chapters.
8.2 Tables and figures
Table 8.1 Vaccines for infectious diseases in development that have reached the clinical testing 
phase and are relevant for the Netherlands
Disease Vaccine Status
Bacterial diseases
Clostridium difficile Toxoid vaccine Phase III, 
FDA fast track designation 
Helicobacter pylori HP3 vaccine (Chiron/Novartis) Phase I completed, limited 
protective immunity
Shigella Live attenuated single-strain 
Shigella vaccine
Killed trivalent whole-cell 
vaccine, bioconjugate
Phase I
Staphylococcus Aureus Staphylococcus Aureus Vaccine 
(SA4Ag)
Phase I promising data. 
Previous phases I-III  
with different vaccine 
candidates all failed, 
safety concerns and low 
efficacy
Streptococcus group A & B Group A:
N-terminal M protein-based 
multivalent vaccines (26-valent 
and 30-valent vaccines) 
Conserved M protein vaccines 
Group B:
Trivalent vaccine
Phase II
Phase I
Phase I, 
Phase II
Tuberculosis 
(all forms all ages)
Whole-cell mycobacteria 
recombinant subunit vaccines
Phase II
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Disease Vaccine Status
Viral diseases
Chikungunya Live recombinant Measles Virus 
based vaccine
Virus-like particle vaccine
Phase I
Cytomegalovirus (CMV) Glycoprotein B vaccine 
DNA vaccine 
live ‘Towne’ vaccine
Phases I and II
Ebola rVSV-ZEBOV (Merck/ NewLink 
Genetics)
ChAd3-ZEBOV (GSK/PHAC)
Ad26-EBOV and MVA-EBOV  
(Johnson & Johnson and Bavarian 
Nordic)
Novavax
Phase III
Phase III
Phase II
Phase I
Epstein–Barr Recombinant gp350 vaccine
Glycoprotein subunit vaccine
Phase II
Hepatitis E Recombinant protein vaccine Phase II
Herpes simplex Glycoprotein subunit vaccines Phases I-III
Marburg virus DNA vaccine Phase I
Middle East Respiratory 
Syndrome-coronavirus 
(MERS-CoV)
MVA-MERS-S Phase I in  
preparation
Parainfluenza type I Live attenuated vaccine Phases I-II
Respiratory syncytial virus 
(RSV)
Live attenuated vaccines
Protein based vaccines
Gene-based vector vaccines
Phases I-II
Severe Acute Respiratory 
Syndrome (SARS)
Recombinant DNA plasmid vaccine Phases I
West Nile Virus Inactivated vaccine Phase I
Source: WHO and clinicaltrial.gov, Website pharmaceutical companies.
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4CMenB multicomponent meningococcal B vaccine
ACIP Advisory Committee on Immunisation Practices
AE adverse events
AEFI adverse events following immunisation
AFP acute flaccid paralysis
aP acellular pertussis
ASIA autoimmune/inflammatory syndrome induced by adjuvants
BES Bonaire, Sint Eustatius and Saba, the Dutch Caribbean
bOPV bivalent oral polio vaccine
CAP community acquired pneumonia
CBS Statistics Netherlands
CC clonal complex
CDC Centres for Disease Control and Prevention
CFR case-fatality rate
CI confidence interval
CIb Centre for Infectious Disease Control
CIN Cervical intraepithelial neoplasia
CMR Continuous Morbidity Registration
CMV Cytomegalovirus
CSF cerebrospinal fluid
CSI Chlamydia trachomatis Screening and Implementation study
DA Decision Aid
DALY Disability Adjusted Life Years
DHD Dutch Hospital data
DNA desoxyribonucleic acid
dPLY detoxified pneumolysin
DTaP combination of diphtheria, tetanus and acellular pertussis vaccines
DTaP-IPV combination of diphtheria, tetanus, acellular pertussis and inactivated polio 
vaccines
DT-IPV combination of diphtheria, tetanus and inactivated polio vaccines
DTP combination of diphtheria, tetanus and pertussis vaccines
DTpa combined reduced-antigen-content diphtheria-tetanus-acellular pertussis 
vaccine
DTwP combination of diphtheria, tetanus and whole-cell pertussis vaccines
DVP Department for Vaccine Supply and Prevention Programmes
ECDC European Centre for Disease Control and Prevention
ED emergency department
EEA European Economic Area
EIA enzyme immunoassay
ELS extensive limb swelling
EMA European Medicines Agency
EPIS-VPD the Epidemic Intelligence Information System for vaccine preventable 
diseases
EU European Union
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F fusion
FDA Food and Drug Administration
FHA filamentous haemagglutinin
Fim2 serotype 2 fimbriae
Fim3 serotype 3 fimbriae
GAPIII the WHO global action plan to minimize poliovirus facility-associated risk
GGD Municipal Health Service
GMC geometric mean IgG concentrations
GP General Practitioner
GSK Glaxo Smith Kline
GW genital warts
HAV hepatitis A virus
HAVANA Study of HPV prevalence among young girls
HBO higher vocational education
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HC Health Council
HCSP the French Council of Public Health
HCW health care workers
HepB hepatitis B virus
Hia Haemophilus influenzae type a
Hib Haemophilus influenzae type b
Hid Haemophilus influenzae type d
Hie Haemophilus influenzae type e
Hif Haemophilus influenzae type f
Hib/MenC-TT combined Haemophilus influenzae type b and Neisseria meningitidis serogroup 
C tetanus toxoid conjugate vaccine
HibMenCY-TT Meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate 
vaccine
HIV human immunodeficiency virus
HN haemagglutinin-neuraminidase
HPA Health Protection Agency
HPV human papillomavirus
hrHPV high-risk human papillomavirus
HTPP hospital-treated primary pneumonia
HZ herpes zoster
ICD International Classification of Diseases
ICER incremental cost-effectiveness ratio
ICPC International Classification of Primary Care
ICU intensive care unit
IDS Centre for Infectious Disease Research, Diagnostics and Screening
IMD invasive meningococcal disease
IPD invasive pneumococcal disease
IPV inactivated polio vaccine
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IRR incidence rate ratio
iVDPV vaccine-derived polioviruses in immunocompromised children
JCVI Joint Committee on Vaccination and Immunisation
LBZ National Register Hospital care
LcM+PppA pneumococcal protective protein A co-administrated with heat-killed-
Lactobacillus casei
LINH the Netherlands Information Network of General Practice
LMR National Medical Registration
lrHPV low-risk human papillomavirus
MATS Meningococcal Antigen Typing System
MBO intermediate vocational education
MCV measles containing vaccine
Men29E Meningococcal serogroup 29E
MenA Meningococcal serogroup A
MENA Middle East and North Africa
MenACWY-CRM quadrivalent meningococcal CMR conjugate vaccine
MenACWY-D quadrivalent meningococcal diphtheria toxoid conjugate vaccine
MenACWY-TT tetravalent meningococcal tetanus toxoid conjugate vaccine
MenB Meningococcal serogroup B
MenC Meningococcal serogroup C
MenCC Meningococcal conjugate vaccines
MenC-PS Meningococcal serogroup C polysaccharide
MenC-TT Meningococcal serogroup C polysaccharide-tetanus toxoid
MenW Meningococcal serogroup W
MenX Meningococcal serogroup X
MenY Meningococcal serogroup Y
MenZ Meningococcal serogroup Z
MERS-CoV Middle East Respiratory Syndrome-coronavirus
MF multiplication factor
MHS Municipal Health Service (GGD)
MIA multiplexed immuno assays based on Luminex technology
MML Laboratories of Medical Microbiology
MMR combination of measles, mumps and rubella vaccines
MMRV combination of measles, mumps, rubella and Varicella vaccines
MSM men who have sex with men
NB non-bacteremic
NI non-invasive
NI non-inferiority
NIAC National Immunisation Advisory Committee
NIP national immunisation programme
NIVEL Netherlands Institute for Health Services Research
NIVEL-PCD NIVEL Primary Care Database
NKR the Netherlands Cancer Registry
NNV numbers needed to vaccinate
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NPG National Influenza Prevention Programme
NRBM Netherlands Reference laboratory for Bacterial Meningitis
NREVSS National Respiratory and Enteric Virus Surveillance System
NTHi nontypeable Haemophilus influenzae strains
NVI Netherlands Vaccine Institute
OMV outer membrane vesicle
OPV oral polio vaccine
OR odds ratio
PASSYON Papillomavirus Surveillance among STI clinic Youngsters
PCR polymerase chain reaction
PCV pneumococcal conjugate vaccine
PCV7-TT heptavalent pneumococcal conjugate tetanus toxoid conjugate vaccine
PEP post-exposure prophylaxis
PHiD-CV 10-valent pneumococcal nontypeable Haemophilus influenza protein D 
conjugate vaccine
PhtD pneumococcal histidine triad D
PIENTER assessing immunisation effect to evaluate the NIP
Pneu Pneumococcal vaccination
PPV  proportion of population vaccinated
PPSV23 23-valent pneumococcal polysaccharide vaccine
Prn pertactin
PRN plaque-reduction neutralisation test
PRP polyribosyl-ribitol-phosphate
Ptx pertussis toxin
QALY quality-adjusted life year
RIVAR multicentre study Risk-Group Infant Vaccination Against Rotavirus
RIVM National Institute for Public Health and the Environment, the Netherlands
RNA Ribonucleic acid
RR relative risk
RSV respiratory syncytial virus
RT real-time
RV Rotavirus
SAGE Strategic Advisory Group of Experts
SARS Severe Acute Respiratory Syndrome
SBA serum bactericidal antibody
SH small hydrophobic
SP-MSD Sanofi Pasteur MSD
SSA Sub-Saharan Africa
SSPE subacute sclerosing panencephalitis
STI sexually transmitted infections
SUR Surinam, Netherlands Antilles and Aruba
SVIM a ‘screen, vaccinate or initiate management’ strategy
Tdap tetanus, diphtheria and pertussis vaccine
T-PEP tetanus post-exposure prophylaxis
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TQS a bedside test for tetanus immunity
TT tetanus toxoid
VDPV Vaccine-derived polio virus
VE vaccine effectiveness
VLP virus-like particle
VO a ‘vaccinate only’ strategy
VPD vaccine-preventable disease
VT-CAP vaccine-type pneumococcal community acquired pneumonia
VT-IPD vaccine-type invasive pneumococcal disease
VZV varicella zoster virus
VWS Ministry of Health, Welfare and Sport
WHO World Health Organization
WIV Belgian Scientific Institute of Public Health
wP whole-cell pertussis
WPV wild polio virus
YLD Years Lived with Disability
YLL Years of Life Lost
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Appendix 1 Surveillance methodology
Disease surveillance
For all the target diseases of the National Immunisation Programme (NIP), the impact of the 
programme can be monitored through mortality, morbidity and laboratory data related to the 
specific diseases.
Mortality data
Statistics Netherlands (CBS) registers mortality data from death certificates on a statutory 
basis. The registration specifies whether it concerns a natural death, a non-natural death or a 
stillborn child. In the event of natural death, the physician should report the following data:
1. the illness or disease that has led to death (primary cause);
2. a. any complication, directly related to the primary cause, which has led to death (secondary 
cause);
 b. additional diseases and specifics present at the moment of death, which have contributed 
to the death (secondary causes).
The CBS codes causes of death according to the International Classification of Diseases (ICD). 
This classification is adjusted every ten years or so, which has to be taken into account when 
following mortality trends. Since statistical year 2013, the data of CBS will use IRIS for 
automatic coding for cause of death. One of the advantages is the increase of international 
comparison of the figures. The change in coding will cause (once-only) considerable shifts in 
the statistics. Data for 2013 and 2014 are still preliminary.
Morbidity data
Notifications
Notifications by law are an important surveillance source for diseases included in the NIP.  
The notification of infectious diseases started in the Netherlands in 1865. Since then, several 
changes in notification have been enforced. Not all diseases targeted by the NIP have been 
notifiable during the entire period. See Table A1.1 for the period of notification for each disease 
[1]. In December 2008, a new law (Wet Publieke Gezondheid) was passed which required the 
notification of all NIP-targeted diseases (except human papillomavirus (HPV)). Since that time, 
physicians, laboratories and heads of institutions have to report 42 notifiable infectious 
diseases, instead of 36, to the Public Health Services.
There are four categories of notifiable disease. Diseases in category A have to be reported 
directly by telephone following a laboratory-confirmed diagnosis. Diseases in categories B1,  
B2 and C must be reported within 24 hours or one working day after laboratory confirmation. 
However, for several diseases there is under-reporting and delays in reporting [2]. In each of 
the last three categories, different intervention measures can be enforced to prevent the 
spread of the disease.
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Table A1.1 Periods and category of statutory notification for vaccine-preventable diseases 
(VPDs) included in the current National Immunisation Programme (NIP) 
Disease Category Periods of notification  
by legislation
Diphtheria B1 from 1872 onwards
Pertussis B2 from 1975 onwards
Tetanus C 1950-1999,  
from December 2008 onwards
Poliomyelitis A from 1923 onwards
Invasive Haemophilus influenzae type b C from December 2008 onwards
Hepatitis B disease B2 from 1950 onwards
Invasive pneumococcal diseasea C from December 2008 onwards
Mumps C 1975-1999,  
from December 2008 onwards
Measles B2 1872-1899,  
from 1975 onwards
Rubella B2 from 1950 onwards
Invasive meningococcal disease C from 1905 onwards
 
a For infants only.
Hospital admissions
Since 2013, the National Register Hospital Care (LBZ), managed by Dutch Hospital Data (DHD) 
receives the discharge diagnoses of all patients who were admitted to hospital. Outpatient 
diagnoses are not registered. Diseases, including all NIP-targeted diseases, are coded as the 
main or subsidiary diagnosis according to the ICD-10 coding system. 
Until 2010, hospital data was managed by the research institute Prismant in the National 
Medical Register (LMR); since 2011, DHD has managed the LMR. Up to 2012, discharge 
diagnoses were coded according to the ICD-9 coding system. 
The coverage of this registration was about 99% until mid-2005. Thereafter, coverage has 
fluctuated due to changes in funding (see Table A1.2). Data presented in this report concerned 
only clinical admissions and were not corrected for changes in coverage. 
Hospital admission data are also susceptible to under-reporting, as shown by De Greeff et al. 
in a paper on meningococcal disease incidence [3].
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Table A1.2 The completeness of LMR/LBZ over the years*, by day admissions and clinic 
admissions 
Year Type of admission Registered Generated (=missing)
2007 Day admission 87% 13%
Clinic admission 89% 11%
2008 Day admission 88% 12%
Clinic admission 88% 12%
2009 Day admission 87% 13%
Clinic admission 88% 12%
2010 Day admission 86% 14%
Clinic admission 89% 11%
2011 Day admission 79% 21%
Clinic admission 85% 15%
2012 Day admission 72% 28%
Clinic admission 82% 18%
2013 Day admission 74% 26%
Clinic admission 84% 16%
2014** Day admission 82% 18%
Clinic admission 99% 1%
* These numbers are an approximation of the exact percentage
Source: Statistics Netherlands (CBS) up to 2009 and Dutch Hospital Data (DHD) from 2010 onwards
** For 2014, the hospitalisation data are preliminary and incomplete.
Data on mortality and hospitalisation are not always reliable, particularly for diseases that 
occur sporadically. For example, tetani cases are sometimes incorrectly registered as tetanus 
[4] and cases of post-poliomyelitis syndrome are sometimes classified as acute poliomyelitis, 
even though these occurred many years ago. Furthermore, cases of acute flaccid paralysis 
(AFP), with causes other than poliovirus infection, are sometimes inadvertently registered as 
cases of acute poliomyelitis [4]. Thus, for poliomyelitis and tetanus, notifications are a more 
reliable source of surveillance.
Laboratory data
Laboratory diagnostics are very important in monitoring infectious diseases and the 
effectiveness of vaccination; about 75% of all infectious diseases can be diagnosed only by 
laboratory tests [5]. However, limited information on patients is registered and, in many cases, 
laboratory confirmation is not sought for self-limiting VPDs. The different laboratory 
surveillance systems for diseases targeted by the NIP are outlined below.
Surveillance and developments in 2014-2015   |  187
Netherlands Reference Laboratory Bacterial Meningitis
The Netherlands Reference Laboratory for Bacterial Meningitis (NRBM) is a collaboration 
between the National Institute for Public Health and the Environment (RIVM) and the Academic 
Medical Centre of Amsterdam (AMC). On a voluntary basis, microbiological laboratories 
throughout the Netherlands send isolates from the blood and cerebrospinal fluid (CSF) of 
patients with invasive bacterial disease (IBD) to the NRBM for further typing. For CSF isolates, 
the coverage is almost complete. Nine sentinel laboratories throughout the country are asked 
to send isolates from all their patients with invasive pneumococcal disease (IPD) and, based on 
the number of CSF isolates, their overall coverage is around 25%. Positive results of pneumococcal, 
meningococcal and Haemophilus influenzae diagnostics and typing are relevant to NIP surveillance.
Virological laboratories
Each week, virological laboratories, which are part of the Dutch Working Group for Clinical 
Virology, send positive results of virological diagnostics to the RIVM. Approximately 22 
laboratories send information regularly. Aggregated results are shown on the RIVM website.  
It is important to bear in mind that the presence of a virus does not automatically imply the 
presence of disease. Since the 1st of December 2014, information on the total number of tests 
done can be reported each week or by year. 
NIVEL Primary care database
Incidence rates of varicella and herpes zoster in general practice were calculated using data 
from the routine electronic health records of general practitioners that are participating in 
Netherlands Institute for Health Services Research (NIVEL) Primary Care Database (NIVEL-
PCD), which incorporates the former LINH (Landelijk Informatie Netwerk Huisartsenzorg) that 
is maintained at the NIVEL. NIVEL-PCD uses routinely recorded data from health care providers 
to monitor health and the utilisation of health services in a representative sample of the Dutch 
population. All complaints and illnesses are recorded using the International Classification of 
Primary Care (ICPC-1). Annual incidence estimates of the total number of new episodes 
appearing in general practice in the Netherlands were made by extrapolating the reporting 
rates in these practices to the total number of Dutch residents, as obtained from CBS.
In 2012, there was a fourfold increase in the number of general practices participating in 
NIVEL-PCD compared with the previous group of LINH practices, resulting in a representative 
sample of 386 participating general practices with approximately 1.2 million registered patients 
(http://www.nivel.nl/NZR/zorgregistraties-eerstelijn). From 2012, incidence rates from NIVEL-PCD 
were calculated using an adjusted procedure: there were changes in definitions of episodes 
and in calculations of incidence, which caused an increase in the incidence for many diseases. 
Episode duration is defined by the time between the first and last consultation registered  
with the same code, and an additional period where patients are considered not susceptible  
(8 weeks for acute morbidities/complaints). Incidence rates are calculated by using a more 
specific selection of patient years [6]. Because of these changes, we decided to report 
previously published incidences based on the old method until 2011 [7] and to report incidence 
rates using the new method starting in 2012 [8]. Due to the new estimation method, the data 
for 2012 (based on 219 practices) and onwards are not comparable to previous years.
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Burden of Disease
The composite health measure, the Disability Adjusted Life Year (DALY), has been developed to 
compare the impact of diseases. The idea behind this approach is that the impact of a 
particular disease can be divided into the number of years of life lost (i.e. premature mortality) 
and the number of years lived at less than full health (i.e. morbidity). The result is a single 
measurement unit that quantifies the years of healthy life lost due to a certain disease or 
infection. The full methodology used to estimate the disease burden of infectious diseases in 
the Netherlands expressed in DALYs is described in the State of Infectious Diseases in the 
Netherlands, 2013 [9, 10].
Vaccine effectiveness
After the implementation of a vaccination in the NIP, vaccine-effectiveness (VE) can be 
routinely estimated using the ‘screening method’ with the following equation: 
VE (%) = 1- [PCV / (1-PCV) * (1-PPV/PPV], 
in which PCV = proportion of cases vaccinated, PPV = proportion of population vaccinated, and 
VE = vaccine-effectiveness.
In addition, several study designs, including case-control and cohort studies, can be used to 
assess VE after implementation [11].
Molecular surveillance of the pathogen
The monitoring of strain variations due to differences in phenotype and/or genotype is an 
important part of information gathering on the emergence of (sub)types, which may be more 
virulent or less effectively controlled by vaccination. It is also a useful tool for improving 
insight into transmission dynamics.
Immunosurveillance
Monitoring the seroprevalence of all NIP-targeted diseases is a way to gather age and sex-
specific information on immunity to these diseases acquired through natural infection or 
vaccination. To this end, a random selection from the general population of the Netherlands is 
periodically asked to donate a blood sample and fill in a questionnaire (PIENTER survey). This 
survey was performed in 1995–1996 (Nblood=10,128) [12] and in 2006–2007 (Nblood=7,904) [13]. 
The oversampling of people living in regions with low vaccine coverage and of immigrants is 
done to gain greater insight into differences in immunity among specific groups.
According to plan, a new survey will be conducted in 2016.
Vaccination coverage
Vaccination coverage data can be used to gain insight into the effectiveness of the NIP. 
Furthermore, this information can identify groups with low vaccine coverage who are at 
increased risk of contracting one of the NIP-targeted diseases. In the Netherlands, all 
vaccinations administered within the framework of the NIP are registered in a central 
electronic (web-based) database at the individual level (Præventis) [14].
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Surveillance of adverse events following vaccination
Passive safety surveillance through an enhanced spontaneous reporting system was operated 
by the RIVM until 2011. An aggregated analysis of all reported adverse events following 
immunisation (AEFI) was published annually. The last report, for 2010, also contains a detailed 
description of the methodology used and a review of trends and important findings over the 
previous 15 years [15].
From 1 January 2011 on, this enhanced spontaneous reporting system of AEFI was taken over 
by the Netherlands Pharmacovigilance Centre (Lareb). Detailed information is available at  
www.lareb.nl.
In view of this transition, comparisons between the period before 2011 and the period running 
from 2011 onward should be made with caution. Furthermore, in 2011 Lareb started a 
campaign among parents of vaccinated children to promote the reporting of AEFIs. In 2014 the 
number of notifications declined by almost 20% compared with 2013 [16]. This is a worrying 
development. The medically trained perception and interpretation of a possible side effect is 
an essential link when it comes to the detection of new information about side effects. 
Therefore sufficient participation of health care providers in the reporting system for adverse 
events is important [16].
In addition, the Centre for Infectious Disease Control (CIb) of the RIVM conducts systematic 
studies to monitor the safety of the NIP, e.q. questionnaire surveys and linkage studies 
between different databases.
Cost-effectiveness
The decision to include a certain vaccination option in the NIP is based on several factors, 
including vaccine safety and efficacy, the avertable disease burden, acceptability and the 
cost-effectiveness of vaccination. Cost-effectiveness is defined as the additional cost per 
additional unit of health benefit produced, as compared with an alternative, such as the 
vaccine already in use or no vaccination. In other words, an economic evaluation of a 
vaccination programme provides information on whether the health gain associated with a 
new vaccine is worth the cost, as compared with other options for spending on health 
improvements or prevention. Most commonly, cost-effectiveness is expressed in cost per 
quality-adjusted life years (QALY), which is a measure of disease burden comprising both the 
quality and the quantity of life. If provided in a transparent and standardised way, evidence of 
the cost-effectiveness can contribute to policy recommendations for vaccinations in the NIP.
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Appendix 2 Morbidity and mortality figures 
Diphtheria ICD9: 032 
ICD10: A36
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality
1997 0 0 0 0 0 0 0
1998 0 0 0 0 0 0 0
1999 0 0 0 0 0 0 0
2000 0 0 0 0 0 0 0
2001 0 0 0 0 0 0 0
2002 0 0 0 0 0 0 0
2003 0 0 0 0 0 0 0
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 0 0
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 0 0
2012 0 0 0 0 0 0 0
2013* 0 0 0 0 0 0 0
2014* 0 0 0 0 0 0 0
Notifications
1997 0 0 0 0 1 0 1
1998 0 0 0 0 0 0 0
1999 0 0 0 0 1 0 1
2000 0 0 0 0 0 0 0
2001 0 0 0 0 0 0 0
2002 0 0 0 0 0 0 0
2003 0 0 0 0 0 0 0
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 0 0
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 1 1
2012 0 0 0 0 0 1 1
2013 0 0 0 0 0 0 0
2014 0 0 0 0 1 0 1
* Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Diphtheria ICD9: 032 
ICD10: A36
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Hospitalisations*
1999 0 0 0 0 0 0 0
2000 0 0 0 0 0 0 0
2001 0 0 0 1 0 0 1
2002 0 0 0 0 0 0 0
2003 0 1 0 0 0 1 2
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 0 0
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 1 1
2010 0 0 0 0 0 1 1
2011 0 0 0 0 0 1 1
2012 0 0 0 0 0 0 0
2013 0 0 0 0 0 0 0
2014** 0 0 0 0 0 1 1
Laboratory diagnoses***
2000 0 0 0 0 0 1 1
2001 0 0 0 0 0 2 2
2002 0 0 0 0 0 1 1
2003 0 0 0 0 0 1 1
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 1 1
2006 0 0 0 0 0 0 0
2007 0 0 0 0 1 2 3
2008 0 0 0 1 0 1 2
2009 0 0 0 0 0 0 0
2010 0 0 0 0 1 1 2
2011 0 0 0 0 3 2 5
2012 0 0 0 0 2 2 4
2013 0 0 0 1 3 1 5
2014 0 0 0 1 4 5 10
*  Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
**  Preliminary and incomplete figures.
*** Number of diphtheria isolates.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Pertussis ICD9: 033 
ICD10: A37
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality
1997 2 0 0 0 0 0 2
1998 1 0 0 0 0 0 1
1999 3 0 0 0 0 0 3
2000 0 0 0 0 0 0 0
2001 0 0 0 0 0 0 0
2002 0 0 0 0 0 0 0
2003 0 0 0 0 0 0 0
2004 1 0 0 0 0 0 1
2005 0 0 0 0 0 0 0
2006 0 0 0 1 0 0 1
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 1 1
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 1 0 0 0 0 0 1
2012 2 0 0 0 0 0 2
2013* 0 0 0 0 0 0 0
2014* 1 0 0 0 0 0 1
Notifications
1997 213 705 821 379 420 126 2,664
1998 134 714 921 316 310 108 2,503
1999 307 1,447 2,526 1,153 1,084 447 6,964
2000 211 976 1,460 564 648 363 4,222
2001 343 1,676 3,011 1,169 1,207 587 7,993
2002 198 666 1,540 856 810 417 4,487
2003 126 372 1,085 557 464 243 2,847
2004 363 1,007 2,745 2,387 2,091 1,133 9,726
2005 183 783 1,286 1,567 1,207 842 5,868
2006 141 469 785 1,353 981 622 4,351
2007 189 450 842 2,882 2,056 1,327 7,746
2008 194 345 776 3,128 2,325 1,477 8,245
2009 162 262 650 2,400 1,964 1,061 6,499
2010 113 165 345 1,266 1,189 637 3,715
2011 159 277 1,003 2,491 1,965 1,216 7,111
2012 235 382 1,521 4,210 4,495 3,004 13,847
2013 77 136 317 890 1,054 931 3,405
2014 258 490 788 2,858 2,719 2,137 9,250
* Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Pertussis ICD9: 033 
ICD10: A37
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Hospitalisations*
1999 351 73 24 12 8 4 472
2000 171 37 12 5 0 5 230
2001 301 40 32 1 2 2 378
2002 188 24 23 4 3 3 245
2003 114 14 9 2 0 1 140
2004 221 42 13 10 3 12 301
2005 131 28 11 5 4 6 185
2006 94 7 2 3 1 3 110
2007 129 7 8 10 5 7 166
2008 124 6 5 2 6 8 151
2009 112 12 1 4 6 6 141
2010 77 6 2 2 2 4 93
2011 97 11 2 4 2 5 121
2012 164 7 1 11 16 13 213
2013 44 5 1 2 2 6 60
2014** 142 11 4 3 7 13 182
*  Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
*  For 3 patients, the age is unknown.
**  Preliminary and incomplete figures.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Tetanus ICD9: 037, 7713
ID10: A33-35
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality
1997 0 0 0 0 0 1 1
1998 0 0 0 0 0 0 0
1999 0 0 0 0 0 0 0
2000 0 0 0 0 0 0 0
2001 0 0 0 0 0 3 3
2002 0 0 0 0 0 0 0
2003 0 0 0 0 0 1 1
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 0 0
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 1 1
2012 0 0 0 0 0 0 0
2013* 0 0 0 0 0 0 0
2014* 0 0 0 0 0 0 0
Notifications
1997 0 0 0 0 1 4 5
1998 0 0 0 0 0 0 0
1999** - - - - - - -
2000** - - - - - - -
2001** - - - - - - -
2002** - - - - - - -
2003** - - - - - - -
2004** - - - - - - -
2005** - - - - - - -
2006** - - - - - - -
2007** - - - - - - -
2008** - - - - - - -
2009 0 0 0 0 0 1 1
2010 0 0 0 0 0 2 2
2011 0 0 0 0 0 5 5
2012 0 0 0 0 1 1 2
2013 0 0 0 0 1 0 1
2014 0 0 0 0 0 0 0
*  Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
** No notifications in 1999 to 2008.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Poliomyelitis ICD9: 045
ICD10: A80
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality (acute)
1997 0 0 0 0 0 1 1
1998 0 0 0 0 0 0 0
1999 0 0 0 0 0 0 0
2000 0 0 0 0 0 2 2
2001 0 0 0 0 1 0 1
2002 0 0 0 0 0 1 1
2003 0 0 0 0 0 3 3
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 0 0
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 0 0
2012 0 0 0 0 0 0 0
2013* 0 0 0 0 0 1 1
2014* 0 0 0 0 0 0 0
Notifications
1997 0 0 0 0 0 0 0
1998 0 0 0 0 0 0 0
1999 0 0 0 0 0 0 0
2000 0 0 0 0 0 0 0
2001 0 0 0 0 0 0 0
2002 0 0 0 0 0 0 0
2003 0 0 0 0 0 0 0
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 0 0
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 0 0
2012 0 0 0 0 0 0 0
2013 0 0 0 0 0 0 0
2014 0 0 0 0 0 0 0
* Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Poliomyelitis ICD9: 045
ICD10: A80
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Hospitalisations*
1999 0 0 0 0 0 0 0
2000 0 0 0 0 0 0 0
2001 0 0 0 0 0 0 0
2002 0 0 0 0 0 0 0
2003 0 0 0 0 0 0 0
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 0 0
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 0 0
2012 0 0 0 0 0 0 0
2013 0 0 0 0 0 0 0
2014** 0 0 0 0 0 0 0
*   Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
**  Preliminary and incomplete figures.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Haemophilus influenzae type b ICD9: 3200
ICD10: A41.5, G00.0
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Notifications*
2009 4 3 0 0 2 6 15
2010 2 6 3 2 2 17 32
2011 2 1 0 0 3 13 19
2012 5 1 0 1 6 9 22
2013 2 9 0 0 1 7 19
2014 4 3 2 1 3 5 18
Hospitalisation (all types)**
1999 4 6 2 2 1 1 16
2000 5 5 0 0 5 5 20
2001 3 3 1 0 4 2 14
2002 10 4 0 2 6 29 51
2003 8 7 1 1 1 2 20
2004 3 7 0 0 4 8 22
2005 11 10 2 0 4 8 35
2006 5 5 2 0 2 5 19
2007 4 6 0 0 0 3 13
2008 3 7 0 0 4 6 20
2009 5 0 0 0 3 5 13
2010 3 4 0 0 2 3 12
2011 3 2 0 0 0 3 8
2012 3 3 1 0 2 5 14
2013 3 7 0 0 1 3 14
2014*** 4 2 0 0 5 8 19
*  Notifiable since 2009
** Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
** For one patient, the age is unknown.
*** Preliminary and incomplete figures.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Haemophilus influenzae type b ICD9: 3200
ICD10: A41.5, G00.0
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Isolates
2000 3 5 0 0 3 4 15
2001 3 5 0 1 4 4 17
2002 7 9 0 0 7 9 32
2003 5 8 2 2 3 11 31
2004 8 7 2 2 8 21 48
2005 9 17 3 0 4 8 41
2006 3 8 3 1 6 3 24
2007 3 8 2 0 2 9 24
2008 3 5 1 2 2 12 25
2009 6 3 1 0 8 14 32
2010 2 7 0 1 4 23 37
2011 3 2 0 2 5 10 22
2012 2 5 2 2 6 11 28
2013 6 7 1 0 4 11 29
2014 5 3 2 1 6 12 29
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Mumps ICD9: 072
ICD10: B26
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality
1997 0 0 0 0 0 0 0
1998 0 0 0 0 0 0 0
1999 0 0 0 0 0 0 0
2000 0 0 0 0 0 0 0
2001 0 0 0 0 0 0 0
2002 0 0 0 0 0 2 2
2003 0 0 0 0 0 0 0
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 1 1
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 0 0
2012 0 0 0 0 0 0 0
2013* 0 0 0 0 0 0 0
2014* 0 0 0 0 0 0 0
Notifications
2008** 0 2 10 5 7 1 25
2009 0 9 8 22 30 2 71
2010 0 4 5 119 435 6 569
2011 1 6 10 169 412 15 613
2012 0 2 12 110 260 13 397
2013 0 3 2 37 152 11 205
2014 0 0 4 5 28 2 39
*   Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
** No notifications between 1 April 1999 and 31 December 2008
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Mumps ICD9: 072
ICD10: B26
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Hospitalisations*
1999 0 1 0 0 1 0 2
2000 0 0 0 0 0 2 2
2001 0 0 0 0 0 1 1
2002 0 1 1 1 0 1 4
2003 0 1 0 0 0 1 2
2004 2 0 1 1 2 0 6
2005 0 0 0 1 2 1 4
2006 0 0 0 1 1 3 5
2007 1 0 0 0 1 2 4
2008 0 4 5 25 9 0 43
2009 0 0 1 2 6 1 10
2010 1 1 0 2 6 0 10
2011 0 1 0 4 7 0 12
2012 2 1 0 3 6 1 14
2013 0 0 0 0 3 2 5
2014** 1 1 1 1 5 2 11
Laboratory diagnoses
1997 - - - - - - 19
1998 - - - - - - 9
1999 - - - - - - 6
2000 - - - - - - 8
2001 - - - - - - 2
2002 - - - - - - 8
2003 - - - - - - 6
2004 - - - - - - 7
2005 - - - - - - 12
2006 - - - - - - 9
2007 - - - - - - 9
2008 - - - - - - 80
2009 - - - - - - 22
2010 - - - - - - 144
2011 - - - - - - 190
2012 - - - - - - 95
2013 - - - - - - 65
2014 - - - - - - 28
*   Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
*  For 1 patient, the age is unknown.
**  Preliminary and incomplete figures.
All ages
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Measles ICD9: 055
ICD10: B05
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality
1997 0 0 0 0 0 0 0
1998 0 0 0 0 1 0 1
1999 0 1 0 1 0 0 2
2000 0 0 0 0 0 0 0
2001 0 0 0 0 0 0 0
2002 0 0 0 0 0 0 0
2003 0 0 0 0 1 0 1
2004 0 0 0 0 0 0 0
2005 0 0 0 0 0 0 0
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 0 0
2012 0 0 0 0 0 0 0
2013* 0 0 0 0 0 0 0
2014* 0 0 0 0 0 0 0
Notifications
1997 1 9 0 0 11 0 21
1998 1 1 2 2 3 0 9
1999 41 738 1112 427 44 2 2,364
2000 19 225 469 237 64 3 1,017
2001 0 3 4 3 7 0 17
2002 0 2 0 1 0 0 3
2003 0 0 1 2 1 0 4
2004 1 1 0 3 6 0 11
2005 0 0 1 1 1 0 3
2006 0 0 0 0 1 0 1
2007 0 1 0 0 8 0 9
2008 4 8 38 39 21 0 110
2009 1 2 2 3 7 0 15
2010 1 2 2 1 9 0 15
2011 2 2 7 14 26 0 51
2012 1 2 0 1 6 0 10
2013 53 425 840 1162 199 9 2,688
2014 20 26 6 19 66 3 140
* Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Measles ICD9: 055
ICD10: B05
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Hospitalisations*
1999 2 39 33 9 8 0 91
2000 1 4 3 1 6 0 15
2001 1 0 0 0 2 0 3
2002 0 0 0 1 1 0 2
2003 0 0 0 0 0 1 1
2004 0 0 0 1 0 0 1
2005 0 0 0 0 1 0 1
2006 0 1 0 0 2 0 3
2007 0 0 0 0 2 0 2
2008 0 0 0 0 2 0 2
2009 0 0 0 0 0 0 0
2010 0 1 0 0 3 0 4
2011 1 0 0 1 6 0 9
2012 1 1 0 0 2 0 4
2013 8 34 41 52 23 1 164
2014** 6 6 0 4 18 1 35
Laboratory diagnoses
1997 - - - - - - 36
1998 - - - - - - 17
1999 - - - - - - 110
2000 - - - - - - 30
2001 - - - - - - 8
2002 - - - - - - 4
2003 - - - - - - 1
2004 - - - - - - 5
2005 - - - - - - 2
2006 - - - - - - 1
2007 - - - - - - 5
2008 - - - - - - 24
2009 - - - - - - 7
2010 - - - - - - 13
2011 - - - - - - 8
2012 - - - - - - 9
2013 - - - - - - 212
2014 - - - - - - 88
*   Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
*  For 6 patients, the age is unknown.
**  Preliminary and incomplete figures.
All ages
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Rubella (Acquired) ICD9: 056
ICD10: B06
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality
1997 0 0 0 0 0 0 0
1998 0 0 0 0 0 0 0
1999 0 0 0 0 0 0 0
2000 0 0 0 0 0 0 0
2001 0 0 0 0 0 0 0
2002 0 0 0 0 1 0 1
2003 0 0 0 0 0 0 0
2004 0 0 0 0 0 0 0
2005 0 0 0 0 1 0 1
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 0 0
2012 0 0 0 0 0 0 0
2013* 0 0 0 0 0 0 0
2014* 0 0 0 0 0 0 0
Notifications
1997 0 8 6 1 4 0 19
1998 0 5 7 0 6 0 18
1999 0 2 0 0 1 0 3
2000 0 1 4 0 7 0 12
2001 0 2 0 0 2 0 4
2002 0 0 0 0 3 0 3
2003 0 0 0 1 0 0 1
2004 2 4 12 33 14 0 65
2005 9 28 66 166 78 2 349
2006 0 0 0 0 4 1 5
2007 0 0 0 0 1 0 1
2008 0 0 0 0 2 0 2
2009 0 0 0 4 2 1 7
2010 0 0 0 0 0 0 0
2011 0 0 0 0 1 2 3
2012 0 0 0 0 1 0 1
2013 0 10 37 7 3 0 57
2014 0 1 0 0 1 0 2
* Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Rubella (Acquired) ICD9: 056
ICD10: B06
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Hospitalisations*
1999 0 1 0 0 0 0 1
2000 0 0 0 0 1 0 1
2001 0 0 0 0 0 0 0
2002 0 0 0 0 0 0 0
2003 1 0 0 0 0 0 1
2004 0 0 0 0 1 0 1
2005 0 0 0 0 0 0 0
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 0 0
2010 0 0 0 0 1 0 1
2011 1 1 0 0 0 1 3
2012 0 0 1 0 0 0 1
2013 0 1 0 0 0 0 1
2014** 0 0 0 0 0 0 0
Laboratory diagnoses
1997 - - - - - - 11
1998 - - - - - - 13
1999 - - - - - - 6
2000 - - - - - - 4
2001 - - - - - - 11
2002 - - - - - - 13
2003 - - - - - - 9
2004 - - - - - - 20
2005 - - - - - - 53
2006 - - - - - - 21
2007 - - - - - - 14
2008 - - - - - - 16
2009 - - - - - - 15
2010 - - - - - - 17
2011 - - - - - - 15
2012 - - - - - - 15
2013 - - - - - - 47
2014 - - - - - - 28
*   Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
**  Preliminary and incomplete figures.
All ages
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Meningococcal disease ICD9: 036.0-4, 036.8-9
ICD10: A39
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality
1997 7 13 6 6 2 7 41
1998 10 19 2 10 2 9 52
1999 9 13 4 7 4 11 48
2000 12 8 1 6 6 9 42
2001 4 16 2 16 10 8 56
2002 4 14 2 8 4 12 44
2003 7 7 0 0 3 3 20
2004 0 5 0 0 2 8 15
2005 3 3 0 3 0 2 11
2006 1 0 1 1 0 1 4
2007 2 3 0 1 0 3 9
2008 1 1 0 0 2 3 7
2009 1 3 0 0 1 1 6
2010 3 2 0 1 0 2 8
2011 2 0 0 0 1 2 5
2012 0 1 0 0 0 0 1
2013* 0 1 0 1 0 1 3
2014* 0 1 0 0 0 5 6
Notifications
1997 64 145 95 118 45 28 495
1998 63 170 82 107 44 35 501
1999 72 166 69 118 57 42 524
2000 79 154 84 104 58 42 521
2001 88 211 93 224 87 63 766
2002 82 173 93 166 91 56 661
2003 62 110 44 64 60 46 386
2004 42 80 25 50 35 34 266
2005 44 71 30 48 30 29 252
2006 25 50 20 34 24 27 180
2007 26 49 24 32 27 23 181
2008 17 47 19 19 17 36 155
2009 23 50 18 25 16 28 160
2010 22 34 14 21 22 28 141
2011 13 25 4 19 20 18 99
2012 18 31 7 15 17 16 104
2013 15 23 6 14 20 31 109
2014 9 16 10 14 10 22 81
* Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Meningococcal disease ICD9: 036.0-4, 036.8-9
ICD10: A39
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Hospitalisations (036.0, 036.2-3)*
1999 112 249 97 167 62 51 741
2000 96 232 108 128 61 48 676
2001 109 288 106 259 77 59 906
2002 103 232 107 172 64 41 731
2003 70 133 43 61 56 41 407
2004 52 98 46 53 28 41 319
2005 44 67 35 45 17 24 234
2006 31 48 25 40 18 19 183
2007 22 55 17 22 23 15 154
2008 18 46 15 13 10 28 130
2009 27 47 24 24 14 12 149
2010 20 37 12 18 11 18 117
2011 18 26 10 20 13 9 98
2012 15 25 11 10 8 10 79
2013 15 20 4 11 15 20 86
2014** 10 10 12 11 8 12 63
Isolates***
2000 79 161 73 102 67 62 544
2001 91 197 82 194 86 69 719
2002 80 154 84 148 86 62 614
2003 61 97 37 53 55 45 348
2004 48 74 24 43 29 41 259
2005 37 60 28 40 25 34 224
2006 25 48 20 29 22 24 168
2007 30 51 20 30 27 28 186
2008 15 47 17 17 18 37 151
2009 24 45 17 19 15 28 148
2010 24 32 13 18 21 28 136
2011 15 23 4 16 19 19 96
2012 18 27 7 11 17 16 96
2013 19 21 6 14 19 36 115
2014 10 16 10 12 11 23 82
*   Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
*  For 39 patients, the age is unknown.
**  Preliminary and incomplete figures.
*** Nontypeables excluded.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Hepatitis B ICD9: 070.2-3
ICD10: B16, B17.0, B18.0, B18.1
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality (B16; Acute)
1997 0 0 0 0 0 2 2
1998 0 0 0 0 0 1 1
1999 0 0 0 0 1 1 2
2000 0 0 0 0 0 1 1
2001 0 0 0 0 0 4 4
2002 0 0 0 0 0 4 4
2003 0 0 0 0 0 3 3
2004 0 0 0 0 1 0 1
2005 0 0 0 0 1 4 5
2006 0 0 0 0 1 3 4
2007 0 0 0 0 1 0 1
2008 0 0 0 0 1 1 2
2009 0 0 0 0 0 0 0
2010 0 0 0 0 0 3 3
2011 0 0 0 0 0 2 2
2012 0 0 0 0 0 2 2
2013* 0 0 0 0 1 3 4
2014* 0 0 0 0 1 3 4
Hospitalisations**
1999 0 0 2 8 56 29 95
2000 1 2 2 8 80 32 127
2001 0 7 1 5 61 26 104
2002 1 0 1 6 57 34 102
2003 0 2 0 8 71 25 106
2004 2 4 0 6 56 21 92
2005 0 0 0 4 56 28 89
2006 0 0 0 5 48 38 92
2007 0 1 0 3 49 27 81
2008 0 1 0 4 37 21 63
2009 0 1 2 4 36 31 74
2010 0 0 0 4 42 19 66
2011 0 0 1 6 30 26 63
2012 0 1 1 2 37 34 76
2013 0 0 0 0 18 30 48
2014*** 0 1 1 4 32 27 66
*   Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
** Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
** For 18 patients, the age is unknown.
*** Preliminary and incomplete figures.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Hepatitis B ICD9: 070.2-3
ICD10: B16, B17.0, B18.0, B18.1
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Notifications (Acute)
1997 1 1 3 15 158 28 206
1998 3 1 5 10 157 37 213
1999 0 4 1 26 148 35 214
2000 0 3 1 31 186 26 247
2001 0 0 2 23 163 33 221
2002 0 0 0 22 193 44 259
2003 0 1 3 22 240 56 322
2004 0 1 0 15 240 40 296
2005 0 0 2 26 227 46 301
2006 0 0 0 20 166 56 242
2007 0 1 1 20 154 50 226
2008 0 0 1 13 170 41 225
2009 0 0 0 11 144 56 211
2010 0 0 0 10 129 60 199
2011 0 0 1 7 98 53 159
2012 0 1 2 9 108 54 174
2013 0 0 0 12 77 56 145
2014 0 0 1 3 81 56 141
Notifications (Chronic)
2000 2 16 15 149 919 121 1,222
2001 2 7 12 158 1,018 159 1,356
2002 0 11 15 200 1,099 183 1,508
2003 3 7 15 132 1,126 197 1,480
2004 2 5 8 128 1,139 208 1,490
2005 0 3 9 97 1,134 268 1,511
2006 2 18 8 85 1,141 300 1,554
2007 0 8 9 95 1,233 265 1,610
2008 0 10 6 87 1,215 295 1,613
2009 0 7 7 85 1,373 348 1,820
2010 0 9 12 77 1,159 328 1,585
2011 0 9 10 77 1,162 319 1,577
2012 0 3 3 55 959 307 1,327
2013 0 4 5 54 829 261 1,153
2014 1 5 3 31 787 247 1,074
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Hepatitis B ICD9: 070.2-3
ICD10: B16, B17.0, B18.0, B18.1
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Laboratory diagnoses
1997 - - - - - - 787
1998 - - - - - - 819
1999 - - - - - - 950
2000 - - - - - - 904
2001 - - - - - - 827
2002 - - - - - - 974
2003 - - - - - - 849
2004 - - - - - - 932
2005 - - - - - - 1,174
2006 - - - - - - 1,361
2007 - - - - - - 1,588
2008 - - - - - - 1,725
2009 - - - - - - 1,553
2010 - - - - - - 1,401
2011 - - - - - - 1,377
2012 - - - - - - 1,020
2013 - - - - - - 676
2014 - - - - - - 392
All ages
212  |   The National Immunisation Programme in the Netherlands
Pneumococcal disease ICD9: 0382, 481, 4823, 3201
ICD10: J13, 18.0, 18.9, G00.1, A40.4
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality (J13; Pneumonia)
1997 0 0 0 0 8 47 55
1998 0 0 0 1 7 48 56
1999 0 0 0 0 4 46 50
2000 0 1 0 0 6 51 58
2001 0 0 0 0 6 51 57
2002 0 0 0 0 3 50 53
2003 0 0 0 1 5 46 52
2004 0 0 0 1 6 41 48
2005 0 0 0 0 6 57 63
2006 0 0 0 0 6 50 56
2007 0 0 0 0 8 39 47
2008 0 0 0 0 0 47 47
2009 0 0 1 1 2 37 41
2010 0 0 0 0 2 43 45
2011 0 0 0 0 1 26 27
2012 0 0 0 0 2 42 44
2013* 0 0 0 0 0 31 31
2014* 0 0 0 0 0 28 28
Notifications**
2008 3 0 1** - - - 4
2009 27 15 1** - - - 43
2010 31 24 2** - - - 57
2011 23 20 4** - - - 47
2012 26 16 2** - - - 44
2013 11 13 4** - - - 28
2014 15 21 2** - - - 38
*   Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
**  Notifiable for 0 to 5 year-old children.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5 yr
Female 0 yr
Female 1-4 yr
Female 5 yr
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Pneumococcal disease ICD9: 0382, 481, 4823, 3201
ICD10: J13, 18.0, 18.9, G00.1, 
A40.4
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Hospitalisations*
1999 123 125 63 51 527 1,619 2,513
2000 112 110 60 53 475 1,725 2,540
2001 107 169 52 47 575 1,671 2,628
2002 96 185 61 42 543 1,789 2,722
2003 108 171 56 71 586 2,034 3,042
2004 119 143 64 43 518 1,918 2,810
2005 92 144 67 49 574 1,932 2,867
2006 76 115 56 44 397 1,853 2,545
2007 42 122 53 45 483 1,945 2,699
2008 33 90 34 31 449 1,932 2,575
2009 53 77 38 47 430 1,991 2,643
2010 63 83 48 41 385 2,180 2,807
2011 36 57 62 50 446 2,348 3,001
2012 24 43 18 29 338 1,983 2,438
2013 15 11 13 23 474 2,140 2,678
2014** 21 15 17 26 369 2,291 2,742
Isolates (meningitis)
2001 51 39 11 7 45 95 248
2002 45 30 9 2 38 120 244
2003 48 24 9 11 37 107 236
2004 58 24 6 3 40 137 268
2005 42 23 6 4 31 129 235
2006 36 22 8 8 28 111 213
2007 24 23 10 3 56 127 243
2008 21 11 3 8 28 119 190
2009 20 8 4 5 45 108 190
2010 25 10 4 2 36 98 176
2011 18 6 5 1 24 109 163
2012 20 6 4 3 22 83 138
2013 9 2 4 0 28 94 137
2014 11 6 7 2 21 96 143
*   Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
*  For 96 patients, the age is unknown.
**  Preliminary and incomplete figures.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Human papillomavirus ICD10: C53
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality (Cervical cancer)
1997 0 0 0 0 58 176 234
1998 0 0 0 1 56 219 276
1999 0 0 0 0 64 189 253
2000 0 0 0 0 73 185 258
2001 0 0 0 0 66 177 243
2002 0 0 0 0 45 142 187
2003 0 0 0 0 47 167 214
2004 0 0 0 0 49 154 203
2005 0 0 0 0 52 183 235
2006 0 0 0 0 44 170 214
2007 0 0 0 0 57 147 204
2008 0 0 0 0 51 193 244
2009 0 0 0 0 40 169 209
2010 0 0 0 0 43 162 205
2011 0 0 0 0 46 143 189
2012 0 0 0 0 42 173 215
2013* 0 0 0 0 47 175 222
2014* 0 0 0 0 50 148 198
Registrations (Cervical Cancer)**
1997 0 0 0 2 397 336 735
1998 0 0 0 0 398 353 751
1999 0 0 0 1 401 300 702
2000 0 0 0 0 345 341 686
2001 0 0 0 1 331 275 607
2002 0 0 0 0 333 318 651
2003 0 0 0 0 318 291 609
2004 0 0 0 1 374 331 706
2005 0 0 0 0 358 326 684
2006 0 0 0 0 367 322 689
2007 0 0 0 0 411 328 739
2008 0 0 0 0 375 332 707
2009 0 0 0 0 381 343 724
2010 0 0 0 0 396 339 735
2011 0 0 0 0 394 359 753
2012 0 0 0 2 402 331 736
2013 0 0 0 0 384 284 668
2014*** 0 0 0 1 452 359 812
*   Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
** Source: Netherlands Cancer Registry (NKR).
*** Preliminary figures.
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Rotavirus
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Hospitalisations (estimation)*
2000 - - - - - - 2,864
2001 - - - - - - 3,312
2002 - - - - - - 3,160
2003 - - - - - - 3,322
2004 - - - - - - 3,000
2005 - - - - - - 4,063
2006 - - - - - - 4,903
2007 - - - - - - 3,948
2008 - - - - - - 5,895
2009 - - - - - - 5,641
2010 - - - - - - 6,442
2011 - - - - - - 4,487
2012 - - - - - - 3,892
2013 - - - - - - 4,399
2014** - - - - - - 1,865
Laboratory diagnoses
1997 - - - - - - 712
1998 - - - - - - 1,094
1999 - - - - - - 1,163
2000 - - - - - - 932
2001 - - - - - - 1,067
2002 - - - - - - 1,004
2003 - - - - - - 1,079
2004 - - - - - - 975
2005 - - - - - - 1,304
2006 - - - - - - 1,585
2007 - - - - - - 1,251
2008 - - - - - - 1,692
2009 - - - - - - 1,936
2010 - - - - - - 2,180
2011 - - - - - - 1,505
2012 - - - - - - 1,287
2013 - - - - - - 1,487
2014 - - - - - - 607
*   Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
**  Preliminary and incomplete figures.
All ages
All ages
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Varicella (Chickenpox) ICD9: 052
ICD10: B01
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality
1997 0 0 0 0 0 0 0
1998 0 2 0 0 0 0 2
1999 0 0 0 2 1 1 4
2000 0 0 0 0 1 0 1
2001 0 1 1 0 1 0 3
2002 2 0 0 0 1 1 4
2003 0 1 0 1 0 4 6
2004 0 1 0 0 0 3 4
2005 0 0 0 0 0 1 1
2006 0 0 1 0 1 1 3
2007 1 1 0 1 1 1 5
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 1 1
2010 0 0 0 0 0 2 2
2011 1 0 0 0 0 0 1
2012 0 0 0 0 0 2 2
2013* 0 0 0 0 0 1 1
2014* 0 0 0 0 1 1 2
Hospitalisations**
2000 44 95 14 6 38 14 211
2001 62 104 19 3 36 9 233
2002 47 113 17 4 29 9 219
2003 78 121 10 6 41 17 273
2004 89 115 20 7 26 12 269
2005 64 119 9 1 28 17 238
2006 108 132 17 4 33 19 313
2007 69 92 19 4 24 23 231
2008 74 111 19 3 38 26 271
2009 67 92 18 6 37 22 242
2010 81 136 21 7 39 31 315
2011 67 118 13 5 34 40 277
2012 63 96 17 6 29 42 253
2013 58 102 18 7 45 51 281
2014*** 77 110 22 6 49 55 319
*   Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
** Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
*** Preliminary and incomplete figures.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Herpes zoster (Shingles) ICD9: 053
ICD10: B02
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality
1997 0 0 0 0 0 14 14
1998 0 0 1 0 1 17 19
1999 0 0 0 0 1 24 25
2000 0 0 0 0 0 14 14
2001 0 0 0 0 1 12 13
2002 0 0 0 0 0 26 26
2003 0 0 0 1 0 13 14
2004 0 0 0 0 0 15 15
2005 0 0 0 0 1 14 15
2006 0 0 0 0 0 24 24
2007 0 0 0 0 1 20 21
2008 0 0 0 0 0 14 14
2009 0 0 0 0 0 20 20
2010 0 0 0 0 0 25 25
2011 0 0 0 0 0 20 20
2012 0 0 0 0 0 21 21
2013* 0 0 0 0 0 21 21
2014* 0 0 0 0 0 26 26
Hospitalisations**
2000 2 6 4 9 68 274 363
2001 1 8 7 9 55 319 399
2002 2 18 7 8 67 340 442
2003 1 9 14 6 51 273 354
2004 4 8 6 7 60 324 409
2005 2 9 5 11 54 278 359
2006 0 11 7 7 43 249 317
2007 1 10 7 8 33 267 326
2008 2 8 5 6 43 259 323
2009 0 2 6 7 63 311 389
2010 1 6 6 8 39 292 352
2011 2 9 7 10 44 288 360
2012 1 6 11 8 42 279 347
2013 1 3 6 5 34 302 351
2014*** 0 9 4 7 56 370 446
*   Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
** Up to 2012, diseases are coded according to the ICD-9 coding system. Starting with 2013, diseases are coded according to the ICD-10 coding 
system.
*** Preliminary and incomplete figures.
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Male 0 yr
Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
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Hepatitis A ICD10: B15
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Mortality (Acute)
1997 0 0 0 0 1 1 2
1998 0 0 0 0 0 1 1
1999 0 0 0 0 0 0 0
2000 0 0 0 0 0 1 1
2001 0 0 0 0 0 3 3
2002 0 0 0 0 0 1 1
2003 0 0 0 0 0 1 1
2004 0 0 0 0 0 1 1
2005 0 0 0 0 0 1 1
2006 0 0 0 0 0 0 0
2007 0 0 0 0 0 0 0
2008 0 0 0 0 0 0 0
2009 0 0 0 0 0 1 1
2010 0 0 0 0 0 0 0
2011 0 0 0 0 0 0 0
2012 0 0 0 0 0 0 0
2013* 0 0 0 0 0 0 0
2014* 0 0 0 0 0 0 0
Notifications
1997 3 96 318 199 253 37 913**
1998 1 114 360 235 446 47 1,210**
1999 2 58 210 148 217 53 694**
2000 3 63 174 146 205 54 647**
2001 2 43 149 126 318 63 704**
2002 0 22 97 119 144 51 433
2003 0 23 81 96 139 50 389
2004 1 21 69 76 227 45 439
2005 0 18 28 41 89 36 212
2006 0 17 59 85 78 38 277
2007 0 5 26 42 60 24 157
2008 0 6 26 43 88 26 189
2009 0 8 34 28 83 23 176
2010 0 18 32 41 127 44 262
2011 0 12 18 22 54 19 125
2012 0 10 21 26 42 22 121
2013 0 7 16 18 49 20 110
2014 0 5 26 27 30 17 105
*   Preliminary figures. Starting with statistical year 2013, the coding of causes of death is partly automatic.
** For 25 patients, the age is unknown.
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Male 1-4 yr
Male 5-9 yr
Male 10-19 yr
Male 20-49 yr
Male 50+ yr
Female 0 yr
Female 1-4 yr
Female 5-9 yr
Female 10-19 yr
Female 20-49 yr
Female 50+ yr
Surveillance and developments in 2014-2015   |  219
Hepatitis A ICD10: B15
Year Age (years) Total N
0 1-4 5-9 10-19 20-49 50+
Laboratory diagnoses
1997 - - - - - - 295
1998 - - - - - - 405
1999 - - - - - - 223
2000 - - - - - - 293
2001 - - - - - - 284
2002 - - - - - - 145
2003 - - - - - - 146
2004 - - - - - - 153
2005 - - - - - - 91
2006 - - - - - - 111
2007 - - - - - - 72
2008 - - - - - - 97
2009 - - - - - - 96
2010 - - - - - - 107
2011 - - - - - - 63
2012 - - - - - - 53
2013 - - - - - - 38
2014 - - - - - - 66
All ages
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Appendix 4 Composition of currently used vaccines in the NIP
Vaccine Composition
M-M-R VaxPro / SP MSD
EU/1/06/337
Mumps, measles and rubella 
vaccine
0.5 ml
Mumps virus (Jeryl Lynn) > 12,500 TCID50 
(tissue culture infectious doses)
Measles virus (Enders’ Edmonston) > 1000 TCID50
Rubella virus (Wistar RA 27/3) > 1000 TCID50
Infanrix IPV / GSK
RVG 34568
Diphtheria, tetanus, pertussis
(acellular component),  
inactivated poliomyelitis  
vaccine
0.5 ml
Adsorbed diphtheria toxoid > 30 IU
Adsorbed tetanus toxoid > 40 IU
Adsorbed pertussis toxoid (PT) 25 µg
Adsorbed filamentous haemagglutinin (FHA) 25 µg
Absorbed pertactin (PRN) 8 µg
Inactivated type 1 poliovirus (Mahoney) 40 DU
Inactivated type 2 poliovirus (MEF-1) 8 DU
Inactivated type 3 poliovirus (Saukett) 32 DU
Infanrix Hexa/GSK
EU/1/00/152
Diphtheria, tetanus, pertussis 
(acellular
component), hepatitis B (rDNA),
inactivated poliomyelitis vaccine 
and conjugated Haemophilus 
influenzae type b-vaccine  
(adsorbed)
0.5 ml
Adsorbed diphtheria toxoid > 30 IU
Adsorbed tetanus toxoid > 40 IU
Adsorbed pertussis toxoid (PT) 25 µg
Adsorbed filamentous haemagglutinin (FHA) 25 µg
Adsorbed pertactin (PRN) 8 µg
Adsorbed recombinant HBsAg protein 10 µg
Inactivated type 1 poliovirus (Mahoney) 40 DU
Inactivated type 2 poliovirus (MEF-1) 8 DU
Inactivated type 3 poliovirus (Saukett) 32 DU
Adsorbed purified capsular polysaccharide of Hib
(PRP) 10 µg covalently bound to tetanus toxoid (T) 
20-40 µg
DT-IPV vaccine/NVI
RVG 17641
Diphtheria (adsorbed), tetanus
(adsorbed) and inactivated 
poliomyelitis vaccine
1 ml
Diphtheria-toxoid* > 5 IU
Tetanus toxoid* > 20 IU
Inactivated poliovirus type 1 > 40 DU
Inactivated poliovirus type 2 > 4 DU
Inactivated poliovirus type 3 > 7.5 DU 
*adsorbed to aluminium phosphate 1.5 mg Al3+
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Vaccine Composition
Engerix-B Junior
RVG24290
Hepatitis B vaccine  
(recombinant)
0.5 ml
Hepatitis B-virus surface antigen, recombinant* 
(S protein) absorbed 10 µg
*produced on genetically-engineered yeast cells
(Saccharomyces cerevisiae)
HBVAXPRO
RVG17316
Hepatitis B vaccine (rDNA)
0.5 ml
Hepatitis B virus surface antigen, recombinant 
(HBsAg)1,2 5 µg
1 Adsorbed on amorphous aluminium  
hydroxyphosphate sulfate (0.25 mg Al+)
2 Produced in Saccharomyces cerevisiae  
(strain 2150-2-3) yeast by recombinant DNA technology
Act-HIB
Haemophilus influenzae type b  
Conjugate Vaccine  
(Tetanus Protein - Conjugate)
0.5 ml
Purified polyribose ribitol phosphate capsular  
polysaccharide (PRP) of Haemophilus influenzae  
type b1 10 µg
1covalently bound to tetanus protein 20 µg
Cervarix / GSK
EU/1/07/419
Human papillomavirus type 16 L1 protein2,3,4 20 µg
Human papillomavirus type 18 L1 protein2,3,4 20 µg
1 adjuvanted by AS04 containing 3-O-desacyl-4’-
monophosphoryl lipid A (MPL)3 50 µg
2 absorbed on aluminium hydroxide, hydrated (Al(OH)3)
0.5 mg AL3+ in total 
3 L1 protein in the form of non-infectious virus-like 
particles (VLPs) produced by recombinant DNA  
technology using a Baculovirus expression system 
which uses Hi-5 Rix4446 cells derived from  
Trichoplusia ni.
NeisVac-C/Baxter
RVG 26343
Conjugated meningococcal C 
saccharide vaccine (adsorbed)
0.5 ml
Neisseria meningitidis (C11-strain)
Polysaccharide O-deacetylated 10 µg
conjugated to tetanus toxoid 10-20 µg
adsorbed to aluminium hydroxide 0.5 mg Al3+
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Vaccine Composition
Synflorix/GSK
EU/1/09/508
Pneumococcal polysaccharide 
conjugate vaccine (adsorbed)
0.5 ml
Pneumococcal polysaccharide serotype 11,2 1 µg
Pneumococcal polysaccharide serotype 41,2 3 µg
Pneumococcal polysaccharide serotype 51,2 1 µg
Pneumococcal polysaccharide serotype 6B1,2 1 µg
Pneumococcal polysaccharide serotype 7F1,2 1 µg
Pneumococcal polysaccharide serotype 9V1,2 1 µg
Pneumococcal polysaccharide serotype 141,2 1 µg
Pneumococcal polysaccharide serotype 18C1,3 3 µg
Pneumococcal polysaccharide serotype 19F1,4 3 µg
Pneumococcal polysaccharide serotype 23F1,2 1 µg
1 absorbed to aluminium phosphate 0.5 mg Al3+
2 conjugated to protein D (obtained from nontypeable
Haemophilus influenzae) carrier protein 9-16 mg
3 conjugated to tetanus toxoid 5-10 mg
3 conjugated to diphtheria toxoid 3-6 mg
More extensive product information can be found at: www.cbg-meb.nl and www.ema.europe.eu.
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Appendix 5 Overview of relevant websites
General information for NIP professionals
RIVM website for professionals: 
http://www.rivm.nl/Onderwerpen/R/Rijksvaccinatieprogramma/ Professionals
Dienst Vaccinvoorziening en Preventieprogramma’s (DVP): 
http://www.rivm.nl/RIVM/Organisatie/Centra/Dienst_Vaccinvoorziening_en_Preventieprogramma_s
Training:  
http://www.rivm.nl/Onderwerpen/R/Rijksvaccinatieprogramma/ Professionals/Scholingsbijeenkomsten
Meldingsplicht infectieziekten:
http://www.rivm.nl/Onderwerpen/M/Meldingsplicht_infectieziekten
General information for the public
RIVM websites for the public:  
http://www.rivm.nl/Onderwerpen/R/Rijksvaccinatieprogramma
www.rijksvaccinatieprogramma.nl
Volksgezondheidenzorg.info:
https://www.volksgezondheidenzorg.info/
Cervical cancer screening programme:
http://www.rivm.nl/Onderwerpen/B/Bevolkingsonderzoek_ baarmoederhalskanker
Other NIP-related RIVM reports
Vaccinatiegraad Rijksvaccinatieprogramma Nederland, Verslagjaar 2015:
http://www.rivm.nl/bibliotheek/rapporten/2015-0067.pdf
Terugblik Rijksvaccinatieprogramma 2014: 
http://www.rivm.nl/bibliotheek/rapporten/2015-0089.pdf
Adverse Events in the Netherlands Vaccination Programme, Reports in 2010 and Review 
1994-2010: http://www.rivm.nl/bibliotheek/rapporten/205051004.pdf
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Product information
M-M-RVAXPRO (MMR):
http://www.rivm.nl/dsresource?objectid=rivmp:183945&type=org& disposition=inline
Infanrix-IPV (DKTP):
http://www.rivm.nl/dsresource?objectid=rivmp:60726&type=org& disposition=inline
Infanrix Hexa (DKTP-Hib-HepB):
http://www.rivm.nl/dsresource?objectid=rivmp:116776&type=org& disposition=inline
DTP (DTP):
http://www.rivm.nl/dsresource?objectid=rivmp:119441&type=org& disposition=inline
Engerix-B Junior (HepB):
http://www.rivm.nl/dsresource?objectid=rivmp:60837&type=org& disposition=inline
HBVAXPRO (HepB adults):
http://www.rivm.nl/dsresource?objectid=rivmp:60857&type=org& disposition=inline
Act-HIB (Hib):
http://www.rivm.nl/dsresource?objectid=rivmp:60910&type=org& disposition=inline
Cervarix (HPV):
http://www.rivm.nl/dsresource?objectid=rivmp:116768&type=org& disposition=inline
NeisVac-C (MenC):
http://www.rivm.nl/dsresource?objectid=rivmp:60983&type=org& disposition=inline
Synflorix (Pneumokokken):
http://www.rivm.nl/dsresource?objectid=rivmp:116782&type=org& disposition=inline
National organisations
Ministry of Health, Welfare and Sports:
http://www.rijksoverheid.nl/onderwerpen/vaccinaties
Health Council:
http://www.gezondheidsraad.nl/
GGD GHOR: 
http://www.ggdghorkennisnet.nl/
Safety of vaccines
Netherlands Pharmacovigilance Centre Lareb:
http://www.lareb.nl/
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College ter Beoordeling van Geneesmiddelen (CBG):
http://www.cbg-meb.nl/
Data sources
Statistics Netherlands (CBS):
http://www.cbs.nl/
Dutch Hospital Data (DHD):
https://www.dhd.nl/
Nederlands instituut voor onderzoek van de gezondheidszorg (NIVEL):
http://www.nivel.nl/
Nederlands Referentielaboratorium voor Bacteriële Meningitis (NRBM):
https://www.amc.nl/web/Het-AMC/Afdelingen/Medische-afdelingen/Medische-Microbiologie/
Onderafdelingen/Het-Nederlands-Referentielaboratorium-voor-Bacteriele-Meningitis.htm
Integrated Primary Care Information (IPCI):
http://www.ipci.nl/
Other research partners
TNO:
https://www.tno.nl/
Nederlandse Werkgroep Klinische Virologie (NWKV):
http://www.nvmm.nl/nwkv
International organisations
World Health Organization (WHO):
http://www.who.int/en/
World Health Organization (WHO) Europe:
http://www.euro.who.int/en/home
European Centre for Disease Prevention and Control (ECDC):
http://ecdc.europa.eu/en/
Centers for Disease Control and Prevention (CDC):
http://www.cdc.gov/
ClinicalTrials.gov:
https://clinicaltrials.gov/
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Advisory Committees
Joint Committee on Vaccination and Immunisation (JCVI):
https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation
Advisory Committee on Immunization Practices (ACIP):
http://www.cdc.gov/vaccines/acip/
Standing Committee on Vaccination (STIKO):
http://www.rki.de/EN/Content/Prevention/Vaccination/Vaccination_node.html 
Safety of vaccines
European Medicines Agency (EMA):
http://www.ema.europa.eu/ema/
U.S. Food and Drug Administration (FDA):
http://www.fda.gov/
International networks
EUVAC-Net:
http://ecdc.europa.eu/en/healthtopics/vaccine-preventable-diseases/euvac/Pages/index.aspx
Vaccine European New Integrated Collaboration Effort (VENICE) III project:
http://venice.cineca.org/
HAVNET:
http://www.rivm.nl/en/Topics/H/HAVNET
National Immunization Technical Advisory Groups (NITAGs):
http://www.nitag-resource.org/
Communication platforms
Epidemic Intelligence Information System (EPIS):
http://ecdc.europa.eu/en/activities/epidemicintelligence/Pages/EpidemicIntelligence_Tools.aspx
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Vaccination of risk groups
Influenza vaccination
RIVM website on Influenza vaccination: 
http://www.rivm.nl/Onderwerpen/G/Griep/Griepprik
Stichting Nationaal Programma Grieppreventie (SNPG):  
http://www.snpg.nl/
Scientific Institute for Quality of Healthcare: 
http://www.iqhealthcare.nl/nl/
Jaarrapportage Surveillance Respiratoire Infectieziekten 2013: 
http://www.rivm.nl/bibliotheek/rapporten/150002006.pdf
Tuberculosis
KNCV Tuberculosis foundation: 
http://www.kncvtbc.nl/ 
Jaarrapportage Surveillance Respiratoire Infectieziekten 2013: 
http://www.rivm.nl/bibliotheek/rapporten/150002006.pdf
Nationaal plan tuberculosebestrijding 2011-2015:
http://www.rivm.nl/bibliotheek/rapporten/215081001.pdf
Travellers vaccination
Landelijk Coördinatiecentrum Reizigersadvisering: 
http://www.lcr.nl/Vaccinaties
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